CUMULATIVE
SUPPLEMENT 12
DECEMBER 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 12

December 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AMERSHAM HEALTH INC (AMERSHAM HLTH)	AMERSHAM HEALTH (AMERSHAM HLTH)
BAXTER PHARMACEUTICAL PRODUCTS INC (BAXTER PHARM PROD)	BAXTER HEALTHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
CHELSEA LABORATORIES INC (CHELSEA LABS)	WATSON LABORATORES INC (WATSON LAB)
CIBA VISION CORP DIV NOVARTIS CO (CIBA)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
CIBA VISION OPHTHALMICS (CIBA VISION OPHTHLMC)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
DEY LABORATORIES INC (DEY)	DEY LP (DEY)
DUPONT MERCK PHARMACEUTICAL CO (DUPONT MERCK)	BRISTOL MYERS SQUIBB PHARMA COMPANY (BRISTOL MYERS SQUIBB)
DUPONT PHARMACEUTICALS CO (DUPONT PHARMA)	BRISTOL MYERS SQUIBB PHARMA COMPANY (BRISTOL MYERS SQUIBB)
DUPONT PHARMACEUTICALS CO PR (DUPONT PHARMA)	BRISTOL MYERS SQUIBB PHARMA COMPANY (BRISTOL MYERS SQUIBB)
GD SEARLE AND CO (SEARLE)	GD SEARLE LLC (GD SEALE LLC)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
LOTUS BIOCHEMICAL CORPORATION (LOTUS BIOCHEM)	NEW RIVER PHARMACEUTICALS INC (NEW RIVER)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
MARSAM PHARMACEUTICALS INC (MARSAM PHARMS)	MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
MEDI PHYSICS AMERSHAM IMAGING (MEDI PHYSICS)	AMERSHAM HEALTH (AMERSHAM HLTH)
MEDI PHYSICS INC (MEDI PHYSICS)	AMERSHAM HEALTH (AMERSHAM HLTH)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)
NYCOMED AMERSHAM (NYCOMED AMERSHAM)	AMERSHAM HEALTH (AMERSHAM HLTH)
NYCOMED AMERSHAM PLC (NYCOMED AMERSHAM)	AMERSHAM HEALTH (AMERSHAM HLTH)
NYCOMED INC (NYCOMED)	AMERSHAM HEALTH (AMERSHAM HLTH)
OHMEDA PHARMACEUTICAL PRODUCTS DIV ANESTHESIA & CRITICAL CARE (OHMEDA)	BAXTER HEATHCARE CORPORATION (BAXTER HLTHCARE CORP)
ROBERTS LABORATORIES INC (ROBERTS LABS)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ROBERTS PHARMACEUTICAL CORP (ROBERTS PHARM)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ROSEMONT PHARMACEUTICAL COR (ROSEMONT)	USL PHARMA INC (USL PHARMA)
SEARLE PHARMACEUTICALS INC (SEARLE)	GD SEARLE LLC (GD SEARLE LLC)
ZENITH GOLDLINE (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	JUN 2001	SEP 2001	DEC 2001
DRUG PRODUCTS LISTED	10360	10155	10094	10166
SINGLE SOURCE	2682 (25.9%)	2665 (26.2%)	2643 (26.2%)	2665 (26.2%
MULTISOURCE	7568 (73.1%)	7380 (72.7%)	7341 (72.7%)	7391 (72.7%
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7078 (69.7%)	7050 (69.8%)	7105 (69.9%
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	302 (3.0%)	291 (2.9%)	286 (2.8%)
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	2	3	4	10
NUMBER OF APPLICANTS	594	579	572	574

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone Tablets

In Cumulative Supplement 6 of the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition, (the Orange Book), the Agency proposed to reclassifiy metaxalone tablets from a drug product not presenting bioequivalence problems to one that has a known or potential bioequivalence problem that requires an in vivo demonstration of bioequivalence as a condtiion of approval for an ANDA. The Agency solicited comments from interested persons to be received no later than November 30, 2001. No comments were received. Accordingly, the therapeutic equivalence category for metaxalone tablets will be changed from a "nonbioproblem drug" to a "bioproblem drug." An ANDA for metaxalone tablets must include acceptable in vivo bioequivalence study or studies.

As long as metaxalone tablets are a single source drug product, no therapeutic equivalence code will be assigned to the product in the Orange Book. If the Agency approves an ANDA for metaxalone tablets, the innovator's NDA for metaxalone (Skelaxin) tablets and the approved ANDA will both be coded as "AB".

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

	@ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC
	@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

TRIAPRIN

	@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

	@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	ABLE	325MG;50MG;40MG	N40390 001	JUL 23, 2001	JUL	NEWA
AB		500MG;50MG;40MG	N40394 001	JUL 23, 2001	JUL	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

AB	WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA

FIORICET W/ CODEINE

AB +	NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG

PHRENILIN WITH CAFFEINE AND CODEINE

AB	AMARIN PHARMS	325MG;50MG;40MG;30MG	N74911 001	AUG 22, 2001	AUG	NEWA

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

+	MIKART	356.4MG;30MG;16MG	N40109 001	AUG 26, 1997	OCT	CRLD

DHC PLUS

	@ PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986	OCT	DISC

SYNALGOS-DC-A

>A>	@ WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N89166 001	MAY 14, 1986	DEC	CAHN
>D>	@ WYETH AYERST	356.4MG;30MG;16MG	N89166 001	MAY 14, 1986	DEC	CAHN

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

+	MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA
AA		300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA
AA		300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA

CAPITAL WITH CODEINE

	@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP

			ACETAMINOPHEN; HYDROCODONE BITARTRATE						
			SOLUTION; ORAL						
			HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	AA		MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001	JUN	NEWA
	AA	+	MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992	JUN	CDFR
				500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	JUN	CDFR
		+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	JUN	CDFR
	AA		PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998	JUN	CDFR
			TABLET; ORAL						
			ANEXSIA 5/325						
>D>	AA		MALLINCKRODT	325MG;5MG	N40409 001	OCT 20, 2000	DEC	CTNA
>A>	AA			325MG;5MG	N40409 001	OCT 20, 2000	DEC	CTNA
			ANEXSIA 7.5/325						
>D>	AA		MALLINCKRODT	325MG;7.5MG	N40405 001	SEP 08, 2000	DEC	CTNA
>A>	AA			325MG;7.5MG	N40405 001	SEP 08, 2000	DEC	CTNA
			HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
		+	ENDO PHARMS	400MG;5MG	N40288 001	NOV 27, 1998	SEP	CTEC
		+		400MG;7.5MG	N40288 002	NOV 27, 1998	SEP	CTEC
		+		400MG;10MG	N40288 003	NOV 27, 1998	SEP	CTEC
>A>	AA		MALLINCKRODT	650MG;10MG	N40084 004	OCT 16, 1996	DEC	NEWA
		+	WATSON LABS	325MG;7.5MG	N40248 001	APR 28, 2000	JUL	DISC
		@		325MG;7.5MG	N40248 001	APR 28, 2000	AUG	DISC
		+		750MG;10MG	N40094 004	MAR 22, 1999	APR	NEWA
			LORTAB						
	AA	+	WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN
			NORCO						
	AA		WATSON LABS	325MG;7.5MG	N40148 003	SEP 12, 2000	APR	NEWA
	AA	+		325MG;7.5MG	N40148 003	SEP 12, 2000	JUL	CRLD
			ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE						
			TABLET; ORAL						
			PERCOCET						
		+	ENDO PHARMS	325MG;7.5MG	N40434 001	NOV 23, 2001	NOV	NEWA
		+		325MG;10MG	N40434 002	NOV 23, 2001	NOV	NEWA
			ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE						
			TABLET; ORAL						
			WYGESIC						
>A>	AA	+	WOMEN FIRST HLTHCARE	650MG;65MG	N84999 001	SEP 03, 1976	DEC	CAHN
>D>	AA	+	WYETH AYERST	650MG;65MG	N84999 001	SEP 03, 1976	DEC	CAHN
			ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE						
			TABLET; ORAL						
			PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN						
	AB		ABLE	650MG;100MG	N75838 001	JUL 11, 2001	JUL	NEWA
		@	HALSEY	325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC
		@		650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC
	AB		MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA
	AB		VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE
TABLET; ORAL
ULTRACET
\+ JOHNSON RW 325MG;37.5MG N21123 001 AUG 15, 2001 AUG NEWA

ACYCLOVIR SODIUM
INJECTABLE; INJECTION
ACYCLOVIR
AP GENSIA SICOR PHARMS EQ 50MG BASE/ML N75627 001 MAR 28, 2001 MAR NEWA
ACYCLOVIR SODIUM
AP AM PHARM PARTNERS EQ 500MG BASE/VIAL N75015 001 APR 30, 1998 OCT CAHN

ALBUTEROL
AEROSOL, METERED; INHALATION
ALBUTEROL
AB ARMSTRONG PHARMS 0.09MG/INH N72273 001 AUG 14, 1996 JUN CAHN
AB GENPHARM 0.09MG/INH N73045 001 AUG 19, 1997 OCT CAHN

ALBUTEROL SULFATE
AEROSOL, METERED; INHALATION
VENTOLIN HFA
\+ GLAXO EQ 0.09MG BASE/INH N20983 001 APR 19, 2001 APR NEWA
CAPSULE; INHALATION
VENTOLIN ROTACAPS
@ GLAXO WELLCOME EQ 0.2MG BASE N19489 001 MAY 04, 1988 JUL DISC
SOLUTION; INHALATION
ACCUNEB
\+ DEY EQ 0.021% BASE N20949 002 APR 30, 2001 APR NEWA
\+ EQ 0.042% BASE N20949 001 APR 30, 2001 APR NEWA
ALBUTEROL SULFATE
AN NEPHRON EQ 0.5% BASE N75664 001 JUN 26, 2001 JUN NEWA
AN ROXANE EQ 0.083% BASE N75129 001 FEB 13, 2001 FEB NEWA
VENTOLIN
@ GLAXO WELLCOME EQ 0.083% BASE N19773 001 APR 23, 1992 JUL DISC
@ EQ 0.5% BASE N19269 002 JAN 16, 1987 JUL DISC
TABLET; ORAL
@ GLAXO WELLCOME EQ 2MG BASE N19112 001 JUL 10, 1986 JUN DISC
@ EQ 4MG BASE N19112 002 JUL 10, 1986 JUN DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
SOLUTION; INHALATION
DUONEB
\+ DEY EQ 0.083% BASE;0.017% N20950 001 MAR 21, 2001 MAR NEWA

ALLOPURINOL
TABLET; ORAL
ZYLOPRIM
AB PROMETHEUS LABS 100MG N16084 001 AUG 19, 1966 MAY CAHN
AB \+ 300MG N16084 002 JAN 14, 1974 MAY CAHN

ALMOTRIPTAN MALATE						
TABLET; ORAL						
AXERT						
PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	MAY	NEWA
+	EQ 12.5MG BASE	N21001 002	MAY 07, 2001	MAY	NEWA
ALPRAZOLAM						
SOLUTION; ORAL						
ALPRAZOLAM						
@ ROXANE	0.5MG/5ML	N74314 001	OCT 31, 1993	SEP	DISC
AMIKACIN SULFATE						
INJECTABLE; INJECTION						
AMIKACIN SULFATE						
@ ABBOTT	EQ 250MG BASE/ML	N63265 001	NOV 30, 1994	APR	DISC
@	EQ 250MG BASE/ML	N63266 001	OCT 31, 1994	APR	DISC
@	EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC
@ ELKINS SINN	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992	APR	DISC
AMINOCAPROIC ACID						
TABLET; ORAL						
AMICAR						
AB + IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG
AMINOCAPROIC						
AB MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA
AMIODARONE HYDROCHLORIDE						
TABLET; ORAL						
AMIODARONE HCL						
AB BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA
AB TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA
AMITRIPTYLINE HYDROCHLORIDE						
TABLET; ORAL						
AMITRIPTYLINE HCL						
@ TEVA	75MG	N85030 001	NOV 22, 1976	JUL	DISC
AMLEXANOX						
PASTE; DENTAL						
APHTHASOL						
+ GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	SEP	CAHN
AMOXICILLIN						
CAPSULE; ORAL						
AMOXICILLIN						
@ LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
@	500MG	N62528 002	AUG 07, 1985	FEB	WDRP
@ MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC
@	500MG	N62067 002	AUG 14, 1980	APR	DISC
@ TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC
@	500MG	N63031 001	FEB 28, 1989	APR	DISC
TRIMOX						

AMOXICILLIN						
CAPSULE; ORAL						
TRIMOX						
@ APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC	
@	500MG	N63099 002	MAR 20, 1992	APR	DISC	
WYMOX						
@ WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC	
@	500MG	N62120 002	APR 28, 1978	APR	DISC	
FOR SUSPENSION; ORAL						
TRIMOX						
@ APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC	
@	125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC	
@	250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC	
AMOXICILLIN; CLAVULANATE POTASSIUM						
FOR SUSPENSION; ORAL						
AUGMENTIN ES-600						
+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001	JUN	NEWA	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE						
CAPSULE, EXTENDED RELEASE; ORAL						
ADDERALL XR 10						
SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	OCT	NEWA	
ADDERALL XR 20						
SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	OCT	NEWA	
ADDERALL XR 30						
+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	OCT	NEWA	
TABLET; ORAL						
ADDERALL 7.5						
SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CRLD	
AMPHOTERICIN B						
INJECTABLE; INJECTION						
AMPHOTERICIN B						
@ ABBOTT	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	
INJECTABLE, LIPID COMPLEX; INJECTION						
AMPHOTEC						
+ INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN	
+	100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN	
AMPICILLIN SODIUM						
INJECTABLE; INJECTION						
AMPICILLIN SODIUM						
@ ELKINS SINN	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY	DISC	
@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY	DISC	
@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY	DISC	
@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY	DISC	
@ HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC	

@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC	
@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY	DISC	
@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC	
@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC	
@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC	
@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC	
@ IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY	DISC	
@ MARSAM	EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988	JUL	DISC	
OMNIPEN-N						
@ WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY	DISC	
@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY	DISC	
@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY	DISC	
TOTACILLIN-N						
SMITHKLINE BEECHAM	EQ 10GM BASE/VIAL	N60677 006	MAY 04, 1976	JUL	CTEC	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL						
AMPICILLIN TRIHYDRATE						
@ BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY	DISC	
@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC	
FOR SUSPENSION; ORAL						
@ MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC	
@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC	
TOTACILLIN						
@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP	
@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL						
PROBAMPACIN						
@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC	

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION						
GENESA						
@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC	

ARDEPARIN SODIUM

INJECTABLE; INJECTION						
NORMIFLO						
@ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	JUL	CAHN	
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	JUL	CAHN	
@ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC	
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC	

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	SEP 21, 2000	FEB	NEWA
+	NEOSAN PHARMS	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	SEP 21, 2000	OCT	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

AP	+	NEOSAN PHARMS	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809 004	AUG 08, 1985	OCT	CAHN

MVC PLUS

@	STERIS	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N18439 002	AUG 08, 1985	SEP	DISC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

LANORINAL

@	LANNETT	325MG;50MG;40MG	N86986 002	OCT 18, 1985	JUL	DISC

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	ANABOLIC	325MG;50MG;40MG;30MG	N75231 001	NOV 30, 2001	NOV	NEWA

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+	WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N11483 004	SEP 06, 1983	NOV	CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN

INVAGESIC FORTE

AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

	@ EON	389MG;32.4MG;65MG	N80044 002	SEP 16, 1983	MAY	DISC

PROPOXYPHENE COMPOUND-65

	@ GENEVA PHARMS	389MG;32.4MG;65MG	N83101 002	JUN 24, 1985	MAY	DISC

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

AB	+	WOMEN FIRST HLTHCARE	325MG;200MG	N11702 003	DEC 29, 1983	NOV	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

ROXIPRIN

	@ ROXANE	325MG;4.5MG;0.38MG	N87743 001	JUN 04, 1982	OCT	DISC

ATENOLOL

TABLET; ORAL

ATENOLOL

	@ GENPHARM	25MG	N74126 003	AUG 26, 1998	JUL	DISC
	@	50MG	N74126 001	MAR 23, 1994	JUL	DISC
	@	100MG	N74126 002	MAR 23, 1994	JUL	DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

LIPITOR

PFIZER

		EQ 10MG BASE	N20702 001	DEC 17, 1996	MAR	CAHN
		EQ 20MG BASE	N20702 002	DEC 17, 1996	MAR	CAHN
		EQ 40MG BASE	N20702 003	DEC 17, 1996	MAR	CAHN
	+	EQ 80MG BASE	N20702 004	APR 07, 2000	MAR	CAHN

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

	ABBOTT	0.05MG/ML	N21146 002	JUL 09, 2001	JUL	NEWA
+		0.1MG/ML	N21146 001	JUL 09, 2001	JUL	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

	@ INWOOD LABS	0.025MG;2.5MG	N85509 001	MAR 09, 1978	FEB	WDRP
AA	LANNETT	0.025MG;2.5MG	N85372 001	FEB 21, 1978	AUG	CMFD
	@ R AND S PHARMA	0.025MG;2.5MG	N85035 001	JUL 05, 1977	MAY	DISC
	@ WEST WARD	0.025MG;2.5MG	N87765 001	MAR 15, 1982	JUL	DISC

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	EON	0.025MG;2.5MG	N86173 001	AUG 28, 1981	AUG	CMFD
	@ PVT FORM	0.025MG;2.5MG	N85766 001	DEC 22, 1978	MAY	DISC

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	PROMETHEUS LABS	3MG	N18689 001	MAY 24, 1985	MAY	CAHN

AZATHIOPRINE

TABLET; ORAL

IMURAN

	@ PROMETHEUS LABS	25MG	N16324 002	MAR 21, 1980	MAY	CAHN
AB	+	50MG	N16324 001	MAR 20, 1968	MAY	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTELIN

+	WALLACE PHARMS	EQ 0.125MG BASE/SPRAY	N20114 001	NOV 01, 1996	OCT	CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION; TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

	@ PFIZER	EQ 1GM BASE;EQ 100MG BASE	N50762 001	DEC 18, 1998	MAY	DISC

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING

ZIBA-RX

	@ PHARMA TEK	500,000 UNITS/BOT	N61737 001	APR 26, 1973	MAY	DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEO-POLYCIN

	@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP

BENDROFLUMETHIAZIDE; NADOLOL							
TABLET; ORAL							
CORZIDE							
KING PHARMS		5MG;40MG	N18647 001	MAY 25, 1983	AUG	CAHN	
+		5MG;80MG	N18647 002	MAY 25, 1983	AUG	CAHN	
BENZQUINAMIDE HYDROCHLORIDE							
INJECTABLE; INJECTION							
EMETE-CON							
+ PFIZER		EQ 50MG BASE/VIAL	N16820 001	MAR 20, 1974	MAY	CAHN	
BETAMETHASONE DIPROPIONATE							
CREAM; TOPICAL							
BETAMETHASONE DIPROPIONATE							
@ CLAY PARK		EQ 0.05% BASE	N74579 001	NOV 26, 1997	APR	DISC	
DISC; TOPICAL							
DIPROSONE							
@ SCHERING		EQ 0.1% BASE	N17829 001	MAY 24, 1977	AUG	DISC	
BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE							
CREAM; TOPICAL							
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB ALTANA		EQ 0.05% BASE;1%	N75502 001	JUN 05, 2001	JUN	NEWA	
AB TARO		EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001	MAY	NEWA	
LOTRISONE							
AB + SCHERING		EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG	
BETAXOLOL HYDROCHLORIDE							
SOLUTION/DROPS; OPHTHALMIC							
BETAXOLOL HCL							
AT BAUSCH AND LOMB		EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA	
BETHANECHOL CHLORIDE							
INJECTABLE; INJECTION							
URECHOLINE							
@ SIDMAK LABS		5MG/ML	N06536 001	OCT 12, 1948	AUG	CAHN	
TABLET; ORAL							
DUVOID							
@ WELLSPRING PHARM		10MG	N86262 001	MAR 22, 1978	JUN	CAHN	
@		25MG	N86263 001	MAR 22, 1978	JUN	CAHN	
@		50MG	N85882 003	MAR 22, 1978	JUN	CAHN	
URECHOLINE							
@ SIDMAK LABS		5MG	N06536 003	FEB 03, 1949	AUG	CAHN	
@		10MG	N06536 002	OCT 12, 1948	AUG	CAHN	
@		25MG	N06536 004	OCT 12, 1948	AUG	CAHN	
@		50MG	N06536 005	JUN 24, 1980	AUG	CAHN	
BIMATOPROST							
SOLUTION/DROPS; OPHTHALMIC							
LUMIGAN							
+ ALLERGAN		0.03%	N21275 001	MAR 16, 2001	MAR	NEWA	

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
TABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC

+	PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC

BISOPROLOL FUMARATE
TABLET; ORAL
BISOPROLOL FUMARATE

AB	COPLEY PHARM	5MG	N75644 001	JUN 26, 2001	JUN	NEWA
AB		10MG	N75644 002	JUN 26, 2001	JUN	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ APOTHECON	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC
	@	5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC
	@	10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC
AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA
AB		5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA
AB		10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA

BLEOMYCIN SULFATE
INJECTABLE; INJECTION
BLEOMYCIN

AP	BEDFORD	EQ 15 UNITS BASE/VIAL	N65042 002	OCT 17, 2001	OCT	NEWA
AP		EQ 30 UNITS BASE/VIAL	N65042 001	OCT 17, 2001	OCT	NEWA

BOSENTAN
TABLET; ORAL
TRACLEER

	ACTELION	62.5MG	N21290 001	NOV 20, 2001	NOV	NEWA
+		125MG	N21290 002	NOV 20, 2001	NOV	NEWA

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN

	@ ALLERGAN	0.5%	N20490 001	MAR 13, 1997	APR	DISC

ALPHAGAN P

+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001	MAR	NEWA

BUDESONIDE
CAPSULE; ORAL
ENTOCORT EC

+	ASTRAZENECA	3MG	N21324 001	OCT 02, 2001	OCT	NEWA

BUPIVACAINE HYDROCHLORIDE
INJECTABLE; SPINAL
MARCAINE

AP	+ ABBOTT	0.75%	N18692 001	MAY 04, 1984	JUN	CAHN

BUPRENORPHINE HYDROCHLORIDE							
INJECTABLE; INJECTION							
BUPRENEX							
AP +	RECKITT BENCKISER	EQ 0.3MG BASE/ML	N18401 001	DEC 29, 1981	JUL	CAHN	
BUPROPION HYDROCHLORIDE							
TABLET, EXTENDED RELEASE; ORAL							
WELLBUTRIN SR							
	GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996	APR	CTEC	
		100MG	N20358 002	OCT 04, 1996	APR	CTEC	
BUSPIRONE HYDROCHLORIDE							
TABLET; ORAL							
BUSPAR							
AB	BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986	MAR	CFTG	
AB		10MG	N18731 002	SEP 29, 1986	MAR	CFTG	
AB		15MG	N18731 003	APR 22, 1996	MAR	NEWA	
AB +		30MG	N18731 004	APR 22, 1996	JUN	CFTG	
BUSPIRONE HCL							
AB	DANBURY PHARMA	5MG	N74253 001	MAR 28, 2001	MAR	NEWA	
AB		10MG	N74253 002	MAR 28, 2001	MAR	NEWA	
AB	MYLAN	15MG	N75272 003	MAR 28, 2001	MAR	NEWA	
AB	MYLAN TECHNOLOGIES	30MG	N76008 001	JUN 28, 2001	JUN	NEWA	
AB	PAR PHARM	7.5MG	N75467 002	MAR 28, 2001	MAR	NEWA	
BUTABARBITAL SODIUM							
TABLET; ORAL							
BUTISOL SODIUM							
+	WALLACE LABS	15MG	N00793 002	JUN 05, 1939	MAY	CTEC	
SODIUM BUTABARBITAL							
@	LANNETT	15MG	N85849 001	AUG 21, 1978	MAY	DISC	
@		30MG	N85866 001	JUL 20, 1978	MAY	DISC	
BUTOCONAZOLE NITRATE							
CREAM; VAGINAL							
GYNAZOLE-1							
+	KV PHARM	2%	N19881 001	FEB 07, 1997	SEP	CTNA	
BUTORPHANOL TARTRATE							
INJECTABLE; INJECTION							
BUTORPHANOL TARTRATE							
AP	APOTEX	2MG/ML	N75697 001	OCT 23, 2001	OCT	NEWA	
BUTORPHANOL TARTRATE PRESERVATIVE FREE							
AP	APOTEX	1MG/ML	N75695 001	OCT 23, 2001	OCT	NEWA	
AP		2MG/ML	N75695 002	OCT 23, 2001	OCT	NEWA	
SPRAY, METERED; NASAL							
BUTORPHANOL TARTRATE							
AB	MYLAN	1MG/SPRAY	N75759 001	AUG 08, 2001	AUG	NEWA	
STADOL							
AB +	BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890 001	DEC 12, 1991	AUG	CFTG	

	CALCITONIN, SALMON						
	INJECTABLE; INJECTION						
	CALCITONIN-SALMON						
	@ ASTRAZENECA	200 IU/ML	N73690	001	APR 14, 1995	JUN	DISC
	CALCITRIOL						
	CAPSULE; ORAL						
	CALCITRIOL						
AB	TEVA	0.25UGM	N75765	001	OCT 12, 2001	OCT	NEWA
AB		0.5UGM	N75765	002	OCT 12, 2001	OCT	NEWA
	ROCALTROL						
AB	ROCHE	0.25UGM	N18044	001	AUG 17, 1978	OCT	CFTG
AB +		0.5UGM	N18044	002	AUG 17, 1978	OCT	CFTG
	CALCIUM ACETATE						
	CAPSULE; ORAL						
	PHOSLO						
	BRAINTREE	EQ 84.5MG CALCIUM	N21160	001	APR 02, 2001	APR	NEWA
	@	EQ 84.5MG CALCIUM	N21160	001	APR 02, 2001	AUG	DISC
	+	EQ 169MG CALCIUM	N21160	002	APR 02, 2001	APR	NEWA
	+ @	EQ 169MG CALCIUM	N21160	002	APR 02, 2001	AUG	DISC
	PHOSLO GELCAPS						
	+ BRAINTREE	EQ 169MG CALCIUM	N21160	003	APR 02, 2001	AUG	NEWA
	CAPTOPRIL						
	TABLET; ORAL						
	CAPTOPRIL						
AB	GENEVA PHARMS TECH	12.5MG	N74481	001	FEB 13, 1996	JAN	CAHN
AB		25MG	N74481	002	FEB 13, 1996	JAN	CAHN
AB		50MG	N74481	003	FEB 13, 1996	JAN	CAHN
AB		100MG	N74481	004	FEB 13, 1996	JAN	CAHN
	CARBACHOL						
	SOLUTION; INTRAOCULAR						
	CARBASTAT						
AT	NOVARTIS	0.01%	N73677	001	APR 28, 1995	FEB	CAHN
	CARBAMAZEPINE						
	TABLET, CHEWABLE; ORAL						
	CARBAMAZEPINE						
AB	CARACO	100MG	N75712	001	JUL 05, 2001	JUL	NEWA
	TABLET, EXTENDED RELEASE; ORAL						
	TEGRETOL-XR						
	NOVARTIS	100MG	N20234	001	MAR 25, 1996	JUL	CRLD
		200MG	N20234	002	MAR 25, 1996	JUL	CRLD
	CARBIDOPA; LEVODOPA						
	TABLET; ORAL						
	CARBIDOPA AND LEVODOPA						
	@ SCS	10MG;100MG	N74080	001	MAR 25, 1994	FEB	WDRP
	@	25MG;100MG	N74080	002	MAR 25, 1994	FEB	WDRP
	@	25MG;250MG	N74080	003	MAR 25, 1994	FEB	WDRP

CARISOPRODOL
TABLET; ORAL
CARISOPRODOL

AA	ABLE	350MG	N40421 001	JUN 21, 2001	JUN	NEWA

CASPOFUNGIN ACETATE
INJECTABLE; IV (INFUSION)
CANCIDAS

+	MERCK RES	50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
+		70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA

CEFACLOR
CAPSULE; ORAL
CECLOR

AB	CEPH INTL	EQ 250MG BASE	N62205 001	JUL 28, 1979	JUN	CAHN
AB		EQ 500MG BASE	N62205 002	JUL 28, 1979	JUN	CAHN

FOR SUSPENSION; ORAL
CEFACLOR

	@ ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
	@	EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC
	@	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

	LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC
AB	+	EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG

CEFACLOR

AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE
TABLET; ORAL
CEFADROXIL

	@ ZENITH GOLDLINE	EQ 1GM BASE	N62774 001	APR 08, 1987	MAY	DISC

CEFAMANDOLE NAFATE
INJECTABLE; INJECTION
MANDOL

	@ LILLY	EQ 1GM BASE/VIAL	N62560 001	SEP 10, 1985	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62560 002	SEP 10, 1985	MAY	DISC

CEFAZOLIN SODIUM
INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HIKMA	EQ 500MG BASE/VIAL	N65047 001	SEP 18, 2001	SEP	NEWA
AP		EQ 1GM BASE/VIAL	N65047 002	SEP 18, 2001	SEP	NEWA
	@ TEVA	EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989	APR	DISC
	@	EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989	APR	DISC
	@	EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989	APR	DISC

KEFZOL

	@ LILLY	EQ 500MG BASE/VIAL	N62557 001	SEP 10, 1985	MAY	DISC
	@	EQ 1GM BASE/VIAL	N62557 002	SEP 10, 1985	MAY	DISC

CEFDITOREN PIVOXIL
TABLET; ORAL
SPECTRACEF
+ TAP PHARM 200MG N21222 001 AUG 29, 2001 AUG NEWA

CEFONICID SODIUM
INJECTABLE; INJECTION
MONOCID
+ @ SMITHKLINE BEECHAM EQ 500MG BASE/VIAL N50579 001 MAY 23, 1984 AUG DISC
+ @ EQ 1GM BASE/VIAL N50579 002 MAY 23, 1984 AUG DISC
@ EQ 1GM BASE/VIAL N63295 001 JUL 26, 1993 APR DISC
@ EQ 10GM BASE/VIAL N50579 004 MAY 23, 1984 AUG DISC

CEFOPERAZONE SODIUM
INJECTABLE; INJECTION
CEFOBID
@ PFIZER EQ 1GM BASE/VIAL N63333 001 MAR 31, 1995 MAY DISC
@ EQ 2GM BASE/VIAL N63333 002 MAR 31, 1995 MAY DISC

CEFORANIDE
INJECTABLE; INJECTION
PRECEF
@ APOTHECON 500MG/VIAL N62579 001 NOV 26, 1984 MAY DISC
@ 1GM/VIAL N62579 002 NOV 26, 1984 MAY DISC
@ 2GM/VIAL N62579 003 NOV 26, 1984 MAY DISC
@ 10GM/VIAL N62579 004 NOV 26, 1984 MAY DISC
@ 20GM/VIAL N62579 005 NOV 26, 1984 MAY DISC

CEFOXITIN SODIUM
INJECTABLE; INJECTION
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
@ MERCK EQ 20MG BASE/ML N50581 003 SEP 20, 1984 JUL DISC
@ EQ 40MG BASE/ML N50581 004 SEP 20, 1984 JUL DISC

CEFTAZIDIME
INJECTABLE; INJECTION
TAZICEF
AP ABBOTT 500MG/VIAL N62662 001 MAR 06, 1986 JAN CAHN
AP 1GM/VIAL N62662 002 MAR 06, 1986 JAN CAHN
AP 1GM/VIAL N64032 001 OCT 31, 1993 JAN CAHN
AP 2GM/VIAL N62662 003 MAR 06, 1986 JAN CAHN
AP 2GM/VIAL N64032 002 OCT 31, 1993 JAN CAHN
AP 6GM/VIAL N62662 004 MAR 06, 1986 JAN CAHN
TAZIDIME IN PLASTIC CONTAINER
@ LILLY 1GM/VIAL N62739 001 JUL 10, 1986 MAY DISC
@ 2GM/VIAL N62739 002 JUL 10, 1986 MAY DISC

CEFUROXIME SODIUM
INJECTABLE; IM-IV
CEFUROXIME
AB AM PHARM PARTNERS EQ 750MG BASE/VIAL N65001 001 MAY 30, 2001 MAY NEWA
AB TEVA EQ 750MG BASE/VIAL N64192 002 APR 16, 1998 MAY CDFR

	CEFUROXIME SODIUM						
	INJECTABLE; IM-IV						
	CEFUROXIME SODIUM						
AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997	MAY	CDFR
	KEFUROX						
AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986	MAY	CDFR
	ZINACEF						
AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983	MAY	CDFR
	INJECTABLE; INJECTION						
	CEFUROXIME						
AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001 002	MAY 30, 2001	MAY	NEWA
	CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER						
	+ B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA
	+	EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA
	KEFUROX IN PLASTIC CONTAINER						
	@ LILLY	EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986	MAY	DISC
	INJECTABLE; INTRAVENOUS						
	@ LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986	MAY	DISC
	CEPHALEXIN						
	CAPSULE; ORAL						
	CEPHALEXIN						
	@ STEVENS J	EQ 500MG BASE	N62869 001	MAR 17, 1988	JUL	DISC
	@ TEVA	EQ 500MG BASE	N62823 001	FEB 05, 1988	MAY	DISC
	KEFLEX						
AB	CEPH INTL	EQ 250MG BASE	N62118 001	MAR 27, 1978	JUN	CAHN
AB		EQ 500MG BASE	N62118 002	MAR 27, 1978	JUN	CAHN
	FOR SUSPENSION; ORAL						
	CEPHALEXIN						
	@ BARR	EQ 125MG BASE/5ML	N62778 001	AUG 06, 1987	MAY	DISC
AB	RANBAXY	EQ 125MG BASE/5ML	N65081 001	JUL 27, 2001	JUL	NEWA
AB		EQ 250MG BASE/5ML	N65081 002	JUL 27, 2001	JUL	NEWA
	KEFLEX						
	+ CEPH INTL	EQ 100MG BASE/ML	N62117 001	MAR 27, 1978	JUN	CAHN
AB		EQ 125MG BASE/5ML	N62117 002	MAR 27, 1978	JUN	CAHN
AB	+	EQ 250MG BASE/5ML	N62117 003	MAR 27, 1978	JUN	CAHN
	TABLET; ORAL						
	KEFLET						
	@ LILLY	EQ 250MG BASE	N62745 001	DEC 01, 1986	JUL	DISC
	@	EQ 500MG BASE	N62745 002	DEC 01, 1986	JUL	DISC
	CEPHALOTHIN SODIUM						
	INJECTABLE; INJECTION						
	KEFLIN IN PLASTIC CONTAINER						
	@ LILLY	EQ 1GM BASE/VIAL	N62549 001	SEP 10, 1985	APR	DISC
	@	EQ 2GM BASE/VIAL	N62549 002	SEP 10, 1985	APR	DISC
	CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE						
	TABLET, EXTENDED RELEASE; ORAL						
	ZYRTEC-D 12 HOUR						
	+ PFIZER	5MG;120MG	N21150 001	AUG 10, 2001	AUG	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

EVOXAC

+ DAIICHI	EQ 30MG BASE	N20989	002	JAN 11, 2000	NOV	CAHN

CHLORAMPHENICOL

CAPSULE; ORAL

CHLORAMPHENICOL

@ ZENITH GOLDLINE	250MG	N62247	001	APR 28, 1980	MAY	DISC

CHLOROMYCETIN

@ PARKEDALE	50MG	N60591	001	DEC 08, 1950	MAY	DISC
@	100MG	N60591	003	DEC 08, 1950	MAY	DISC
@	250MG	N60591	002	DEC 08, 1950	MAY	DISC

MYCHEL

+ ARMENPHARM	250MG	N60851	001	JUN 20, 1967	MAY	CRLD

SOLUTION/DROPS; OPHTHALMIC

CHLORAMPHENICOL

@ AKORN	0.5%	N62042	001	AUG 31, 1981	FEB	WDRP
@ ALCON	0.5%	N62628	001	SEP 25, 1985	MAY	DISC

CHLOROPTIC

+ ALLERGAN	0.5%	N50091	001	MAR 20, 1968	MAY	CTEC

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZACHEL

@ RACHELLE	5MG	N85086	001	MAY 11, 1976	FEB	WDRP
@	10MG	N84639	001	MAY 11, 1976	FEB	WDRP
@	25MG	N85087	001	MAY 11, 1976	FEB	WDRP

CHLORDIAZEPOXIDE HCL

@ FERRANTE	5MG	N85118	001	SEP 02, 1981	FEB	WDRP
@	10MG	N85119	001	SEP 02, 1976	FEB	WDRP
@	25MG	N85120	001	SEP 02, 1976	FEB	WDRP
@ GENEVA PHARMS	5MG	N84678	001	JUN 15, 1976	JUL	DISC
@	10MG	N84041	001	JUN 15, 1976	MAY	DISC
@	25MG	N84679	002	SEP 07, 1976	MAY	DISC
@ IMPAX LABS	5MG	N86213	001	JUL 10, 1979	JUL	DISC
@	25MG	N86212	001	JUL 10, 1979	JUL	DISC
@ ROSEMONT	5MG	N84644	001	FEB 24, 1976	MAY	DISC
@	25MG	N84645	001	FEB 24, 1976	JUL	DISC

CHLORHEXIDINE GLUCONATE

TABLET; DENTAL

PERIOCHIP

>A>	+ DEXCEL PHARMA	2.5MG	N20774	001	MAY 15, 1998	DEC	CAHN
>D>	+ PERIO PRODS	2.5MG	N20774	001	MAY 15, 1998	DEC	CAHN

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

@ TEVA	EQ 150MG BASE	N87504	001	JAN 13, 1982	JUL	DISC

CHLOROTHIAZIDE
TABLET; ORAL
CHLOROTHIAZIDE

@ ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC
@ CHELSEA LABS	250MG	N86795 001	AUG 15, 1983	JUL	DISC
@ DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC

CHLORPHENIRAMINE MALEATE
INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE

@ STERIS	10MG/ML	N86096 001	OCT 09, 1979	JUL	DISC

TABLET; ORAL

@ GENEVA PHARMS	4MG	N80961 001	DEC 20, 1972	MAY	DISC
AA + ICN	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL

@ GENEVA PHARMS	12MG;75MG	N88940 001	JAN 26, 1989	SEP	DISC
DRIZE						
@ ASCHER	12MG;75MG	N88359 001	FEB 13, 1986	SEP	DISC
ORNADE						
@ SMITHKLINE BEECHAM	12MG;75MG	N12152 004	JAN 06, 1981	SEP	DISC

CHLORPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
CHLORPROMAZINE HCL

@ STERIS	25MG/ML	N80365 001	FEB 13, 1974	MAY	DISC

CHLORTHALIDONE
TABLET; ORAL
CHLORTHALIDONE

@ GENEVA PHARMS	25MG	N87380 001	MAY 01, 1981	JUL	DISC

CHLORZOXAZONE
TABLET; ORAL
CHLORZOXAZONE

@ DANBURY PHARMA	500MG	N81019 001	JUL 29, 1991	MAY	DISC

CICLOPIROX
CREAM; TOPICAL
LOPROX

+ MEDICIS	0.77%	N18748 001	DEC 30, 1982	NOV	CAHN

GEL; TOPICAL

+ MEDICIS	0.77%	N20519 001	JUL 21, 1997	NOV	CAHN

LOTION; TOPICAL

+ MEDICIS	0.77%	N19824 001	DEC 30, 1988	NOV	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN
AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN
AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN

CINOXACIN

CAPSULE; ORAL

CINOBAC

	LILLY	250MG	N18067 001	JUN 13, 1980	JUL	CTEC
+		500MG	N18067 002	JUN 13, 1980	JUL	CTEC

CINOXACIN

	@ TEVA	250MG	N73005 001	FEB 28, 1992	JUL	DISC
	@	500MG	N73006 001	FEB 28, 1992	JUL	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HCL

AB	+ PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG

CLINDAMYCIN HCL

AB	RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
AB		EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

BT	GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000	SEP	CAHN

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG

CLINDAMYCIN PHOSPHATE

	@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
	@ ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
	@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
	@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
	@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
	@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA
AP		EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA
AP		EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

	@ COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
	@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA

AB2		0.05%	N75733 001	AUG 22, 2001	AUG	NEWA
	CLOMIPRAMINE HYDROCHLORIDE					
	CAPSULE; ORAL					
	ANAFRANIL					
AB	TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
AB +		50MG	N19906 002	DEC 29, 1989	JUN	CAHN
AB		75MG	N19906 003	DEC 29, 1989	JUN	CAHN
	CLONAZEPAM					
	TABLET; ORAL					
	CLONAZEPAM					
AB	CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB		1MG	N75423 002	APR 27, 2001	APR	NEWA
AB		2MG	N75423 003	APR 27, 2001	APR	NEWA
	CLONIDINE HYDROCHLORIDE					
	INJECTABLE; INJECTION					
	DURACLON					
+	ELAN PHARMS	0.1MG/ML	N20615 001	OCT 02, 1996	SEP	CAHN
	CLORAZEPATE DIPOTASSIUM					
	CAPSULE; ORAL					
	CLORAZEPATE DIPOTASSIUM					
	@ ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
	@	7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
	@	15MG	N71779 001	JUL 14, 1987	JAN	DISC
	TABLET; ORAL					
	@ GENEVA PHARMS	3.75MG	N72512 001	MAY 11, 1990	JUL	DISC
	COLCHICINE; PROBENECID					
	TABLET; ORAL					
	PROBENECID AND COLCHICINE					
	@ IMPAX LABS	0.5MG;500MG	N83720 002	SEP 06, 1977	OCT	DISC
	CORTICOTROPIN					
	INJECTABLE; INJECTION					
	H.P. ACTHAR GEL					
BC +	QUESTCOR PHARMS	40 UNITS/ML	N08372 006	FEB 06, 1956	AUG	CAHN
BC +		80 UNITS/ML	N08372 008	FEB 06, 1956	AUG	CAHN
	CORTISONE ACETATE					
	TABLET; ORAL					
	CORTISONE ACETATE					
	@ CHELSEA LABS	25MG	N85884 001	MAY 15, 1978	MAY	DISC
	CROMOLYN SODIUM					
	AEROSOL, METERED; INHALATION					
	INTAL					
+	AVENTIS	0.8MG/INH	N18887 001	DEC 05, 1985	SEP	CAHN
	SOLUTION/DROPS; OPHTHALMIC					
	CROMOLYN SODIUM					
AT	NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA

		CYCLACILLIN						
		TABLET; ORAL						
		CYCLACILLIN						
		@ TEVA	250MG	N62895	001	AUG 04, 1988	MAY	DISC
		@	500MG	N62895	002	AUG 04, 1988	MAY	DISC
		CYCLOSPORINE						
		SOLUTION; ORAL						
>A>		CYCLOSPORINE						
>A>	AB	SIDMAK LABS	100MG/ML	N65054	001	DEC 18, 2001	DEC	NEWA
>A>		NEORAL						
>D>	+	NOVARTIS	100MG/ML	N50716	001	JUL 14, 1995	DEC	CFTG
>A>	AB +		100MG/ML	N50716	001	JUL 14, 1995	DEC	CFTG
		CYPROHEPTADINE HYDROCHLORIDE						
		TABLET; ORAL						
		CYPROHEPTADINE HCL						
		@ GENEVA PHARMS	4MG	N86808	001	FEB 24, 1981	JUL	DISC
		CYTARABINE						
		INJECTABLE; INJECTION						
		CYTARABINE						
	AP +	GENSIA SICOR PHARMS	500MG/VIAL	N75206	002	DEC 30, 1998	NOV	CRLD
		DACARBAZINE						
		INJECTABLE; INJECTION						
		DACARBAZINE						
	AP	BEDFORD	200MG/VIAL	N75812	001	JUN 15, 2001	JUN	NEWA
	AP	FAULDING	200MG/VIAL	N75940	001	OCT 18, 2001	OCT	NEWA
		DAUNORUBICIN HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		DAUNORUBICIN HCL						
	AP	SUPERGEN	EQ 5MG BASE/VIAL	N65034	001	NOV 20, 2001	NOV	NEWA
		DEFEROXAMINE MESYLATE						
		INJECTABLE; INJECTION						
		DESFERAL						
	+	NOVARTIS	2MG/VIAL	N16267	002	MAY 25, 2000	NOV	NEWA
		DELAVIRDINE MESYLATE						
		TABLET; ORAL						
		RESCRIPTOR						
		AGOURON	100MG	N20705	001	APR 04, 1997	AUG	CRLD
	+		200MG	N20705	002	JUL 14, 1999	AUG	NEWA
		DESERPIDINE; HYDROCHLOROTHIAZIDE						
		TABLET; ORAL						
		ORETICYL 25						
		@ ABBOTT	0.125MG;25MG	N12148	001	DEC 14, 1959	MAR	DISC
		ORETICYL 50						
		@ ABBOTT	0.125MG;50MG	N12148	003	DEC 14, 1959	MAR	DISC

	DESERPIDINE; HYDROCHLOROTHIAZIDE						
	TABLET; ORAL						
	ORETICYL FORTE						
	@ ABBOTT	0.25MG;25MG	N12148 002	DEC 14, 1959	MAR	DISC	
>A>	DESLORATADINE						
>A>	TABLET; ORAL						
>A>	CLARINEX						
>A>	+ SCHERING PLOUGH	5MG	N21165 001	DEC 21, 2001	DEC	NEWA	
	DESONIDE						
	OINTMENT; TOPICAL						
	DESONIDE						
AB	ALTANA	0.05%	N75751 001	MAR 12, 2001	MAR	NEWA	
	DESOXIMETASONE						
	CREAM; TOPICAL						
	TOPICORT						
AB	+ MEDICIS	0.25%	N17856 001	FEB 28, 1977	NOV	CAHN	
	TOPICORT LP						
AB	+ MEDICIS	0.05%	N18309 001	MAR 28, 1980	NOV	CAHN	
	GEL; TOPICAL						
	TOPICORT						
AB	+ MEDICIS	0.05%	N18586 001	MAR 29, 1982	NOV	CAHN	
	OINTMENT; TOPICAL						
	@ MEDICIS	0.05%	N18594 001	JAN 17, 1985	NOV	CAHN	
AB	+	0.25%	N18763 001	SEP 30, 1983	NOV	CAHN	
	DEXAMETHASONE						
	TABLET; ORAL						
	DEXAMETHASONE						
	@ DANBURY PHARMA	0.75MG	N80968 001	MAY 03, 1973	MAY	DISC	
	DEXAMETHASONE SODIUM PHOSPHATE						
	INJECTABLE; INJECTION						
	DEXAMETHASONE SODIUM PHOSPHATE						
	@ DELL LABS	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP	
	@ GENSIA SICOR PHARMS	EQ 4MG PHOSPHATE/ML	N81125 001	AUG 31, 1990	MAY	DISC	
	OINTMENT; OPHTHALMIC						
	DECADRON						
	@ MERCK	EQ 0.05% PHOSPHATE	N11977 001	SEP 02, 1959	MAY	DISC	
	MAXIDEX						
	+ ALCON	EQ 0.05% PHOSPHATE	N83342 001	OCT 23, 1973	MAY	CTEC	
	SOLUTION/DROPS; OTIC						
	DEXAMETHASONE SODIUM PHOSPHATE						
	@ AKORN	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP	
	DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE						
	SOLUTION/DROPS; OPHTHALMIC						
	NEODECADRON						
	+ MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001	JUL 06, 1959	MAY	CTEC	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

@	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986	MAY	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN
@		0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	MAY	DISC

SUSPENSION/DROPS; OPHTHALMIC

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544 001	OCT 29, 1984	FEB	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

FOCALIN

	NOVARTIS	2.5MG	N21278 001	NOV 13, 2001	NOV	NEWA
		5MG	N21278 002	NOV 13, 2001	NOV	NEWA
+		10MG	N21278 003	NOV 13, 2001	NOV	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	BARR	5MG	N40361 001	JAN 31, 2001	JAN	NEWA
AA		10MG	N40361 002	JAN 31, 2001	JAN	NEWA

DEXTROSTAT

AA +	SHIRE RICHWOOD	10MG	N84051 002	MAY 29, 1975	JAN	CFTG

DIAZEPAM

GEL; RECTAL

DIASTAT

+	XCEL PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997	JUL	CAHN
		5MG/ML	N20648 002	JUL 29, 1997	JUL	CAHN
		10MG/2ML	N20648 003	JUL 29, 1997	JUL	CAHN
		15MG/3ML	N20648 004	JUL 29, 1997	JUL	CAHN
+		20MG/4ML	N20648 005	JUL 29, 1997	JUL	CAHN

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB	EON	50MG	N75582 001	FEB 23, 2001	FEB	NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+	BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000	MAR	CAHN

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>A> AB	MYLAN	100MG	N76152 001	DEC 13, 2001	DEC	NEWA

		DICLOXACILLIN SODIUM						
		CAPSULE; ORAL						
		DYCILL						
		@ SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC	
		@	EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC	
		DICYCLOMINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		DICYCLOMINE HCL						
		@ HALSEY	10MG	N84505 001	OCT 21, 1986	MAY	DISC	
		INJECTABLE; INJECTION						
		BENTYL PRESERVATIVE FREE						
>D>	AP	AVENTIS PHARMS	10MG/ML	N08370 002	OCT 15, 1984	DEC	CRLD	
>A>	AP	+	10MG/ML	N08370 002	OCT 15, 1984	DEC	CRLD	
		DICYCLOMINE HCL						
		@ STERIS	10MG/ML	N80614 001	FEB 11, 1986	JUL	DISC	
		DIETHYLPROPION HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		TENUATE DOSPAN						
		+ AVENTIS PHARMS	75MG	N12546 001	NOV 07, 1960	JUL	CTEC	
		TEPANIL TEN-TAB						
		@ 3M	75MG	N17956 001	MAY 25, 1977	JUL	DISC	
		DILTIAZEM HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		DILTIAZEM HCL						
	AB2	MYLAN	120MG	N75124 002	MAR 18, 1998	MAR	CTEC	
		INJECTABLE; INJECTION						
	AP	INTL MEDICATION	5MG/ML	N75749 001	NOV 21, 2001	NOV	NEWA	
		DIPHENHYDRAMINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		DIPHENHYDRAMINE HCL						
		@ CHELSEA LABS	50MG	N85083 001	JUN 29, 1976	MAY	DISC	
		@ NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP	
		@	50MG	N86544 001	FEB 08, 1979	FEB	WDRP	
		INJECTABLE; INJECTION						
		DIPHENHYDRAMINE HCL PRESERVATIVE FREE						
		@ AM PHARM PARTNERS	50MG/ML	N80586 002	JAN 10, 1973	JUL	DISC	
		DISULFIRAM						
		TABLET; ORAL						
		ANTABUSE						
		ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	JAN	CAHN	
		+	500MG	N88483 001	DEC 08, 1983	JAN	CAHN	
		@ SIDMAK LABS	250MG	N07883 003	NOV 03, 1970	MAR	CAHN	
		@	500MG	N07883 002	JUN 01, 1953	MAR	CAHN	

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE						
AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001	JUN	NEWA	
AB		EQ 2MG BASE	N75750 002	JUN 08, 2001	JUN	NEWA	
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001	JUN	NEWA	
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001	JUN	NEWA	
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA	
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA	
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA	
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA	

DOXYCYCLINE

FOR SUSPENSION; ORAL

	DOXYCHEL						
	@ RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP	
	VIBRAMYCIN						
+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC	

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXY-LEMMON						
	@ TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC	
	@	EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC	
	DOXYCYCLINE HYCLATE						
	@ CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC	
	@	EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC	
AB	HALSEY	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN	
	@	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC	
AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN	
	@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC	

CAPSULE, COATED PELLETS; ORAL

	@ SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC	

INJECTABLE; INJECTION

	DOXYCHEL HYCLATE						
	@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP	
	DOXYCYCLINE						
	@ BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC	
	@	EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY	DISC	
	@ ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC	
	@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC	
	DOXYCYCLINE HYCLATE						
	@ LEDERLE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY	DISC	
	@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY	DISC	

TABLET; ORAL

	DOXY-LEMMON						
	@ TEVA	EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY	DISC	
	DOXYCYCLINE HYCLATE						
AB	HALSEY	EQ 100MG BASE	N62269 001	SEP 03, 1980	JUN	CAHN	
AB		EQ 100MG BASE	N62269 002	NOV 08, 1982	JUN	CAHN	
	@	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC	
	DOXYCYCLINE HYLATE						

DOXYCYCLINE HYCLATE
TABLET; ORAL
DOXYCYCLINE HYLATE

@	HALSEY	EQ 50MG BASE	N62269 003	SEP 03, 1980	JUN	CAHN
	PERIOSTAT					
+	COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001	FEB	NEWA

DROPERIDOL; FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

@	ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72027 001	APR 13, 1989	JUL	DISC

DROSPIRENONE; ETHINYL ESTRADIOL
TABLET; ORAL-28
YASMIN

+	BERLEX LABS	3MG;0.03MG	N21098 001	MAY 11, 2001	MAY	NEWA

DUTASTERIDE
CAPSULE; ORAL
DUTASTERIDE

+	GLAXOSMITHKLINE	0.5MG	N21319 001	NOV 20, 2001	NOV	NEWA

DYCLONINE HYDROCHLORIDE
SOLUTION; TOPICAL
DYCLONE

@	ASTRAZENECA	0.5%	N09925 002	JUN 13, 1974	AUG	DISC
@		1%	N09925 001	AUG 03, 1955	AUG	DISC

ENALAPRIL MALEATE
TABLET; ORAL
ENALAPRIL MALEATE

AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN	NEWA
AB		5MG	N75657 002	JAN 23, 2001	JAN	NEWA
AB		10MG	N75657 003	JAN 23, 2001	JAN	NEWA
AB		20MG	N75657 004	JAN 23, 2001	JAN	NEWA
AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR	NEWA
AB		5MG	N75178 001	MAR 23, 2001	MAR	NEWA
AB		10MG	N75178 003	MAR 23, 2001	MAR	NEWA
AB		20MG	N75178 004	MAR 23, 2001	MAR	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	5MG;12.5MG	N75909 001	OCT 15, 2001	OCT	NEWA
AB		10MG;25MG	N75909 002	OCT 15, 2001	OCT	NEWA
AB	EON	5MG;12.5MG	N76116 001	SEP 19, 2001	SEP	NEWA
AB		10MG;25MG	N76116 002	SEP 19, 2001	SEP	NEWA
AB	MYLAN	5MG;12.5MG	N75624 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75624 002	SEP 18, 2001	SEP	NEWA
AB	TARO PHARM INDS	5MG;12.5MG	N75788 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75788 002	SEP 18, 2001	SEP	NEWA
AB	TEVA	5MG;12.5MG	N75727 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75727 002	SEP 18, 2001	SEP	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
VASERETIC

AB	MERCK RES LABS	5MG;12.5MG	N19221 003	JUL 12, 1995	SEP	CFTG
AB	+	10MG;25MG	N19221 001	OCT 31, 1986	SEP	CFTG

ENFLURANE
LIQUID; INHALATION
ENFLURANE

AN	MINRAD	99.9%	N74396 001	JUL 29, 1994	FEB	CAHN

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

+	AVENTIS	30MG/0.3ML	N20164 001	MAR 29, 1993	APR	CAHN
+		40MG/0.4ML	N20164 002	JAN 30, 1998	APR	CAHN
+		60MG/0.6ML	N20164 003	MAR 27, 1998	APR	CAHN
+		80MG/0.8ML	N20164 004	MAR 27, 1998	APR	CAHN
+		90MG/0.6ML	N20164 006	JUN 02, 2000	APR	CAHN
+		100MG/ML	N20164 005	MAR 27, 1998	APR	CAHN
+		120MG/0.8ML	N20164 007	JUN 02, 2000	APR	CAHN
+		150MG/ML	N20164 008	JUN 02, 2000	APR	CAHN

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	ASTRAZENECA	0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;1%	N17751 006	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N21384 001	AUG 30, 1976	SEP	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
CITANEST FORTE

@	ASTRAZENECA	0.005MG/ML;4%	N14763 008	JUN 29, 1970	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001	JUN 29, 1970	SEP	NEWA

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	DENTSPLY PHARM	0.005MG/ML;0.5%	N17751 004	AUG 30, 1976	APR	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE

@	INTL MEDICATION	0.01MG/ML;1%	N86402 001	FEB 04, 1980	JUL	DISC
@	STERIS	0.01MG/ML;1%	N80377 003	FEB 20, 1974	JUL	DISC
@		0.01MG/ML;2%	N80377 004	FEB 20, 1974	JUL	DISC

LIDOCATON

@	PHARMATON	0.02MG/ML;2%	N84728 001	AUG 17, 1983	FEB	WDRP

XYLOCAINE W/ EPINEPHRINE

@	ASTRAZENECA	0.01MG/ML;2%	N06488 003	NOV 19, 1948	SEP	DISC
+	DENTSPLY PHARM	0.01MG/ML;2%	N21381 001	NOV 19, 1948	SEP	NEWA

	0.02MG/ML;2%	N21381 002	NOV 19, 1948	SEP	NEWA	

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL						
TEVETEN HCT						
UNIMED PHARMS	600MG;12.5MG	N21268 001	NOV 01, 2001	NOV	NEWA	
+	600MG;25MG	N21268 002	NOV 01, 2001	NOV	NEWA	

ERGOCALCIFEROL

CAPSULE; ORAL						
VITAMIN D						
@ IMPAX LABS	50,000 IU	N80951 001	JUL 13, 1973	FEB	DISC	

ERGOLOID MESYLATES

TABLET; ORAL						
ERGOLOID MESYLATES						
@ DANBURY PHARMA	1MG	N87244 001	AUG 16, 1982	JUL	DISC	
TABLET; SUBLINGUAL						
@ DANBURY PHARMA	1MG	N87183 001	APR 16, 1981	JUL	DISC	

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)						
INVANZ						
+ MERCK	EQ 1GM BASE/VIAL	N21337 001	NOV 21, 2001	NOV	NEWA	

ERYTHROMYCIN

SOLUTION; TOPICAL						
ERYTHROMYCIN						
@ CLAY PARK	2%	N63038 001	JAN 11, 1991	APR	DISC	
AT	2%	N63038 001	JAN 11, 1991	MAY	CMFD	
TABLET, DELAYED RELEASE; ORAL						
E-BASE						
@ BARR	333MG	N63028 001	MAY 15, 1990	APR	DISC	
ILOTYCIN						
@ DISTA	250MG	N61910 001	FEB 27, 1975	MAY	DISC	

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL						
ERYTHROMYCIN ESTOLATE						
+ BARR	EQ 250MG BASE	N62162 002	JUN 15, 1981	MAY	CTEC	
@ DANBURY PHARMA	EQ 250MG BASE	N62087 001	JUN 14, 1979	APR	DISC	
ILOSONE						
@ LILLY	EQ 125MG BASE	N61897 001	JAN 06, 1975	MAY	DISC	
@	EQ 250MG BASE	N61897 002	JAN 06, 1975	MAY	DISC	
FOR SUSPENSION; ORAL						
@ DISTA	EQ 125MG BASE/5ML	N61893 001	JAN 06, 1975	MAY	DISC	
SUSPENSION/DROPS; ORAL						
@ LILLY	EQ 100MG BASE/ML	N61894 003	JAN 07, 1975	APR	DISC	
TABLET; ORAL						
@ LILLY	EQ 500MG BASE	N61896 001	JAN 03, 1975	APR	DISC	
TABLET, CHEWABLE; ORAL						
@ DISTA	EQ 125MG BASE	N61895 001	JAN 03, 1975	MAY	DISC	
@	EQ 250MG BASE	N61895 002	JAN 03, 1975	MAY	DISC	

ERYTHROMYCIN ETHYLSUCCINATE
TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

@	BARR	EQ 400MG BASE	N62256	001	APR 28, 1980	MAY	DISC

ERYTHROMYCIN GLUCEPTATE
INJECTABLE; INJECTION
ILOTYCIN GLUCEPTATE

@	DISTA	EQ 250MG BASE/VIAL	N50370	001	JUN 23, 1964	JUL	DISC
@		EQ 500MG BASE/VIAL	N50370	002	JUN 23, 1964	JUL	DISC
@		EQ 1GM BASE/VIAL	N50370	003	JUN 23, 1964	JUL	DISC

ERYTHROMYCIN STEARATE
TABLET; ORAL
ERYTHROMYCIN STEARATE

@	BARR	EQ 500MG BASE	N63179	001	MAY 15, 1990	MAY	DISC
@	ZENITH GOLDLINE	EQ 250MG BASE	N61461	001	SEP 04, 1971	MAY	DISC
@		EQ 500MG BASE	N61461	002	APR 11, 1980	MAY	DISC

WYAMYCIN S

@	WYETH AYERST	EQ 250MG BASE	N61675	001	OCT 06, 1972	APR	DISC
@		EQ 500MG BASE	N61675	002	JUL 13, 1973	APR	DISC

ESOMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED REL PELLETS; ORAL
NEXIUM

+	ASTRAZENECA	EQ 20MG BASE	N21153	001	FEB 20, 2001	FEB	NEWA
+		EQ 40MG BASE	N21153	002	FEB 20, 2001	FEB	NEWA

ESTRADIOL VALERATE
INJECTABLE; INJECTION
DELESTROGEN

+	KING PHARMS	10MG/ML	N09402	002	AUG 18, 1962	AUG	CAHN
AO +		20MG/ML	N09402	004	JUN 23, 1961	AUG	CAHN
AO +		40MG/ML	N09402	003	FEB 24, 1961	AUG	CAHN

ESTRADIOL; NORETHINDRONE ACETATE
FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870	001	AUG 07, 1998	MAR	CAHN
+		0.05MG/24HR;0.25MG/24HR	N20870	002	AUG 07, 1998	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET; ORAL-28
PREMPRO

+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20527	001	NOV 17, 1995	JAN	CTNA
+		0.625MG;0.625MG;5MG;5MG	N20527	003	JAN 09, 1998	JAN	CTNA

PREMPRO (PREMARIN;CYCRIN)

+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303	001	DEC 30, 1994	JAN	CTNA

ESTROGENS, ESTERIFIED

TABLET; ORAL

ESTRATAB

@ SOLVAY — 0.3MG — N86715 001 APR 08, 1981 JUL DISC

@ — 0.625MG — N83209 001 JUN 17, 1977 JUL DISC

MENEST

\+ MONARCH PHARMS — 0.3MG — N84951 001 SEP 28, 1977 JUL CTEC

0.625MG — N84948 001 SEP 28, 1977 JUL CTEC

ESTROPIPATE

TABLET; ORAL

ORTHO-EST

AB WOMEN FIRST HLTHCARE — 0.75MG — N89567 001 FEB 27, 1991 JAN CAHN

AB — 1.5MG — N89582 001 JUL 17, 1991 JAN CAHN

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HCL

AB BARR — 400MG — N76057 001 NOV 26, 2001 NOV NEWA

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

\+ ORGANON INC — 0.015MG;0.12MG — N21187 001 OCT 03, 2001 OCT NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB \+ WYETH AYERST — 0.02MG;0.1MG — N20683 001 MAR 27, 1997 APR CTEC

AVIANE-21

AB DURAMED — 0.02MG;0.1MG — N75796 002 APR 30, 2001 APR NEWA

TABLET; ORAL-21, ORAL-28

ENPRESSE-21

AB DURAMED — 0.03MG,0.04MG;0.03MG,0.05MG; 0.075MG,0.125MG — N75809 001 JUL 16, 2001 JUL NEWA

TABLET; ORAL-28

ALESSE

AB WYETH AYERST — 0.02MG;0.1MG — N20683 002 MAR 27, 1997 APR CTEC

AVIANE-28

AB DURAMED — 0.02MG;0.1MG — N75796 001 APR 30, 2001 APR NEWA

ENPRESSE-28

AB DURAMED — 0.03MG,0.04MG;0.03MG,0.05MG; 0.075MG,0.125MG — N75809 002 JUL 16, 2001 JUL NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

\+ JOHNSON RW — 0.02MG/24HR;0.015MG/24HR — N21180 001 NOV 20, 2001 NOV NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

LOESTRIN FE 1.5/30

AB	+ PARKE DAVIS	0.03MG;1.5MG	N17355 001	APR 30, 1973	FEB	CFTG

LOESTRIN FE 1/20

AB	+ PARKE DAVIS	0.02MG;1MG	N17354 001	APR 30, 1973	FEB	CFTG

MICROGESTIN FE 1.5/30

AB	WATSON LABS	0.03MG;1.5MG	N75548 001	FEB 05, 2001	FEB	NEWA

MICROGESTIN FE 1/20

AB	WATSON LABS	0.02MG;1MG	N75647 001	FEB 05, 2001	FEB	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB	DURAMED	0.03MG;0.3MG	N75840 001	NOV 30, 2001	NOV	NEWA

TABLET; ORAL-28

AB	DURAMED	0.03MG;0.3MG	N75840 002	NOV 30, 2001	NOV	NEWA

ETHOSUXIMIDE

SYRUP; ORAL

ZARONTIN

AA	+ PARKE DAVIS	250MG/5ML	N80258 001	FEB 13, 1974	JAN	CRLD

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

	@ DENTSPLY PHARM	0.5%	N17751 003	AUG 30, 1976	APR	CAHN
	+	1%	N17751 005	AUG 30, 1976	APR	CAHN

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB	ANDRX PHARM	400MG	N75829 001	NOV 30, 2001	NOV	NEWA
AB		500MG	N75829 002	NOV 30, 2001	NOV	NEWA
AB	TEVA	400MG	N75665 003	FEB 05, 2001	FEB	NEWA

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

AB	GENPHARM	50MG	N75635 001	SEP 19, 2001	SEP	NEWA

VEPESID

AB	+ BRISTOL	50MG	N19557 001	DEC 30, 1986	SEP	CFTG

INJECTABLE; INJECTION

ETOPOSIDE

	@ PIERRE FABRE	20MG/ML	N74813 001	JUL 09, 1997	SEP	WDAG

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

	@ BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906 001	FEB 27, 1998	JUN	DISC
	@	EQ 1GM BASE/VIAL	N20906 002	FEB 27, 1998	JUN	NEWA

FAMCICLOVIR

TABLET; ORAL

FAMVIR

		NOVARTIS	125MG	N20363 003	DEC 11, 1995	JAN	CAHN
			250MG	N20363 001	APR 26, 1996	JAN	CAHN
	+		500MG	N20363 002	JUN 29, 1994	JAN	CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

	AP	ABBOTT	10MG/ML	N75870 001	NOV 23, 2001	NOV	NEWA
	AP		10MG/ML	N75905 001	NOV 23, 2001	NOV	NEWA
	AP	AM PHARM PARTNERS	10MG/ML	N75709 001	APR 16, 2001	APR	NEWA
	AP	APOTHECON	10MG/ML	N75707 001	APR 16, 2001	APR	NEWA
	@		10MG/ML	N75707 001	APR 16, 2001	MAY	DISC
	AP	BEDFORD	10MG/ML	N75651 001	APR 16, 2001	APR	NEWA
	AP		10MG/ML	N75684 001	APR 16, 2001	APR	NEWA
	AP	ESI LEDERLE	10MG/ML	N75488 001	APR 16, 2001	APR	NEWA
	AP	FAULDING	10MG/ML	N75705 001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE

	AP	AM PHARM PARTNERS	10MG/ML	N75813 001	APR 16, 2001	APR	NEWA
	AP	APOTHECON	10MG/ML	N75708 001	APR 16, 2001	APR	NEWA
	@		10MG/ML	N75708 001	APR 16, 2001	MAY	DISC
	AP	BEDFORD	10MG/ML	N75622 001	APR 16, 2001	APR	NEWA
	AP	BEN VENUE	10MG/ML	N75825 001	APR 17, 2001	APR	NEWA
	AP	ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001	APR	NEWA
	AP	FAULDING	10MG/ML	N75669 001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	AP	BAXTER HLTHCARE	0.4MG/ML	N75591 001	MAY 10, 2001	MAY	NEWA
>A>	AP	ABBOTT	0.4MG/ML	N75729 001	DEC 17, 2001	DEC	NEWA

PEPCID

	AP +	MERCK	10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE

	AP +	MERCK	10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

	AP +	MERCK	0.4MG/ML	N20249 001	FEB 18, 1994	MAY	CFTG

TABLET; ORAL

FAMOTIDINE

	AB	CARLSBAD	20MG	N75805 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75805 002	APR 16, 2001	APR	NEWA
	AB	DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA
	AB		40MG	N75062 001	APR 16, 2001	APR	NEWA
	AB	DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75718 002	APR 16, 2001	APR	NEWA
	AB	EON	20MG	N75793 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75793 002	APR 16, 2001	APR	NEWA
	AB	GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75302 002	APR 16, 2001	APR	NEWA
	AB	GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA
	AB		40MG	N75457 002	APR 18, 2001	APR	NEWA
	AB	INVAMED	20MG	N75607 001	MAY 10, 2001	MAY	NEWA
	AB		40MG	N75607 002	MAY 10, 2001	MAY	NEWA

>A>	AB	MUTUAL PHARM	20MG	N75639 002	DEC 12, 2001	DEC	NEWA
>A>	AB		40MG	N75639 001	DEC 12, 2001	DEC	NEWA
	AB	MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75704 002	APR 16, 2001	APR	NEWA
	AB	PUREPAC PHARM	20MG	N75650 001	SEP 14, 2001	SEP	NEWA
	AB		40MG	N75650 002	SEP 14, 2001	SEP	NEWA
	AB	TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75311 002	APR 16, 2001	APR	NEWA
	AB	TORPHARM	20MG	N75611 001	JUL 23, 2001	JUL	NEWA
	AB		40MG	N75611 002	JUL 23, 2001	JUL	NEWA
	AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75786 002	APR 16, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75511 002	APR 16, 2001	APR	NEWA
		PEPCID					
	AB	MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
	AB +		40MG	N19462 002	OCT 15, 1986	APR	CFTG

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

	ASTRAZENECA	2.5MG	N19834 004	SEP 22, 1994	OCT	CRLD
		5MG	N19834 001	JUL 25, 1991	OCT	CRLD

FENOFIBRATE

TABLET; ORAL

TRICOR

	ABBOTT	54MG	N21203 001	SEP 04, 2001	AUG	NEWA
	+	160MG	N21203 003	SEP 04, 2001	SEP	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC

	ALZA	1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
		1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
		2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

>D>		FENTANYL CITRATE					
>D>	AP	ABBOTT	EQ 0.05MG BASE/ML	N70636 001	APR 30, 1990	DEC	DISC
>A>		@	EQ 0.05MG BASE/ML	N70636 001	APR 30, 1990	DEC	DISC
>D>	AP		EQ 0.05MG BASE/ML	N70637 001	APR 30, 1990	DEC	DISC
>A>		@	EQ 0.05MG BASE/ML	N70637 001	APR 30, 1990	DEC	DISC
		FENTANYL CITRATE PRESERVATIVE FREE					
		@ MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	ALPHAPHARM	50MG	N75442 001	JUL 31, 2001	JUL	NEWA
AB		100MG	N75442 002	JUL 31, 2001	JUL	NEWA
AB		150MG	N75442 003	JUL 31, 2001	JUL	NEWA

FLECAINIDE ACETATE
TABLET; ORAL
TAMBOCOR

AB		3M	50MG	N18830 004	AUG 23, 1988	JUL	CFTG
AB			100MG	N18830 001	OCT 31, 1985	JUL	CFTG
AB	+		150MG	N18830 003	JUN 03, 1988	JUL	CFTG

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

AP		AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001	FEB	NEWA

FLUDEOXYGLUCOSE, F-18
INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18

	+	DOWNSTATE CLINCL	4-90mCi/ML	N20306 002	SEP 25, 2001	SEP	NEWA

FLUNISOLIDE
SPRAY, METERED; NASAL
NASALIDE

BX	+	IVAX RES	0.025MG/SPRAY	N18148 001	SEP 24, 1981	NOV	CAHN

NASAREL

BX	+	IVAX RES	0.025MG/SPRAY	N20409 001	MAR 08, 1995	NOV	CAHN

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

	@	CLAY PARK	0.01%	N86810 001	MAR 04, 1982	APR	DISC
	@		0.025%	N86811 001	MAR 04, 1982	APR	DISC

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR

	@	MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	JUN 11, 1963	MAY	DISC

FLUOROMETHOLONE
SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP

AB		NOVARTIS	0.1%	N70185 001	FEB 27, 1986	FEB	CAHN

FLUOROURACIL
CREAM; TOPICAL
CARAC

	+	DERMIK LABS	0.5%	N20985 001	OCT 27, 2000	MAY	CTNA

FLUOXETINE HYDROCHLORIDE
CAPSULE; ORAL
FLUOXETINE

AB		BARR	EQ 20MG BASE	N74803 001	AUG 02, 2001	AUG	NEWA
AB		DR REDDYS LABS LTD	EQ 40MG BASE	N75465 003	AUG 02, 2001	AUG	NEWA
AB		GENEVA PHARMS	EQ 10MG BASE	N75049 001	AUG 02, 2001	AUG	NEWA

PROZAC

AB		LILLY	EQ 10MG BASE	N18936 006	DEC 23, 1992	AUG	CFTG

AB		EQ 20MG BASE	N18936 001	DEC 29, 1987	AUG	CFTG
AB	+	EQ 40MG BASE	N18936 003	JUN 15, 1999	AUG	CFTG
	CAPSULE, DELAYED REL PELLETS; ORAL					
	PROZAC WEEKLY					
	+ LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001	FEB	NEWA
	SOLUTION; ORAL					
	FLUOXETINE					
AT	TEVA	EQ 20MG BASE/5ML	N75506 001	AUG 02, 2001	AUG	NEWA
	PROZAC					
AT	+ LILLY	EQ 20MG BASE/5ML	N20101 001	APR 24, 1991	AUG	CFTG
	TABLET; ORAL					
	FLUOXETINE HCL					
AB	ALPHAPHARM	EQ 10MG BASE	N75755 001	AUG 02, 2001	AUG	NEWA
	+	EQ 20MG BASE	N75755 002	AUG 02, 2001	AUG	NEWA
	PROZAC					
AB	+ LILLY	EQ 10MG BASE	N20974 001	MAR 09, 1999	AUG	CFTG

FLUPHENAZINE DECANOATE

	INJECTABLE; IM-SC					
	FLUPHENAZINE DECANOATE					
AO	APOTEX	25MG/ML	N75918 001	AUG 17, 2001	AUG	NEWA

FLUPHENAZINE HYDROCHLORIDE

	TABLET; ORAL					
	PERMITIL					
	Ø SCHERING	10MG	N12034 006	JAN 07, 1964	OCT	DISC

FLURAZEPAM HYDROCHLORIDE

	CAPSULE; ORAL					
	FLURAZEPAM HCL					
	Ø CHELSEA LABS	15MG	N72368 001	MAR 30, 1989	JUL	DISC
	Ø PUREPAC PHARM	15MG	N71927 001	SEP 09, 1987	JUL	DISC
	Ø	30MG	N71551 001	SEP 09, 1987	JUL	DISC

FLURBIPROFEN

	TABLET; ORAL					
	FLURBIPROFEN					
AB	CARACO	50MG	N75058 001	APR 27, 2001	APR	NEWA
AB		100MG	N75058 002	APR 27, 2001	APR	NEWA

FLUTAMIDE

	CAPSULE; ORAL					
	EULEXIN					
AB	+ SCHERING	125MG	N18554 001	JAN 27, 1989	SEP	CFTG
	FLUTAMIDE					
AB	BARR	125MG	N75820 001	SEP 18, 2001	SEP	NEWA
AB	EON	125MG	N75818 001	SEP 18, 2001	SEP	NEWA
AB	IVAX PHARMS	125MG	N75780 001	SEP 19, 2001	OCT	NEWA
AB	TEVA	125MG	N75298 001	SEP 18, 2001	SEP	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

AB	BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA
AB		50MG	N75897 002	JAN 25, 2001	JAN	NEWA
AB		100MG	N75897 003	JAN 25, 2001	JAN	NEWA
AB	GENPHARM	50MG	N75950 001	OCT 15, 2001	OCT	NEWA
AB		100MG	N75950 002	OCT 15, 2001	OCT	NEWA
AB	INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
AB		50MG	N75887 002	JAN 05, 2001	JAN	NEWA
AB		100MG	N75887 003	JAN 05, 2001	JAN	NEWA
AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
AB		50MG	N75899 002	JAN 17, 2001	JAN	NEWA
AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
AB	TORPHARM	25MG	N75902 001	MAY 07, 2001	MAY	NEWA
AB		50MG	N75902 002	MAY 07, 2001	MAY	NEWA
AB		100MG	N75902 003	MAY 07, 2001	MAY	NEWA
AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA

FOLIC ACID
TABLET; ORAL
FOLIC ACID

@	IMPAX LABS	1MG	N80686 001	JUL 20, 1973	OCT	DISC

FOLLITROPIN ALFA
INJECTABLE; INJECTION
GONAL-F

+	SERONO	1,200 IU/VIAL	N20378 004	FEB 28, 2001	AUG	NEWA

>A> FONDAPARINUX SODIUM
>A> INJECTABLE; SUBCUTANEOUS
>A> ARIXTRA

>A> +	FONDA BV	2.5MG/0.5ML	N21345 001	DEC 07, 2001	DEC	NEWA

FORMOTEROL FUMARATE
CAPSULE; INHALATION
FORADIL

+	NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA

FROVATRIPTAN SUCCINATE
TABLET; ORAL
FROVA

+	ELAN PHARMS	EQ 2.5MG BASE	N21006 001	NOV 08, 2001	NOV	NEWA

	GABAPENTIN						
	CAPSULE; ORAL						
	NEURONTIN						
JAN NEWA	PFIZER	100MG	N20235 001	DEC 30, 1993	MAR	CAHN	
JAN NEWA		300MG	N20235 002	DEC 30, 1993	MAR	CAHN	
JAN NEWA	+	400MG	N20235 003	DEC 30, 1993	MAR	CAHN	
OCT NEWA	SOLUTION; ORAL						
OCT NEWA	+ PARKE DAVIS	250MG/5ML	N21129 001	MAR 02, 2000	OCT	CMFD	
JAN NEWA							
JAN NEWA	**GALANTAMINE HYDROBROMIDE**						
JAN NEWA	SOLUTION; ORAL						
JAN NEWA	REMINYL						
JAN NEWA	+ JANSSEN	4MG/ML	N21224 001	JUN 22, 2001	JUN	NEWA	
JAN NEWA	TABLET; ORAL						
MAY NEWA	JANSSEN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA	
MAY NEWA		EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA	
MAY NEWA	+	EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA	
APR NEWA							
APR NEWA	**GEMFIBROZIL**						
APR NEWA	TABLET; ORAL						
MAR NEWA	GEMFIBROZIL						
MAR NEWA	AB GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995	JAN	CAHN	
MAR NEWA							
	GENTAMICIN SULFATE						
	CREAM; TOPICAL						
	GENTAMICIN SULFATE						
	@ BAUSCH AND LOMB	EQ 0.1% BASE	N64056 001	APR 29, 1994	MAY	DISC	
OCT DISC	INJECTABLE; INJECTION						
	@ GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149 001	NOV 21, 1991	MAY	DISC	
	@	EQ 40MG BASE/ML	N63106 002	NOV 21, 1991	APR	DISC	
	@ STERIS	EQ 10MG BASE/ML	N62318 002	AUG 20, 1981	APR	DISC	
	@	EQ 40MG BASE/ML	N62318 001	JUN 02, 1981	APR	DISC	
AUG NEWA	U-GENCIN						
	@ PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP	
	@	EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP	
	INJECTABLE; INTRATHECAL						
	GARAMYCIN						
DEC NEWA	@ SCHERING	EQ 2MG BASE/ML	N50505 001	OCT 01, 1979	APR	DISC	
	OINTMENT; OPHTHALMIC						
	GENTACIDIN						
	AT NOVARTIS	EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN	
	@	EQ 0.3% BASE	N62501 001	JUL 26, 1984	MAY	DISC	
FEB NEWA	OINTMENT; TOPICAL						
	GARAMYCIN						
	@ SCHERING	EQ 0.1% BASE	N60463 001	MAR 15, 1966	SEP	DISC	
	GENTAMICIN						
	AT + CLAY PARK	EQ 0.1% BASE	N62351 001	FEB 18, 1982	SEP	CTEC	
NOV NEWA	GENTAMICIN SULFATE						
	@ BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001	APR 29, 1994	MAY	DISC	
	SOLUTION/DROPS; OPHTHALMIC						
	GENTACIDIN						
	AT NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN	

	GENTAMICIN SULFATE					
	SOLUTION/DROPS; OPHTHALMIC					
	GENTAK					
AT	AKORN	EQ 0.3% BASE	N64163 001	OCT 12, 2001	OCT	NEWA
	GENTAMICIN SULFATE					
	@ ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001	NOV 25, 1985	APR	DISC
	GLIPIZIDE					
	TABLET; ORAL					
	GLIPIZIDE					
AB	GENEVA PHARMS TECH	5MG	N74542 001	JUN 20, 1995	JAN	CAHN
AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN
AB	TORPHARM	5MG	N75795 001	JUN 13, 2001	JUN	NEWA
AB		10MG	N75795 002	JUN 13, 2001	JUN	NEWA
	GLUTETHIMIDE					
	TABLET; ORAL					
	GLUTETHIMIDE					
	@ CELLTECH PHARMS	500MG	N85171 001	DEC 22, 1976	SEP	DISC
	GLYCOPYRROLATE					
	INJECTABLE; INJECTION					
	GLYCOPYRROLATE					
	@ GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC
	TABLET; ORAL					
	ROBINUL					
+	FIRST HORIZON	1MG	N12827 001	AUG 11, 1961	AUG	CAHN
	ROBINUL FORTE					
+	FIRST HORIZON	2MG	N12827 002	AUG 11, 1961	AUG	CAHN
	GRANISETRON HYDROCHLORIDE					
	SOLUTION; ORAL					
	KYTRIL					
+	ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	NEWA
	GRISEOFULVIN, MICROCRYSTALLINE					
	SUSPENSION; ORAL					
	GRIFULVIN V					
+	J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD
	@ JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC
	GRISEOFULVIN, ULTRAMICROCRYSTALLINE					
	TABLET; ORAL					
	GRISACTIN ULTRA					
	@ WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC
	@	250MG	N62178 002	MAR 13, 1980	APR	DISC
	ULTRAGRIS-165					
	@ SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC
	ULTRAGRIS-330					
	@ SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992	MAY	DISC

HALOPERIDOL

TABLET; ORAL

HALDOL

>D>	AB		JOHNSON RW	0.5MG	N15921	001	APR 12, 1967	DEC	CAHN
>D>	AB			1MG	N15921	002	APR 12, 1967	DEC	CAHN
>D>	AB			2MG	N15921	003	APR 12, 1967	DEC	CAHN
>D>	AB	+		5MG	N15921	004	APR 16, 1974	DEC	CAHN
>D>	AB			10MG	N15921	005	APR 16, 1974	DEC	CAHN
>D>	AB	+		20MG	N15921	006	FEB 02, 1982	DEC	CAHN
>A>	AB		ORTHO MCNEIL	0.5MG	N15921	001	APR 12, 1967	DEC	CAHN
>A>	AB			1MG	N15921	002	APR 12, 1967	DEC	CAHN
>A>	AB			2MG	N15921	003	APR 12, 1967	DEC	CAHN
>A>	AB	+		5MG	N15921	004	APR 16, 1974	DEC	CAHN
>A>	AB			10MG	N15921	005	APR 16, 1974	DEC	CAHN
>A>	AB	+		20MG	N15921	006	FEB 02, 1982	DEC	CAHN

HALOPERIDOL

			@ DANBURY PHARMA	1MG	N70982	001	MAR 06, 1987	JUL	DISC
			@ ROXANE	0.5MG	N71128	001	FEB 17, 1987	AUG	DISC
			@	1MG	N71129	001	FEB 17, 1987	AUG	DISC
			@	2MG	N71130	001	FEB 17, 1987	AUG	DISC
			@	5MG	N71131	001	FEB 17, 1987	AUG	DISC
			@	10MG	N71132	001	MAY 12, 1987	NOV	DISC
			@	20MG	N71133	001	MAY 12, 1987	AUG	DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

>D>	AO	+	JOHNSON RW	EQ 50MG BASE/ML	N18701	001	JAN 14, 1986	DEC	CAHN
>D>	AO	+		EQ 100MG BASE/ML	N18701	002	JAN 31, 1997	DEC	CAHN
>A>	AO	+	ORTHO MCNEIL	EQ 50MG BASE/ML	N18701	001	JAN 14, 1986	DEC	CAHN
>A>	AO	+		EQ 100MG BASE/ML	N18701	002	JAN 31, 1997	DEC	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

>D>	AA	+	JOHNSON RW	EQ 2MG BASE/ML	N15922	001	APR 12, 1967	DEC	CAHN
>A>	AA	+	ORTHO MCNEIL	EQ 2MG BASE/ML	N15922	001	APR 12, 1967	DEC	CAHN

HALOPERIDOL INTENSOL

			@ ROXANE	EQ 2MG BASE/ML	N72045	001	APR 12, 1988	AUG	DISC

INJECTABLE; INJECTION

HALDOL

>D>	AP	+	JOHNSON RW	EQ 5MG BASE/ML	N15923	001	MAY 18, 1971	DEC	CAHN
>A>	AP	+	ORTHO MCNEIL	EQ 5MG BASE/ML	N15923	001	MAY 18, 1971	DEC	CAHN

HALOPERIDOL

	AP		AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689	001	MAR 09, 2001	JUN	CTNA
	AP		BEDFORD	EQ 5MG BASE/ML	N75858	001	JUN 18, 2001	JUN	NEWA
	AP		GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N76035	001	AUG 29, 2001	AUG	NEWA

HALOPERIDOL LACTATE

	AP		AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689	001	MAR 09, 2001	MAR	NEWA

HALOTHANE
LIQUID; INHALATION
HALOTHANE
@ BH 99.99% N84977 001 JUL 14, 1976 JAN DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM
@ ABBOTT 10,000 UNITS/ML N40095 001 JUL 26, 1996 MAY DISC
HEPARIN SODIUM PRESERVATIVE FREE
@ PHARMA SERVE NY 1,000 UNITS/ML N86129 001 FEB 22, 1980 FEB WDRP

HOMATROPINE METHYLBROMIDE
TABLET; ORAL
HOMAPIN-10
@ MISSION PHARMA 10MG N86308 001 APR 11, 1979 JUL DISC
HOMAPIN-5
@ MISSION PHARMA 5MG N86309 001 APR 11, 1979 JUL DISC

HYALURONIDASE
INJECTABLE; INJECTION
WYDASE
@ WYETH AYERST 150 UNITS/ML N06343 002 MAR 22, 1950 JUL DISC
@ 150 UNITS/VIAL N06343 006 MAR 06, 1951 JUL DISC
@ 1,500 UNITS/VIAL N06343 005 MAR 06, 1951 JUL DISC

HYDRALAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDRALAZINE HCL
AP AM PHARM PARTNERS 20MG/ML N40388 001 MAR 13, 2001 MAR NEWA

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 25MG;15MG;0.1MG N85549 001 SEP 29, 1977 MAY DISC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 50MG N83232 001 JAN 24, 1975 MAY DISC
@ HALSEY 25MG N83972 001 OCT 03, 1974 MAY DISC
@ 50MG N83972 002 OCT 03, 1974 MAY DISC
@ IMPAX LABS 25MG N84029 001 JUL 05, 1977 MAY DISC
@ 50MG N83607 002 JUN 06, 1977 MAY DISC
@ PHARMERAL 25MG N84325 001 JUN 24, 1976 MAY DISC
@ 50MG N84324 001 JUN 24, 1976 MAY DISC
@ PVT FORM 50MG N86597 001 OCT 11, 1978 JUL DISC
@ WEST WARD 50MG N84878 001 JAN 31, 1977 MAY DISC

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL						
HYDRO-RESERP						
@ ABC HOLDING	50MG;0.125MG	N84714	002	JUN 29, 1982	MAY	DISC
HYDROCHLOROTHIAZIDE W/ RESERPINE						
@ DANBURY PHARMA	25MG;0.125MG	N84466	001	JAN 07, 1977	MAY	DISC
@	50MG;0.125MG	N84467	001	JAN 07, 1977	MAY	DISC
RESERPINE AND HYDROCHLOROTHIAZIDE-50						
@ WEST WARD	50MG;0.125MG	N88189	001	MAY 10, 1984	FEB	WDRP

HYDROCORTISONE

CREAM; TOPICAL						
DERMACORT						
@ MONARCH PHARMS	1%	N83011	002	APR 26, 1973	SEP	WDAG
HC (HYDROCORTISONE)						
@ C AND M PHARMA	0.5%	N80482	003	MAR 20, 1973	FEB	WDRP
@	1%	N80482	004	MAR 20, 1973	FEB	WDRP
HYDROCORTISONE						
@ TOPIDERM	1%	N89273	001	FEB 17, 1989	FEB	WDRP
NUTRACORT						
@ HEALTHPOINT	1%	N80442	003	APR 04, 1972	JUL	DISC
PROCTOCORT						
@ MONARCH PHARMS	1%	N83011	001	APR 26, 1973	FEB	DISC
LOTION; TOPICAL						
ACTICORT						
@ BAKER NORTON	1%	N86535	001	FEB 04, 1981	JUL	DISC
BETA-HC						
@ BETA DERMAC	1%	N89495	001	JAN 25, 1988	FEB	WDRP
GLYCORT						
@ HERAN	1%	N87489	001	OCT 03, 1983	FEB	WDRP
HYDROCORTISONE						
@ MERICON	0.5%	N85282	001	JUN 05, 1978	MAY	DISC
@	1%	N85282	002	FEB 26, 1987	MAY	DISC
OINTMENT; TOPICAL						
HC (HYDROCORTISONE)						
@ C AND M PHARMA	1%	N80481	002	MAR 20, 1973	FEB	WDRP
POWDER; FOR RX COMPOUNDING						
H-CORT						
@ TORCH	100%	N87834	001	MAR 29, 1982	FEB	WDRP
SOLUTION; TOPICAL						
TEXACORT						
AT + SIRIUS LABS	1%	N80425	001	DEC 22, 1971	JUN	CAHN
+	2.5%	N81271	001	APR 17, 1992	MAY	CAHN
TABLET; ORAL						
HYDROCORTISONE						
@ IMPAX LABS	20MG	N80781	001	AUG 02, 1973	OCT	DISC
@ LANNETT	20MG	N85070	001	MAY 07, 1976	MAY	DISC

HYDROCORTISONE ACETATE

CREAM; TOPICAL						
MICORT-HC						
FERNDALE LABS	2.5%	N40396	001	FEB 27, 2001	FEB	NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL

NEO-CORTEF

@ PHARMACIA AND UPJOHN — 1%;EQ 3.5MG BASE/GM — N60751 002 MAY 18, 1965 APR DISC

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

@ AKORN — 1.5%;EQ 3.5MG BASE/ML — N60188 001 OCT 26, 1968 FEB WDRP

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

LOCOID

>A> + FERNDALE LABS — 0.1% — N19116 001 FEB 25, 1987 DEC CAHN

>D> + YAMANOUCHI — 0.1% — N19116 001 FEB 25, 1987 DEC CAHN

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB ALTANA — 0.2% — N75085 001 JUL 31, 2001 JUL NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEO-OTOSOL-HC

@ ALCON — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62423 001 AUG 25, 1983 APR DISC

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

+ MONARCH PHARMS — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N50169 001 DEC 18, 1964 MAY CTEC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@ ALCON UNIVERSAL — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62874 001 MAY 11, 1988 MAY DISC

SUSPENSION/DROPS; OTIC

@ ALCON UNIVERSAL — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62488 001 NOV 06, 1985 APR DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

@ ABBOTT — 50MG/ML — N86821 001 SEP 05, 1979 JUL DISC

@ AM PHARM PARTNERS — 25MG/ML — N88184 001 MAR 31, 1983 JUL DISC

@ — 50MG/ML — N88185 001 MAR 31, 1983 JUL DISC

@ STERIS — 25MG/ML — N85778 001 OCT 05, 1979 MAY DISC

TABLET; ORAL

@ PAR PHARM — 10MG — N87602 001 JAN 22, 1982 JUL DISC

@ — 25MG — N87603 001 JAN 22, 1982 JUL DISC

@ — 50MG — N87604 001 JAN 22, 1982 JUL DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@ GENEVA PHARMS — EQ 50MG HCL — N81128 001 JUN 28, 1991 MAY DISC

@ — EQ 100MG HCL — N81129 001 JUN 28, 1991 MAY DISC

	@ VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

IBUPROFEN
TABLET; ORAL
IBUPROFEN

AB	BASF	400MG	N75682 001	NOV 14, 2001	NOV	NEWA
AB		600MG	N75682 002	NOV 14, 2001	NOV	NEWA
AB		800MG	N75682 003	NOV 14, 2001	NOV	NEWA
AB	DR REDDYS LABS INC	400MG	N76112 001	OCT 31, 2001	OCT	NEWA
AB		600MG	N76112 002	OCT 31, 2001	OCT	NEWA
AB		800MG	N76112 003	OCT 31, 2001	OCT	NEWA
	@ LEDERLE	400MG	N70629 001	SEP 19, 1986	OCT	DISC
	@	600MG	N70630 001	SEP 19, 1986	OCT	DISC

IMATINIB MESYLATE
CAPSULE; ORAL
GLEEVEC

	NOVARTIS	50MG	N21335 001	MAY 10, 2001	MAY	NEWA
+		100MG	N21335 002	MAY 10, 2001	MAY	NEWA

IMIPRAMINE HYDROCHLORIDE
TABLET; ORAL
IMIPRAMINE HCL

	@ ROXANE	25MG	N83799 002	AUG 05, 1977	SEP	DISC
	@	50MG	N83799 003	AUG 05, 1977	SEP	DISC

TOFRANIL

AB	TYCO HLTHCARE	10MG	N87844 001	MAY 22, 1984	JUN	CAHN
AB		25MG	N87845 001	MAY 22, 1984	JUN	CAHN
AB +		50MG	N87846 001	MAY 22, 1984	JUN	CAHN

IMIPRAMINE PAMOATE
CAPSULE; ORAL
TOFRANIL-PM

	TYCO HLTHCARE	EQ 75MG HCL	N17090 001	MAR 15, 1973	JUN	CAHN
		EQ 100MG HCL	N17090 004	MAR 08, 1974	JUN	CAHN
		EQ 125MG HCL	N17090 003	MAR 08, 1974	JUN	CAHN
+		EQ 150MG HCL	N17090 002	MAR 15, 1973	JUN	CAHN

INDAPAMIDE
TABLET; ORAL
INDAPAMIDE

AB	GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
AB		2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

INDINAVIR SULFATE
CAPSULE; ORAL
CRIXIVAN

	MERCK RES LABS	EQ 100MG BASE	N20685 006	APR 19, 2000	AUG	NEWA

INSULIN ASPART RECOMBINANT
INJECTABLE; SUBCUTANEOUS
NOVOLOG

+	NOVO NORDISK	100 UNITS/ML	N20986 001	JUN 07, 2000	NOV	CDFR

INSULIN ASPART; INSULIN ASPART PROTAMINE
INJECTABLE; SUBCUTANEOUS
NOVOLOG MIX 70/30
+ NOVO NORDISK — 30 UNITS/ML;70 UNITS/ML — N21172 001 NOV 01, 2001 NOV NEWA

IOPAMIDOL
INJECTABLE; INJECTION
IOPAMIDOL-300
>D> AP ABBOTT — 61% — N74638 001 APR 30, 1997 DEC DISC
>A> @ — 61% — N74638 001 APR 30, 1997 DEC DISC

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN ASLUNG PHARM — 0.02% — N75693 001 JAN 26, 2001 JAN NEWA
AN BAUSCH AND LOMB — 0.02% — N75835 001 OCT 15, 2001 OCT NEWA
AN NEPHRON — 0.02% — N75562 001 SEP 27, 2001 SEP NEWA
AN NOVEX — 0.02% — N75441 001 MAR 28, 2001 MAR NEWA
AN WARRICK PHARMS — 0.02% — N75507 001 JAN 19, 2001 JAN NEWA

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE
AN MINRAD — 99.9% — N74416 001 SEP 30, 1994 FEB CAHN

ISONIAZID
SYRUP; ORAL
ISONIAZID
+ CAROLINA MEDCL — 50MG/5ML — N88235 001 NOV 10, 1983 MAY CTEC
@ MIKART — 50MG/5ML — N81118 001 JUL 21, 1997 MAY DISC
TABLET; ORAL
@ HALSEY — 100MG — N80136 001 NOV 13, 1970 MAY DISC

ISOSORBIDE MONONITRATE
TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE
AB ZENITH GOLDLINE — 30MG — N75448 002 AUG 07, 2001 AUG NEWA
AB — 120MG — N75448 003 AUG 07, 2001 AUG NEWA

ISOTRETINOIN
CAPSULE; ORAL
ACCUTANE
+ HLR — 20MG — N18662 004 MAR 28, 1983 APR CTEC

KANAMYCIN SULFATE
INJECTABLE; INJECTION
KANAMYCIN SULFATE
@ LOCH — EQ 75MG BASE/2ML — N63021 001 JUL 31, 1992 MAY DISC
@ — EQ 500MG BASE/2ML — N63022 001 JUL 31, 1992 MAY DISC
@ — EQ 1GM BASE/3ML — N63025 001 JUL 31, 1992 APR DISC
@ STERIS — EQ 1GM BASE/3ML — N62520 003 MAY 09, 1985 MAY DISC

KANAMYCIN SULFATE
INJECTABLE; INJECTION
KANTREX

	+ APOTHECON	EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC
	+	EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC
	+	EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC

KETAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
KETAMINE HCL

>A>	AP BIONICHE PHARMA	EQ 50MG BASE/ML	N76092 002	DEC 28, 2001	DEC	NEWA

KETOCONAZOLE
CREAM; TOPICAL
NIZORAL

	AB + JANSSEN	2%	N19084 001	DEC 31, 1985	JUL	CAHN

KETOROLAC TROMETHAMINE
INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

	AP APOTEX	15MG/ML	N75631 002	JUN 29, 2001	JUN	NEWA
	AP	30MG/ML	N75626 001	JUL 24, 2001	JUL	NEWA
	AP	30MG/ML	N75631 001	JUN 29, 2001	JUN	NEWA
	@ APOTHECON	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC
	@	30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC
	@ BEDFORD	15MG/ML	N75230 002	OCT 25, 1999	OCT	DISC
	@	30MG/ML	N75230 001	OCT 25, 1999	OCT	DISC

LABETALOL HYDROCHLORIDE
INJECTABLE; INJECTION
LABETALOL HCL

	@ APOTHECON	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC

TRANDATE

	AP + PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN

LACTULOSE
SOLUTION; ORAL
LACTULOSE

	AA VINTAGE PHARMS	10GM/15ML	N75993 001	JUL 26, 2001	JUL	NEWA

SOLUTION; ORAL, RECTAL

	@ ROXANE	10GM/15ML	N73590 001	MAY 29, 1992	SEP	DISC

LAMOTRIGINE
TABLET, CHEWABLE; ORAL
LAMICTAL CD

	GLAXO WELLCOME	2MG	N20764 004	SEP 08, 2000	MAR	NEWA

LANSOPRAZOLE
FOR SUSPENSION, EXTENDED RELEASE; ORAL
PREVACID

	TAP PHARM	15MG/PACKET	N21281 001	MAY 03, 2001	MAY	NEWA
	+	30MG/PACKET	N21281 002	MAY 03, 2001	MAY	NEWA

LEPIRUDIN
INJECTABLE; INJECTION
REFLUDAN
\+ BERLEX LABS — 50MG/VIAL — N20807 001 MAR 06, 1998 NOV CAHN

LEUCOVORIN CALCIUM
INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE
AP LUITPOLD — EQ 50MG BASE/VIAL — N40338 001 JAN 31, 2001 JAN NEWA

LEUPROLIDE ACETATE
INJECTABLE; INJECTION
LEUPROLIDE ACETATE
AP GENZYME — 1MG/0.2ML — N75721 001 NOV 29, 2001 NOV NEWA

LEVOCARNITINE
INJECTABLE; INJECTION
CARNITOR
AP + SIGMA TAU — 200MG/ML — N20182 001 DEC 16, 1992 MAR CFTG
LEVOCARNITINE
AP BEDFORD — 200MG/ML — N75567 001 MAR 29, 2001 MAR NEWA
AP GENSIA SICOR PHARMS — 200MG/ML — N75881 001 MAR 29, 2001 MAR NEWA
AP LUITPOLD — 200MG/ML — N75861 001 JUN 22, 2001 JUN NEWA

LEVODOPA
CAPSULE; ORAL
DOPAR
@ SHIRE LABS — 250MG — N16913 001 JUN 04, 1970 MAY DISC
TABLET; ORAL
@ SHIRE LABS — 250MG — N16913 004 JUL 06, 1972 JUN DISC
@ — 500MG — N16913 005 JUL 06, 1972 JUN DISC
LARODOPA
ROCHE — 250MG — N16912 003 JUN 04, 1970 JUN CRLD
\+ — 500MG — N16912 004 JUN 04, 1970 JUN CRLD

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
POLOCAINE W/ LEVONORDEFRIN
AP DENTSPLY PHARM — 0.05MG/ML;2% — N89517 001 APR 14, 1988 JUL CAHN

LEVOTHYROXINE SODIUM
TABLET; ORAL
LEVOXYL
BX + JONES PHARMA — 0.025MG — N21301 001 MAY 25, 2001 MAY NEWA
BX — 0.025MG — N21301 001 MAY 25, 2001 JUL CRLD
BX — 0.05MG — N21301 002 MAY 25, 2001 MAY NEWA
BX — 0.075MG — N21301 003 MAY 25, 2001 MAY NEWA
BX — 0.088MG — N21301 004 MAY 25, 2001 MAY NEWA
BX — 0.1MG — N21301 005 MAY 25, 2001 MAY NEWA
BX — 0.112MG — N21301 006 MAY 25, 2001 MAY NEWA
BX — 0.125MG — N21301 007 MAY 25, 2001 MAY NEWA
BX — 0.137MG — N21301 008 MAY 25, 2001 MAY NEWA

BX		0.15MG	N21301 009	MAY 25, 2001	MAY	NEWA
BX		0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA
BX		0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA
BX		0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA
BX	+	0.3MG	N21301 012	MAY 25, 2001	JUL	CRLD
	UNITHROID					
BX	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC
BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
BX	+	0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC
LIDOCAINE HYDROCHLORIDE						
INJECTABLE; INJECTION						
	LIDOCAINE HCL					
	@ STERIS	1%	N80377 001	FEB 20, 1974	JUL	DISC
	@	2%	N80377 002	FEB 20, 1974	JUL	DISC
	LIDOCATON					
	@ PHARMATON	2%	N84727 001	AUG 17, 1983	FEB	WDRP
	XYLOCAINE					
	@ ASTRAZENECA	2%	N06488 002	NOV 19, 1948	SEP	DISC
AP	+ DENTSPLY PHARM	2%	N21380 001	NOV 19, 1948	SEP	NEWA
LINCOMYCIN HYDROCHLORIDE						
INJECTABLE; INJECTION						
	LINCOCIN					
	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC
	LINCOMYCIN HCL					
	@ STERIS	EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC
LISINOPRIL						
TABLET; ORAL						
	ZESTRIL					
AB	ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC
LITHIUM CARBONATE						
CAPSULE; ORAL						
	ESKALITH					
AB	SMITHKLINE BEECHAM	300MG	N16860 001	APR 06, 1970	JUN	CRLD
	LITHIUM CARBONATE					
AB	ABLE	300MG	N76121 001	SEP 27, 2001	SEP	NEWA
	+ ROXANE	600MG	N17812 003	JAN 28, 1987	JUN	CRLD
LOMEFLOXACIN HYDROCHLORIDE						
TABLET; ORAL						
	MAXAQUIN					
	+ UNIMED PHARMS	EQ 400MG BASE	N20013 001	FEB 21, 1992	SEP	CAHN

		LOPERAMIDE HYDROCHLORIDE						
		CAPSULE; ORAL						
		LOPERAMIDE HCL						
		@ ROXANE	2MG	N73080 001	NOV 27, 1991	JUL	DISC	
		LORATADINE						
		TABLET; ORAL						
		CLARITIN						
AB	+	SCHERING	10MG	N19658 001	APR 12, 1993	SEP	CFTG	
		LORAZEPAM						
		TABLET; ORAL						
		LORAZEPAM						
AB		RANBAXY	0.5MG	N76045 001	AUG 29, 2001	AUG	NEWA	
AB			1MG	N76045 002	AUG 29, 2001	AUG	NEWA	
AB			2MG	N76045 003	AUG 29, 2001	AUG	NEWA	
		@ WATSON LABS	0.5MG	N71086 001	MAR 23, 1987	JUL	DISC	
		LOSARTAN POTASSIUM						
		TABLET; ORAL						
		COZAAR						
		MERCK RES LABS	50MG	N20386 002	APR 14, 1995	AUG	CRLD	
	+		100MG	N20386 003	OCT 13, 1998	AUG	NEWA	
		LOTEPREDNOL ETABONATE						
		SUSPENSION/DROPS; OPHTHALMIC						
		ALREX						
	+	BAUSCH AND LOMB	0.2%	N20803 001	MAR 09, 1998	OCT	CAHN	
		LOTEMAX						
	+	BAUSCH AND LOMB	0.5%	N20583 001	MAR 09, 1998	OCT	CAHN	
		LOVASTATIN						
		TABLET; ORAL						
>A>		LOVASTATIN						
>A>	AB	EON	10MG	N75636 001	DEC 17, 2001	DEC	NEWA	
>A>	AB		20MG	N75636 002	DEC 17, 2001	DEC	NEWA	
>A>	AB		40MG	N75636 003	DEC 17, 2001	DEC	NEWA	
>A>	AB	GENEVA PHARMS	10MG	N75300 001	DEC 17, 2001	DEC	NEWA	
>A>	AB		20MG	N75300 002	DEC 17, 2001	DEC	NEWA	
>A>	AB		40MG	N75300 003	DEC 17, 2001	DEC	NEWA	
>A>	AB	GENPHARM	10MG	N75935 001	DEC 17, 2001	DEC	NEWA	
>A>	AB		20MG	N75935 002	DEC 17, 2001	DEC	NEWA	
>A>	AB		40MG	N75935 003	DEC 17, 2001	DEC	NEWA	
>A>	AB	MYLAN	10MG	N75451 001	DEC 17, 2001	DEC	NEWA	
>A>	AB		20MG	N75451 002	DEC 17, 2001	DEC	NEWA	
>A>	AB		40MG	N75451 003	DEC 17, 2001	DEC	NEWA	
>A>	AB	PUREPAC PHARM	10MG	N75828 001	DEC 17, 2001	DEC	NEWA	
>A>	AB		20MG	N75828 002	DEC 17, 2001	DEC	NEWA	
>A>	AB		40MG	N75828 003	DEC 17, 2001	DEC	NEWA	
>A>	AB	TEVA	10MG	N75551 003	DEC 17, 2001	DEC	NEWA	
>A>	AB		20MG	N75551 002	DEC 17, 2001	DEC	NEWA	
>A>	AB		40MG	N75551 001	DEC 17, 2001	DEC	NEWA	

	LOVASTATIN							
	TABLET; ORAL							
>A>	MEVACOR							
>D>	MERCK	10MG	N19643	002	MAR 28, 1991	DEC	CFTG	
>A> AB		10MG	N19643	002	MAR 28, 1991	DEC	CFTG	
>D>		20MG	N19643	003	AUG 31, 1987	DEC	CFTG	
>A> AB		20MG	N19643	003	AUG 31, 1987	DEC	CFTG	
>D> +		40MG	N19643	004	DEC 14, 1988	DEC	CFTG	
>A> AB +		40MG	N19643	004	DEC 14, 1988	DEC	CFTG	
>A>	LOVASTATIN; NIACIN							
>A>	TABLET, EXTENDED RELEASE; ORAL							
>A>	ADVICOR							
>A>	KOS	20MG;500MG	N21249	001	DEC 17, 2001	DEC	NEWA	
>A>		20MG;750MG	N21249	002	DEC 17, 2001	DEC	NEWA	
>A> +		20MG;1GM	N21249	003	DEC 17, 2001	DEC	NEWA	
	MANNITOL							
	INJECTABLE; INJECTION							
	MANNITOL 25%							
	@ ASTRAZENECA	12.5GM/50ML	N89240	001	MAY 06, 1987	SEP	DISC	
	MECLIZINE HYDROCHLORIDE							
	TABLET; ORAL							
	MECLIZINE HCL							
	@ CHELSEA LABS	12.5MG	N85269	001	NOV 11, 1976	MAY	DISC	
	MEGESTROL ACETATE							
	SUSPENSION; ORAL							
	MEGACE							
AB +	BRISTOL MYERS SQUIBB	40MG/ML	N20264	001	SEP 10, 1993	JUL	CFTG	
	MEGESTROL ACETATE							
AB	PAR PHARM	40MG/ML	N75671	001	JUL 25, 2001	JUL	NEWA	
	MELOXICAM							
	TABLET; ORAL							
	MOBIC							
	BOEHRINGER INGELHEIM	7.5MG	N20938	001	APR 13, 2000	JUL	CRLD	
+		15MG	N20938	002	AUG 23, 2000	JUL	NEWA	
	MENOTROPINS (FSH;LH)							
	INJECTABLE; INJECTION							
	HUMEGON							
	@ ORGANON	75 IU/VIAL;75 IU/VIAL	N20328	001	SEP 01, 1994	OCT	DISC	
	@	150 IU/VIAL;150 IU/VIAL	N20328	002	SEP 01, 1994	OCT	DISC	
	PERGONAL							
BX +	SERONO	75 IU/AMP;75 IU/AMP	N17646	001	AUG 22, 1975	OCT	CTEC	
BX +		150 IU/AMP;150 IU/AMP	N17646	002	MAY 20, 1985	OCT	CTEC	
	MEPERIDINE HYDROCHLORIDE							
	INJECTABLE; INJECTION							
	MEPERIDINE HCL							
	@ ASTRAZENECA	50MG/ML	N89784	001	MAR 31, 1989	JUN	DISC	

	@	100MG/ML	N89788 001	MAR 31, 1989	JUN	DISC

MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION

	MEPIVACAINE HCL					
	@ INTL MEDICATION	1%	N87509 001	OCT 05, 1982	JUL	DISC
	POLOCAINE					
AP	DENTSPLY PHARM	3%	N88653 001	AUG 21, 1984	JUL	CAHN

MEPROBAMATE
TABLET; ORAL

	AMOSENE					
	@ FERNDALE LABS	400MG	N84030 001	MAY 10, 1974	FEB	WDRP
	MEPROBAMATE					
	@ HALSEY	400MG	N80699 002	OCT 16, 1972	MAY	DISC
	@ IMPAX LABS	200MG	N14322 002	JUL 23, 1973	AUG	DISC
	@	400MG	N14322 001	JUL 15, 1963	AUG	DISC

MEQUINOL; TRETINOIN
SOLUTION; TOPICAL

	SOLAGE					
+	WESTWOOD SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999	JUN	CAHN

MESALAMINE
SUPPOSITORY; RECTAL

	CANASA					
+	AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA

MESNA
INJECTABLE; INTRAVENOUS

	MESNA					
AP	AM PHARM PARTNERS	100MG/ML	N75811 001	APR 26, 2001	APR	NEWA
AP	GENSIA SICOR PHARMS	100MG/ML	N75764 001	APR 27, 2001	APR	NEWA
	MESNEX					
AP +	ASTA	100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG

METAPROTERENOL SULFATE
SOLUTION; INHALATION

	METAPROTERENOL SULFATE					
AN	NEPHRON	0.4%	N71855 001	JUL 14, 1988	AUG	CAHN
AN		0.6%	N71726 001	JUL 14, 1988	AUG	CAHN
AN	NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA
AN		0.6%	N75403 001	FEB 28, 2001	FEB	NEWA

SYRUP; ORAL

	ALUPENT					
	@ BOEHRINGER INGELHEIM	10MG/5ML	N17571 001	MAY 23, 1975	NOV	DISC
	METAPROTERENOL SULFATE					
	@ COPLEY PHARM	10MG/5ML	N73034 001	AUG 30, 1991	NOV	DISC
AA +	MORTON GROVE	10MG/5ML	N74702 001	MAR 24, 1997	NOV	CRLD
	@ TEVA	10MG/5ML	N72761 001	FEB 27, 1992	NOV	DISC

METHADONE HYDROCHLORIDE
TABLET; ORAL

		METHADONE HCL						
AA		EON	40MG	N75082	001	MAR 25, 1998	NOV	CDFR
AA	+	ROXANE	40MG	N17058	001	MAR 14, 1973	NOV	CDFR
AA			40MG	N74081	001	APR 28, 1995	NOV	CDFR
		METHADOSE						
AA		MALLINCKRODT	40MG	N74184	001	APR 29, 1993	NOV	CDFR

METHAMPHETAMINE HYDROCHLORIDE
TABLET; ORAL

		DESOXYN						
	+	ABBOTT	5MG	N05378	002	DEC 31, 1943	JUL	CTEC
		METHAMPHETAMINE HCL						
		@ REXAR	5MG	N84931	001	JAN 19, 1976	JUL	DISC
		@	10MG	N84931	002	AUG 22, 1977	JUL	DISC

METHAZOLAMIDE
TABLET; ORAL

		METHAZOLAMIDE						
		@ APPLIED ANAL	25MG	N40011	001	JUL 17, 1997	MAY	DISC
		@	50MG	N40011	002	JUL 17, 1997	MAY	DISC

METHIMAZOLE
TABLET; ORAL

		METHIMAZOLE						
AB		EON	5MG	N40411	001	MAR 27, 2001	MAR	NEWA
AB			10MG	N40411	002	MAR 27, 2001	MAR	NEWA
	+	GENPHARM	20MG	N40350	003	JUN 07, 2001	JUN	NEWA

METHOCARBAMOL
TABLET; ORAL

			ROBAXIN						
>D>	AA	+	ROBINS AH	500MG	N11011	004	MAR 03, 1961	DEC	CAHN
>A>	AA	+	SCHWARZ PHARMA	500MG	N11011	004	MAR 03, 1961	DEC	CAHN
			ROBAXIN-750						
>D>	AA	+	ROBINS AH	750MG	N11011	006	JUL 16, 1962	DEC	CAHN
>A>	AA	+	SCHWARZ PHARMA	750MG	N11011	006	JUL 16, 1962	DEC	CAHN

METHOTREXATE SODIUM
TABLET; ORAL

		TREXALL						
		BARR	EQ 5MG BASE	N40385	001	MAR 21, 2001	MAR	NEWA
			EQ 7.5MG BASE	N40385	002	MAR 21, 2001	MAR	NEWA
			EQ 10MG BASE	N40385	003	MAR 21, 2001	MAR	NEWA
	+		EQ 15MG BASE	N40385	004	MAR 21, 2001	MAR	NEWA

METHOXAMINE HYDROCHLORIDE
INJECTABLE; INJECTION

		VASOXYL						
		@ GLAXO WELLCOME	20MG/ML	N06772	001	MAR 28, 1949	SEP	WDAG

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
METHSCOPOLAMINE BROMIDE
@ PVT FORM 2.5MG N80970 001 OCT 18, 1976 MAY DISC
PAMINE
\+ BRADLEY PHARMS 2.5MG N08848 001 APR 09, 1953 MAY CTEC

METHYCLOTHIAZIDE
TABLET; ORAL
METHYCLOTHIAZIDE
@ PAR PHARM 2.5MG N89135 001 FEB 12, 1986 JUL DISC
@ 5MG N89136 001 FEB 12, 1986 JUL DISC

METHYLDOPA
TABLET; ORAL
METHYLDOPA
@ LEDERLE 125MG N70070 003 OCT 15, 1985 MAY DISC

METHYLPHENIDATE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD
\+ CELLTECH PHARMS 20MG N21259 001 APR 03, 2001 APR NEWA
TABLET; ORAL
METHYLPHENIDATE HCL
AB ABLE 5MG N40404 001 MAR 29, 2001 MAR NEWA
AB 10MG N40404 002 MAR 29, 2001 MAR NEWA
AB 20MG N40404 003 MAR 29, 2001 MAR NEWA
TABLET, EXTENDED RELEASE; ORAL
METADATE ER
AB CELLTECH PHARMS 10MG N40306 001 OCT 20, 1999 APR CTEC
METHYLPHENIDATE HCL
AB ABLE 20MG N76032 001 MAY 09, 2001 MAY NEWA
AB DANBURY PHARMA 20MG N40410 001 FEB 09, 2001 FEB NEWA
>A> AB PUREPAC PHARM 20MG N75450 001 DEC 21, 2001 DEC NEWA

METHYLPREDNISOLONE ACETATE
INJECTABLE; INJECTION
DEPO-MEDROL
PHARMACIA AND UPJOHN 40MG/ML N11757 001 APR 27, 1959 MAY CTEC
METHYLPREDNISOLONE ACETATE
@ STERIS 40MG/ML N85600 001 MAR 14, 1979 MAY DISC

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-MEDROL ACETATE
@ PHARMACIA AND UPJOHN 0.25%;EQ 3.5MG BASE/GM N60611 002 DEC 07, 1964 MAY DISC
@ 1%;EQ 3.5MG BASE/GM N60611 001 DEC 07, 1964 MAY DISC

METHYLPREDNISOLONE SODIUM SUCCINATE
INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE
@ GENSIA SICOR PHARMS EQ 500MG BASE/VIAL N81267 001 NOV 30, 1992 MAY DISC

	@	EQ 1GM BASE/VIAL	N81268 001	NOV 30, 1992	MAY	DISC	
	METHYLTESTOSTERONE						
	TABLET; BUCCAL						
	ORETON						
	@ SCHERING	10MG	N80281 001	AUG 03, 1979	FEB	DISC	
	TABLET; BUCCAL/SUBLINGUAL						
	METHYLTESTOSTERONE						
	@ IMPAX LABS	10MG	N84287 001	JUL 16, 1974	JUL	DISC	
	@ LILLY	10MG	N80256 001	DEC 22, 1971	JUL	DISC	
	TABLET; ORAL						
	@ LILLY	25MG	N80256 002	DEC 22, 1971	JUL	DISC	
	METIPRANOLOL HYDROCHLORIDE						
	SOLUTION/DROPS; OPHTHALMIC						
	METIPRANOLOL						
AT	FALCON PHARMS	0.3%	N75720 001	AUG 06, 2001	AUG	NEWA	
	OPTIPRANOLOL						
AT +	BAUSCH AND LOMB	0.3%	N19907 001	DEC 29, 1989	AUG	CFTG	
	METOCLOPRAMIDE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	METOCLOPRAMIDE HCL						
	@ ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC	
	SOLUTION; INJECTION						
	METOCLOPRAMIDE						
AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA	
	SOLUTION; ORAL						
AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR	
	METOCLOPRAMIDE HCL						
AA	PHARM VENTURES	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993	NOV	CAHN	
	TABLET; ORAL						
AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN	
AB		EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN	
	@ MUTUAL PHARM	EQ 5MG BASE	N71536 002	JAN 16, 1997	JUL	DISC	
	@	EQ 10MG BASE	N71536 001	APR 28, 1993	JUL	DISC	
	REGLAN						
>D> AB	ROBINS AH	EQ 5MG BASE	N17854 002	MAY 05, 1987	DEC	CAHN	
>D> AB +		EQ 10MG BASE	N17854 001	DEC 30, 1980	DEC	CAHN	
>A> AB	SCHWARZ PHARMA	EQ 5MG BASE	N17854 002	MAY 05, 1987	DEC	CAHN	
>A> AB +		EQ 10MG BASE	N17854 001	DEC 30, 1980	DEC	CAHN	
	METOCURINE IODIDE						
	INJECTABLE; INJECTION						
	METUBINE IODIDE						
	@ LILLY	2MG/ML	N06632 003	FEB 15, 1952	SEP	WDAG	
	METOPROLOL SUCCINATE						
	TABLET, EXTENDED RELEASE; ORAL						
	TOPROL-XL						
+	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA	
		EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	JUL	CRLD	
		EQ 100MG TARTRATE	N19962 002	JAN 10, 1992	JUL	CRLD	

METRONIDAZOLE							
INJECTABLE; INJECTION							
METRO I.V.							
@ B BRAUN	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC		
METRONIDAZOLE							
@ ABBOTT	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC		
@ ELKINS SINN	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC		
TABLET; ORAL							
PROTOSTAT							
@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC		
@	500MG	N18871 002	MAR 02, 1983	MAR	DISC		
MEZLOCILLIN SODIUM MONOHYDRATE							
INJECTABLE; INJECTION							
MEZLIN							
@ BAYER	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC		
@	EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC		
@	EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC		
@	EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC		
@	EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC		
MIDAZOLAM HYDROCHLORIDE							
INJECTABLE; INJECTION							
MIDAZOLAM HCL							
AP AM PHARM PARTNERS	EQ 1MG BASE/ML	N75154 002	JUN 20, 2000	OCT	CAHN		
AP	EQ 5MG BASE/ML	N75154 001	JUN 20, 2000	OCT	CAHN		
@ APOTHECON	EQ 1MG BASE/ML	N75620 001	NOV 01, 2000	MAY	DISC		
@	EQ 5MG BASE/ML	N75620 002	NOV 01, 2000	MAY	DISC		
@	EQ 5MG BASE/ML	N75641 001	OCT 19, 2000	MAY	DISC		
@ ASTRAZENECA	EQ 5MG BASE/ML	N75263 001	JUN 26, 2000	MAY	DISC		
@ BEDFORD	EQ 5MG BASE/ML	N75249 001	JUN 23, 2000	SEP	DISC		
@ BEN VENUE	EQ 5MG BASE/ML	N75455 001	JUN 20, 2000	SEP	DISC		
MINOCYCLINE HYDROCHLORIDE							
CAPSULE; ORAL							
MINOCIN							
AB LEDERLE	EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	NEWA		
AB +	EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CRLD		
MINOCYCLINE HCL							
AB DANBURY PHARMA	EQ 100MG BASE	N63065 001	DEC 30, 1991	MAR	CRLD		
AB IMPAX LABS	EQ 75MG BASE	N65005 003	APR 18, 2001	APR	NEWA		
VECTRIN							
@ MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	MAY	DISC		
@	EQ 100MG BASE	N63067 001	JUL 31, 1990	MAY	DISC		
POWDER, EXTENDED RELEASE; DENTAL							
ARESTIN							
+ ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA		
MIRTAZAPINE							
TABLET, ORALLY DISINTEGRATING; ORAL							
REMERON SOLTAB							
+ ORGANON INC	15MG	N21208 001	JAN 12, 2001	JAN	NEWA		

		30MG	N21208 002	JAN 12, 2001	JAN	NEWA
		45MG	N21208 003	JAN 12, 2001	JAN	NEWA
	MORPHINE SULFATE					
	CAPSULE, EXTENDED RELEASE; ORAL					
	KADIAN					
+	FAULDING PHARMS	20MG	N20616 001	JUL 03, 1996	JUN	CAHN
+		30MG	N20616 004	MAR 09, 2001	JUN	NEWA
+		50MG	N20616 002	JUL 03, 1996	JUN	CAHN
+		60MG	N20616 005	MAR 09, 2001	JUN	NEWA
+		100MG	N20616 003	JUL 03, 1996	JUN	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	MORPHINE SULFATE					
AB	WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA
	ORAMORPH SR					
BC	ELAN PHARMS	15MG	N19977 004	NOV 23, 1994	SEP	CAHN
BC		30MG	N19977 001	AUG 15, 1991	SEP	CAHN
BC		60MG	N19977 002	AUG 15, 1991	SEP	CAHN
BC		100MG	N19977 003	AUG 15, 1991	SEP	CAHN
	MOXIFLOXACIN HYDROCHLORIDE					
	INJECTABLE; IV (INFUSION)					
	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
+	BAYER	160MG/100ML	N21277 001	NOV 30, 2001	NOV	NEWA
	NABUMETONE					
	TABLET; ORAL					
	NABUMETONE					
AB	TEVA	750MG	N75189 002	SEP 24, 2001	SEP	NEWA
	NADOLOL					
	TABLET; ORAL					
	CORGARD					
AB	APOTHECON	40MG	N18063 001	DEC 10, 1979	AUG	CRLD
	NADOLOL					
AB	GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN
AB		40MG	N74501 002	NOV 09, 1995	JAN	CAHN
AB		80MG	N74501 003	NOV 09, 1995	JAN	CAHN
	NAFCILLIN SODIUM					
	INJECTABLE; INJECTION					
	NAFCILLIN SODIUM					
	@ APOTHECON	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC
+		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD
	@	EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC
	@	EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC
	@	EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC
	@ MARSAM	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC
	@	EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN
	@	EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC
	@	EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC
	@	EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC

NAFCILLIN SODIUM
INJECTABLE; INJECTION
NALLPEN
@ SMITHKLINE BEECHAM — EQ 500MG BASE/VIAL — N61999 001 JUL 10, 1978 MAY DISC
@ — EQ 1GM BASE/VIAL — N61999 002 JUL 10, 1978 MAY DISC
@ — EQ 2GM BASE/VIAL — N61999 003 JUL 10, 1978 MAY DISC
@ — EQ 10GM BASE/VIAL — N61999 004 JUL 17, 1978 MAY DISC
UNIPEN
@ WYETH AYERST — EQ 500MG BASE/VIAL — N50320 001 JUN 23, 1970 MAY DISC
@ — EQ 500MG BASE/VIAL — N62717 001 DEC 16, 1986 MAY DISC
@ — EQ 1GM BASE/VIAL — N62717 002 DEC 16, 1986 MAY DISC
@ — EQ 2GM BASE/VIAL — N50320 003 JUN 23, 1970 MAY DISC
@ — EQ 2GM BASE/VIAL — N62717 004 DEC 16, 1986 MAY DISC
@ — EQ 4GM BASE/VIAL — N50320 004 JUN 23, 1970 MAY DISC
@ — EQ 10GM BASE/VIAL — N50320 005 DEC 21, 1978 MAY DISC
UNIPEN IN PLASTIC CONTAINER
@ WYETH AYERST — EQ 1GM BASE/VIAL — N50320 002 JUN 23, 1970 MAY DISC

NALBUPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
NALBUPHINE HCL
@ ASTRAZENECA — 10MG/ML — N72070 001 APR 10, 1989 JUN DISC
@ — 20MG/ML — N72073 001 APR 10, 1989 JUN DISC

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE
@ WYETH AYERST — 0.02MG/ML — N70188 001 SEP 24, 1986 JAN DISC
@ — 0.02MG/ML — N70189 001 SEP 24, 1986 JAN DISC
@ — 0.4MG/ML — N70190 001 SEP 24, 1986 JAN DISC
@ — 0.4MG/ML — N70191 001 SEP 24, 1986 JAN DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
TABLET; ORAL
NALOXONE HCL AND PENTAZOCAINE
AB AMIDE PHARM — EQ 0.5MG BASE;EQ 50MG BASE — N75735 001 JUL 11, 2001 JUL NEWA

NANDROLONE PHENPROPIONATE
INJECTABLE; INJECTION
DURABOLIN
@ ORGANON — 25MG/ML — N11891 001 OCT 30, 1959 NOV DISC
@ — 50MG/ML — N11891 002 APR 05, 1961 NOV DISC

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
ALBALON
AT ALLERGAN — 0.1% — N80248 001 MAR 24, 1972 JUL CRLD
AT + — 0.1% — N80248 001 MAR 24, 1972 AUG CRLD
NAPHCON FORTE
@ ALCON — 0.1% — N80229 001 MAR 06, 1974 JUL DISC
OPCON
@ BAUSCH AND LOMB — 0.1% — N87506 001 DEC 01, 1981 JUL DISC
VASOCON

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
VASOCON

AT		NOVARTIS	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN

NAPROXEN
TABLET; ORAL
NAPROXEN

>A>	AB	INTERPHARM	250MG	N75927 001	DEC 18, 2001	DEC	NEWA
>A>	AB		375MG	N75927 002	DEC 18, 2001	DEC	NEWA
>A>	AB		500MG	N75927 003	DEC 18, 2001	DEC	NEWA

TABLET, EXTENDED RELEASE; ORAL

AB	+	ALPHAPHARM	375MG	N75390 001	APR 19, 2001	APR	NEWA
AB	+		500MG	N75390 002	APR 19, 2001	APR	NEWA

NAPROXEN SODIUM
TABLET; ORAL
NAPROXEN SODIUM

AB		GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN
AB			EQ 500MG BASE	N74495 002	DEC 05, 1994	JAN	CAHN

NEDOCROMIL SODIUM
AEROSOL, METERED; INHALATION
TILADE

	+	AVENTIS	1.75MG/INH	N19660 001	DEC 30, 1992	SEP	CAHN

NEFAZODONE HYDROCHLORIDE
TABLET; ORAL
SERZONE

		BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	APR	CTEC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION; IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATES

		@ STERIS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664 001	APR 08, 1986	MAY	DISC

NEOSPORIN G.U. IRRIGANT

		MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001	JUN 28, 1966	MAY	CTEC
	+		EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001	JUN 28, 1966	NOV	CRLD

SOLUTION/DROPS; OPHTHALMIC
STATROL

		@ ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339 001	NOV 30, 1984	JUL	DISC

NESIRITIDE
FOR SOLUTION; INTRAVENOUS
NATRECOR

	+	SCIOS	1.5MG/VIAL	N20920 001	AUG 10, 2001	AUG	NEWA

NETILMICIN SULFATE
INJECTABLE; INJECTION
NETROMYCIN
@ SCHERING — EQ 100MG BASE/ML — N50544 003 FEB 28, 1983 MAY DISC

NIFEDIPINE
CAPSULE; ORAL
NIFEDIPINE
@ CHASE LABS NJ — 10MG — N72409 001 JUL 04, 1990 FEB WDRP
@ — 20MG — N73421 001 JUN 19, 1991 FEB WDRP
TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
AB1 BAYER — 30MG — N20198 001 APR 21, 1993 APR CTEC
NIFEDIPINE
AB2 BIOVAIL — 30MG — N75289 002 FEB 06, 2001 FEB NEWA
AB1 ELAN PHARM — 60MG — N75659 001 OCT 26, 2001 OCT NEWA
PROCARDIA XL
AB2 + PFIZER — 30MG — N19684 001 SEP 06, 1989 FEB CTEC

NITROFURAZONE
OINTMENT; TOPICAL
NITROFURAZONE
@ CLAY PARK — 0.2% — N84968 001 JAN 25, 1978 MAY DISC
POWDER; TOPICAL
FURACIN
@ ROBERTS LABS — 0.2% — N83791 001 OCT 17, 1975 FEB WDRP
SOLUTION; TOPICAL
NITROFURAZONE
@ CLAY PARK — 0.2% — N85130 001 NOV 02, 1978 MAY DISC
+ WENDT — 0.2% — N87081 001 JUL 22, 1981 MAY CTEC

NITROGLYCERIN
AEROSOL; SUBLINGUAL
NITROLINGUAL
@ POHL BOSKAMP — 0.4MG/SPRAY — N18705 001 OCT 31, 1985 APR DISC

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
RAVOCAINE AND NOVOCAIN W/ LEVOPHED
@ EASTMAN KODAK — EQ 0.033MG BASE/ML;2%;0.4% — N08592 003 MAR 11, 1955 SEP WDAG

NORETHINDRONE ACETATE
TABLET; ORAL
NORETHINDRONE ACETATE
AB BARR — 5MG — N75951 001 MAY 25, 2001 MAY NEWA

NORTRIPTYLINE HYDROCHLORIDE
CAPSULE; ORAL
PAMELOR
AB TYCO HLTHCARE — EQ 10MG BASE — N18013 001 AUG 01, 1977 JUN CAHN
AB — EQ 25MG BASE — N18013 002 AUG 01, 1977 JUN CAHN
AB — EQ 50MG BASE — N18013 004 JUN 14, 1979 JUN CAHN

AB	+		EQ 75MG BASE	N18013 003	JUN 14, 1979	JUN	CAHN
	SOLUTION; ORAL						
AA		TYCO HLTHCARE	EQ 10MG BASE/5ML	N18012 001	AUG 01, 1977	JUN	CAHN
	NYSTATIN						
	CREAM; TOPICAL						
		NILSTAT					
		@ LEDERLE	100,000 UNITS/GM	N61445 001	APR 02, 1971	MAY	DISC
		NYSTATIN					
		@ TEVA	100,000 UNITS/GM	N61966 001	MAY 25, 1976	MAY	DISC
	OINTMENT; TOPICAL						
		NILSTAT					
		@ LEDERLE	100,000 UNITS/GM	N61444 001	MAR 29, 1971	MAY	DISC
		NYSTATIN					
AT	+	ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY	CTEC
	SUSPENSION; ORAL						
		@ ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY	DISC
		@ TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY	DISC
		@	100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY	DISC
		@ THAMES	100,000 UNITS/ML	N62876 001	FEB 29, 1988	JUL	DISC
	TABLET; ORAL						
		@ EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC
		@ ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC
	TABLET; VAGINAL						
		KOROSTATIN					
		@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP
	NYSTATIN; TRIAMCINOLONE ACETONIDE						
	OINTMENT; TOPICAL						
		MYCO-TRIACET II					
		@ TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY	DISC
		NYSTATIN AND TRIAMCINOLONE ACETONIDE					
		@ CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY	DISC
	OLANZAPINE						
	TABLET; ORAL						
		ZYPREXA					
		LILLY	15MG	N20592 005	SEP 09, 1997	JUN	CRLD
	+		20MG	N20592 006	SEP 09, 1997	JUN	CMFD
	OMEPRAZOLE						
	CAPSULE, DELAYED REL PELLETS; ORAL						
		OMEPRAZOLE					
AB		ANDRX PHARMS	10MG	N75347 001	NOV 16, 2001	NOV	NEWA
AB			20MG	N75347 002	NOV 16, 2001	NOV	NEWA
AB			40MG	N75347 003	NOV 16, 2001	NOV	NEWA
		PRILOSEC					
AB		ASTRAZENECA	10MG	N19810 003	OCT 05, 1995	NOV	CFTG
AB	+		20MG	N19810 001	SEP 14, 1989	NOV	CFTG
AB	+		40MG	N19810 002	JAN 15, 1998	NOV	CFTG

	OXACILLIN SODIUM						
	INJECTABLE; INJECTION						
	BACTOCILL						
	@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC	
	@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC	
	OXACILLIN SODIUM						
AP +	APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD	
AP +		EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD	
	@ IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC	
	@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC	
	@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC	
	OXAPROZIN						
	TABLET; ORAL						
	DAYPRO						
AB +	SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG	
	OXAPROZIN						
AB	DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA	
AB	EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA	
AB	GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA	
AB	GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA	
AB	INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA	
AB	MYLAN	600MG	N75851 001	AUG 17, 2001	AUG	NEWA	
AB	PUREPAC PHARM	600MG	N75843 001	OCT 03, 2001	OCT	NEWA	
AB	WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA	
	OXAZEPAM						
	CAPSULE; ORAL						
	SERAX						
AB	FAULDING PHARMS	10MG	N15539 002	SEP 29, 1966	JUN	CAHN	
AB		15MG	N15539 004	SEP 29, 1966	JUN	CAHN	
AB +		30MG	N15539 006	SEP 29, 1966	JUN	CAHN	
	TABLET; ORAL						
	+ FAULDING PHARMS	15MG	N15539 008	NOV 16, 1967	JUN	CAHN	
	OXCARBAZEPINE						
	SUSPENSION; ORAL						
	TRILEPTAL						
	+ NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001	MAY	NEWA	
	OXYCODONE HYDROCHLORIDE						
	TABLET; ORAL						
	ROXICODONE						
	ELAN PHARMS	15MG	N21011 001	AUG 31, 2000	SEP	CAHN	
	+	30MG	N21011 002	AUG 31, 2000	SEP	CAHN	
	TABLET, EXTENDED RELEASE; ORAL						
	OXYCONTIN						
>D>	+ PURDUE PHARMA LP	10MG	N20553 001	DEC 12, 1995	DEC	CRLD	
>A>		10MG	N20553 001	DEC 12, 1995	DEC	CRLD	
>D>	+	20MG	N20553 002	DEC 12, 1995	DEC	CRLD	

>A>		20MG	N20553 002	DEC 12, 1995	DEC	CRLD
	@	160MG	N20553 005	MAR 15, 2000	JUN	DISC
	OXYTETRACYCLINE HYDROCHLORIDE					
	CAPSULE; ORAL					
	OXYTETRACYCLINE HCL					
	@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
	@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP
	@ WEST WARD	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC
	TERRAMYCIN					
	+ PFIZER	EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC
	PACLITAXEL					
	INJECTABLE; INJECTION					
	PACLITAXEL					
AP	BEDFORD	6MG/ML	N75190 001	JUL 27, 2001	JUL	NEWA
AP	MYLAN	6MG/ML	N75278 001	JUL 23, 2001	JUL	NEWA
AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA
	PAMIDRONATE DISODIUM					
	INJECTABLE; INJECTION					
	AREDIA					
AP +	NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG
AP +		90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG
	PAMIDRONATE DISODIUM					
AP	BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA
AP		90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA
	PANCURONIUM BROMIDE					
	INJECTABLE; INJECTION					
	PANCURONIUM BROMIDE					
	@ ASTRAZENECA	1MG/ML	N72210 001	MAR 31, 1988	JUL	DISC
	@	2MG/ML	N72211 001	MAR 31, 1988	JUL	DISC
	@	2MG/ML	N72213 001	MAR 31, 1988	JUL	DISC
	PANTOPRAZOLE SODIUM					
	INJECTABLE; IV (INFUSION)					
	PROTONIX IV					
	+ WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA
	TABLET, DELAYED RELEASE; ORAL					
	PROTONIX					
	+ WYETH AYERST	EQ 20MG BASE	N20987 002	JUN 12, 2001	JUN	NEWA
	PEMOLINE					
	TABLET; ORAL					
	PEMOLINE					
AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA
AB		37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA
AB		75MG	N75726 001	MAR 30, 2001	MAR	NEWA
AB	WATSON LABS	18.75MG	N75287 001	JUN 13, 2001	JUN	NEWA

PENCICLOVIR SODIUM						
CREAM; TOPICAL						
DENAVIR						
+ NOVARTIS	1%	N20629 001	SEP 24, 1996	JUL	CAHN	
PENICILLIN G POTASSIUM						
FOR SOLUTION; ORAL						
PENICILLIN						
@ TEVA	200,000 UNITS/5ML	N60307 002	MAY 27, 1964	JUL	DISC	
@	400,000 UNITS/5ML	N60307 004	MAY 27, 1964	JUL	DISC	
PENICILLIN-2						
@ TEVA	250,000 UNITS/5ML	N60307 003	MAY 27, 1964	JUL	DISC	
TABLET; ORAL						
PENICILLIN G POTASSIUM						
@ MYLAN	200,000 UNITS	N60781 001	FEB 11, 1966	NOV	DISC	
@	250,000 UNITS	N60781 002	FEB 11, 1966	NOV	DISC	
@	400,000 UNITS	N60781 003	FEB 11, 1966	NOV	DISC	
@	500,000 UNITS	N60781 005	MAR 10, 1980	NOV	DISC	
@	800,000 UNITS	N60781 004	FEB 11, 1966	NOV	DISC	
@ TEVA	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC	
@	250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC	
@	400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC	
@	500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC	
WYETH AYERST	200,000 UNITS	N60413 001	JUL 23, 1948	NOV	CTEC	
	250,000 UNITS	N60413 002	JUL 23, 1948	NOV	CTEC	
+	400,000 UNITS	N60413 003	JUL 23, 1948	NOV	CRLD	
PENICILLIN G PROCAINE						
INJECTABLE; INJECTION						
PENICILLIN G PROCAINE						
@ PFIZER	300,000 UNITS/VIAL	N60099 001	NOV 10, 1948	MAY	DISC	
@	1,500,000 UNITS/VIAL	N60099 002	NOV 10, 1948	MAY	DISC	
PFIZERPEN-AS						
@ PFIZER	300,000 UNITS/ML	N60286 001	NOV 01, 1950	MAY	DISC	
@	600,000 UNITS/ML	N60286 002	NOV 01, 1950	MAY	DISC	
WYCILLIN						
+ KING PHARMS	300,000 UNITS/ML	N60101 002	APR 26, 1948	MAY	CTEC	
+	600,000 UNITS/ML	N60101 001	APR 26, 1948	MAY	CTEC	
PENICILLIN G SODIUM						
INJECTABLE; IM-IV						
PENICILLIN G SODIUM						
+ BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	FEB 26, 2001	FEB	NEWA	
@ MARSAM	5,000,000 UNITS/VIAL	N63014 001	SEP 13, 1988	FEB	DISC	
PENICILLIN V POTASSIUM						
FOR SOLUTION; ORAL						
PENICILLIN V POTASSIUM						
@ MYLAN	EQ 125MG BASE/5ML	N61624 002	AUG 07, 1972	MAY	DISC	
@	EQ 250MG BASE/5ML	N61624 001	JUN 05, 1972	MAY	DISC	
V-CILLIN K						
@ LILLY	EQ 125MG BASE/5ML	N60004 001	AUG 21, 1958	MAY	DISC	

	@	EQ 250MG BASE/5ML	N60004	002	APR 07, 1967	MAY	DISC
	TABLET; ORAL						
	PEN-VEE K						
AB	+ WYETH AYERST	EQ 500MG BASE	N60006	003	JAN 13, 1958	MAY	CRLD
	PENICILLIN V POTASSIUM						
AB	+ BIOCHEMIE	EQ 500MG BASE	N64071	002	NOV 30, 1995	MAY	CTEC
	@ MYLAN	EQ 250MG BASE	N61530	001	NOV 18, 1971	MAY	DISC
	@	EQ 500MG BASE	N61530	002	MAR 20, 1972	MAY	DISC
	V-CILLIN K						
	@ LILLY	EQ 125MG BASE	N60003	001	SEP 17, 1957	MAY	DISC
	@	EQ 250MG BASE	N60003	002	SEP 17, 1957	MAY	DISC
	@	EQ 500MG BASE	N60003	003	SEP 17, 1957	MAY	DISC
	PENTOBARBITAL						
	ELIXIR; ORAL						
	NEMBUTAL						
	@ ABBOTT	18.2MG/5ML	N83244	001	JAN 08, 1975	JUL	DISC
	PENTOBARBITAL SODIUM						
	CAPSULE; ORAL						
	NEMBUTAL SODIUM						
	@ ABBOTT	50MG	N84093	001	JAN 14, 1975	JUL	DISC
	SUPPOSITORY; RECTAL						
	NEMBUTAL						
	@ ABBOTT	30MG	N83247	001	JAN 25, 1982	JUL	DISC
	@	60MG	N83247	002	JAN 25, 1982	JUL	DISC
	@	120MG	N83247	003	JAN 25, 1982	JUL	DISC
	@	200MG	N83247	004	JAN 25, 1982	JUL	DISC
	PERFLUTREN						
	INJECTABLE; INTRAVENOUS						
	DEFINITY						
	+ DUPONT PHARMS	6.52MG/ML	N21064	001	JUL 31, 2001	JUL	NEWA
	PERPHENAZINE						
	CONCENTRATE; ORAL						
	PERPHENAZINE						
	+ PHARM ASSOC	16MG/5ML	N40360	001	MAY 25, 2001	MAY	NEWA
	TRILAFON						
	@ SCHERING	16MG/5ML	N11557	001	DEC 12, 1958	MAR	DISC
	PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM						
	TABLET; ORAL						
	SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL						
	+ ABLE	200MG;800MG;160MG	N21105	001	JUN 26, 2001	JUN	NEWA
	PHENDIMETRAZINE TARTRATE						
	CAPSULE; ORAL						
	PHENDIMETRAZINE TARTRATE						
	@ EON	35MG	N85633	001	JUL 13, 1978	JUL	DISC
	@	35MG	N85694	001	JUN 05, 1978	MAY	DISC
AA	+	35MG	N85695	001	JUN 05, 1978	JUL	CRLD
	@	35MG	N85702	001	JUN 07, 1978	JUL	DISC

	PHENDIMETRAZINE TARTRATE						
	CAPSULE, EXTENDED RELEASE; ORAL						
	PHENDIMETRAZINE TARTRATE						
BC	+ EON	105MG	N18074 001	APR 16, 1979	JUL	CRLD	
	@ GENEVA PHARMS	105MG	N87378 001	NOV 03, 1981	JUL	DISC	
	TABLET; ORAL						
	PHENAZINE-35						
	@ ABC HOLDING	35MG	N85512 001	MAY 06, 1977	MAY	DISC	
	PHENDIMETRAZINE TARTRATE						
	@ EON	35MG	N85402 001	MAY 19, 1978	MAY	DISC	
	@	35MG	N85497 001	AUG 19, 1977	MAY	DISC	
	@ MIKART	35MG	N89452 001	OCT 30, 1991	JUL	DISC	
	@ ROSEMONT	35MG	N84399 001	MAY 28, 1981	MAY	DISC	
	STATOBEX						
	@ TEVA	35MG	N86013 001	DEC 16, 1977	JUL	DISC	
	X-TROZINE						
	@ SHIRE RICHWOOD	35MG	N86550 001	SEP 16, 1981	JUL	DISC	
	@	35MG	N86551 001	SEP 16, 1981	JUL	DISC	
	@	35MG	N86552 001	SEP 16, 1981	JUL	DISC	
	PHENTERMINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	OBY-TRIM						
	@ SHIRE RICHWOOD	30MG	N87764 001	MAR 18, 1982	JUL	DISC	
	PHENTERMINE HCL						
	@ ABC HOLDING	30MG	N85411 001	SEP 10, 1980	MAY	DISC	
AA	ABLE	30MG	N40403 001	AUG 30, 2001	AUG	NEWA	
AA		30MG	N40427 001	AUG 30, 2001	AUG	NEWA	
	@ ROSEMONT	30MG	N84487 001	APR 09, 1982	MAY	DISC	
	TABLET; ORAL						
AA	ABLE	37.5MG	N40402 001	AUG 30, 2001	AUG	NEWA	
	+ EON	30MG	N88605 001	SEP 28, 1987	MAY	CMFD	
	PHENYTOIN						
	SUSPENSION; ORAL						
	PHENYTOIN						
AB	UDL	125MG/5ML	N40342 001	JAN 31, 2001	JAN	NEWA	
	PHENYTOIN SODIUM, EXTENDED						
	CAPSULE; ORAL						
>A>	PHENYTEK						
>A>	+ MYLAN	200MG	N40298 002	DEC 06, 2001	DEC	NEWA	
>A>	+	300MG	N40298 003	DEC 06, 2001	DEC	NEWA	
>A>	PIMECROLIMUS						
>A>	CREAM; TOPICAL						
>A>	ELIDEL						
>A>	+ NOVARTIS	1%	N21302 001	DEC 13, 2001	DEC	NEWA	

PIPERAZINE CITRATE
SYRUP; ORAL
PIPERAZINE CITRATE
@ LANNETT EQ 500MG BASE/5ML N80963 001 JUL 25, 1974 MAY DISC
TABLET; ORAL
@ IMPAX LABS EQ 250MG BASE N80874 001 JUL 19, 1973 MAY DISC

PIPOBROMAN
TABLET; ORAL
VERCYTE
@ ABBOTT 25MG N16245 002 JUL 01, 1966 JUL DISC

PORACTANT ALFA
SUSPENSION; INTRATRACHEAL
CUROSURF
\+ DEY 80MG/ML N20744 001 NOV 18, 1999 SEP CAIN

POTASSIUM CHLORIDE
TABLET, EXTENDED RELEASE; ORAL
K-DUR 10
AB KEY PHARMS 10MEQ N19439 002 JUN 13, 1986 APR CTEC

PRAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
PRAZOSIN HCL
@ PUREPAC PHARM EQ 1MG BASE N72991 001 MAY 16, 1989 JUL DISC
@ EQ 2MG BASE N72921 001 MAY 16, 1989 JUL DISC
@ EQ 5MG BASE N72992 001 MAY 16, 1989 JUL DISC

PREDNICARBATE
OINTMENT; TOPICAL
DERMATOP
\+ AVENTIS PHARMS 0.1% N19568 001 SEP 23, 1991 MAR CMFD

PREDNISOLONE
SYRUP; ORAL
PREDNISOLONE
AA KV PHARM 5MG/5ML N40423 001 OCT 22, 2001 OCT NEWA
PRELONE
AA \+ MURO 5MG/5ML N89654 001 JAN 17, 1989 OCT CFTG
TABLET; ORAL
PREDNISOLONE
@ CHELSEA LABS 5MG N85085 002 FEB 23, 1977 MAY DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
VASOCIDIN
AT NOVARTIS 0.5%;10% N88791 001 OCT 05, 1984 FEB CAHN
SUSPENSION/DROPS; OPHTHALMIC
METIMYD
\+ SCHERING 0.5%;10% N10210 001 FEB 24, 1956 FEB CTEC
PREDAMIDE

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

	PREDAMIDE					
	@ AKORN	0.5%;10%	N88059 001	JUL 29, 1983	FEB	WDRP
	SULPHRIN					
	@ BAUSCH AND LOMB	0.5%;10%	N88089 001	DEC 28, 1982	FEB	WDRP

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

	INFLAMASE FORTE					
AT +	NOVARTIS	EQ 0.9% PHOSPHATE	N80751 002	DEC 19, 1973	FEB	CAHN
	INFLAMASE MILD					
AT +	NOVARTIS	EQ 0.11% PHOSPHATE	N80751 001	DEC 19, 1973	FEB	CAHN
	PREDNISOLONE SODIUM PHOSPHATE					
	@ AKORN	EQ 0.11% PHOSPHATE	N83358 001	AUG 21, 1974	FEB	WDRP
	@	EQ 0.9% PHOSPHATE	N83358 002	AUG 21, 1974	FEB	WDRP
	@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001	OCT 24, 1991	MAY	DISC
	@	EQ 0.9% PHOSPHATE	N81044 001	OCT 24, 1991	MAY	DISC

PREDNISONE

TABLET; ORAL

	METICORTEN					
	@ SCHERING	1MG	N09766 002	SEP 15, 1955	NOV	DISC
	PREDNISONE					
	@ CHELSEA LABS	5MG	N85084 002	DEC 15, 1981	MAY	DISC
	@ EVERYLIFE	1MG	N84440 001	FEB 25, 1975	NOV	DISC
	@	2.5MG	N84440 002	FEB 25, 1975	NOV	DISC
	@	5MG	N84440 003	FEB 25, 1975	NOV	DISC
	@ GENEVA PHARMS	5MG	N80336 002	JUL 29, 1976	MAY	DISC
	@ HALSEY	10MG	N86595 001	APR 10, 1979	JUL	DISC
	@ LANNETT	20MG	N84275 001	JUN 27, 1974	MAY	DISC
AB +	ROXANE	1MG	N87800 001	APR 22, 1982	NOV	CRLD
AB	TRIGEN	5MG	N40362 002	AUG 29, 2001	AUG	NEWA
AB		10MG	N40362 001	AUG 29, 2001	AUG	NEWA

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CITANEST PLAIN					
	@ ASTRAZENECA	4%	N14763 007	NOV 18, 1965	SEP	DISC
+	DENTSPLY PHARM	4%	N21382 001	NOV 18, 1965	SEP	NEWA

PRIMIDONE

SUSPENSION; ORAL

	MYSOLINE					
+	XCEL PHARMS	250MG/5ML	N10401 001	JUL 05, 1956	JUL	CAHN

TABLET; ORAL

AB	ELAN PHARMA	50MG	N09170 003	MAR 08, 1954	MAY	CFTG
AB	XCEL PHARMS	50MG	N09170 003	MAR 08, 1954	JUL	CAHN
AB +		250MG	N09170 002	MAR 08, 1954	JUL	CAHN
	PRIMIDONE					
AB	LANNETT	50MG	N84903 002	MAY 24, 2001	MAY	NEWA

PROCHLORPERAZINE
SUPPOSITORY; RECTAL

	COMPAZINE						
AB	SMITHKLINE BEECHAM	2.5MG	N11127 003	FEB 09, 1959	JUL	CFTG
AB		5MG	N11127 001	SEP 27, 1957	JUL	CFTG
	PROCHLORPERAZINE						
AB	ABLE	2.5MG	N40407 001	JUL 11, 2001	JUL	NEWA
AB		5MG	N40407 002	JUL 11, 2001	JUL	NEWA
AB		25MG	N40407 003	JUL 11, 2001	JUL	NEWA

PROCHLORPERAZINE EDISYLATE
INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE						
@ WYETH AYERST	EQ 5MG BASE/ML	N86348 001	JUL 05, 1979	JUL	DISC

PROCHLORPERAZINE MALEATE
TABLET; ORAL

PROCHLORPERAZINE MALEATE						
AB	GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001	JUL 19, 1996	JAN	CAHN
AB		EQ 10MG BASE	N40101 002	JUL 19, 1996	JAN	CAHN
AB		EQ 25MG BASE	N40101 003	JUL 19, 1996	JAN	CAHN

PROGESTERONE
INJECTABLE; INJECTION

PROGESTERONE						
AO	AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001	APR	NEWA
AO +	SCHEIN	50MG/ML	N17362 002	MAY 08, 1978	OCT	CAHN
AO +	STERIS	50MG/ML	N17362 002	MAY 08, 1978	APR	CFTG

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY; RECTAL

PROMETHACON						
@ POLYMEDICA	50MG	N84902 001	OCT 05, 1981	MAY	DISC

TABLET; ORAL

PHENERGAN						
WYETH AYERST	12.5MG	N07935 002	MAR 29, 1951	MAY	CTEC
PROMETHAZINE HCL						
@ LANNETT	12.5MG	N80949 001	JUL 28, 1976	MAY	DISC
@	25MG	N80949 002	JUN 28, 1976	MAY	DISC
@	50MG	N80949 003	JUN 28, 1976	MAY	DISC
@ PVT FORM	25MG	N83658 001	OCT 01, 1976	MAY	DISC

PROPAFENONE HYDROCHLORIDE
TABLET; ORAL

PROPAFENONE HCL						
AB	MUTUAL PHARM	150MG	N75998 001	NOV 29, 2001	NOV	NEWA
AB		225MG	N75998 002	NOV 29, 2001	NOV	NEWA
AB		300MG	N75998 003	NOV 29, 2001	NOV	NEWA
RYTHMOL						
AB +	ABBOTT	300MG	N19151 002	NOV 27, 1989	NOV	CFTG

PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
PROPOXYPHENE HCL

@	GENEVA PHARMS	65MG	N83125 002	APR	14, 1976	MAY	DISC
@	IMPAX LABS	65MG	N83317 001	OCT	23, 1973	MAY	DISC

PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA

	WYETH AYERST LABS	60MG	N18553 004	MAR	18, 1987	AUG	CRLD
		80MG	N18553 002	APR	19, 1983	AUG	CRLD
		120MG	N18553 003	APR	19, 1983	AUG	CRLD

TABLET; ORAL
PROPRANOLOL HCL

@	LEDERLE	10MG	N70125 001	JUL	30, 1985	MAY	DISC
@		20MG	N70126 001	JUL	30, 1985	OCT	DISC
@		40MG	N70127 001	JUL	30, 1985	SEP	DISC
@	WATSON LABS	20MG	N70549 001	APR	11, 1986	MAY	DISC

PROTRIPTYLINE HYDROCHLORIDE
TABLET; ORAL
PROTRIPTYLINE HCL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG	24, 1995	JAN	CAHN
AB		10MG	N73645 001	AUG	24, 1995	JAN	CAHN

VIVACTIL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG	24, 1995	MAR	CTNA
AB +		10MG	N73645 001	AUG	24, 1995	MAR	CTNA
@	SIDMAK LABS	5MG	N16012 001	SEP	27, 1967	MAR	DISC
@		10MG	N16012 002	SEP	27, 1967	MAR	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SYRUP; ORAL
TRILITRON

@	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474 001	FEB	12, 1985	FEB	WDRP

QUETIAPINE FUMARATE
TABLET; ORAL
SEROQUEL

	ZENECA	EQ 200MG BASE	N20639 003	SEP	26, 1997	NOV	CRLD
+		EQ 300MG BASE	N20639 005	JUL	26, 2000	NOV	NEWA

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE

BX +	BERLEX LABS	324MG	N16647 001	DEC	08, 1969	MAR	CTEC

QUINIDINE GLUCONATE

BX	DANBURY PHARMA	324MG	N87810 001	SEP	29, 1982	MAR	CTEC
@	GENEVA PHARMS	324MG	N89894 001	DEC	15, 1988	MAR	DISC
BX	MUTUAL PHARM	324MG	N89338 001	FEB	11, 1987	MAR	CTEC

QUINIDINE SULFATE
TABLET; ORAL
QUINIDINE SULFATE

	@ IMPAX LABS	200MG	N83347 001	DEC 08, 1976	FEB	DISC
>A> AB	KING PHARMS	200MG	N85175 001	SEP 30, 1976	DEC	CAHN
	@ MUTUAL PHARM	300MG	N81031 001	APR 14, 1989	MAY	DISC
>D> AB	SMITHKLINE BEECHAM	200MG	N85175 001	SEP 30, 1976	DEC	CAHN
	@ WEST WARD	200MG	N83862 001	SEP 02, 1976	MAY	DISC

RANITIDINE HYDROCHLORIDE
CAPSULE; ORAL
ZANTAC 150

@ GLAXO WELLCOME	EQ 150MG BASE	N20095 001	MAR 08, 1994	AUG	DISC

TABLET; ORAL
RANITIDINE HCL

@ BOEHRINGER INGELHEIM	EQ 150MG BASE	N74662 001	AUG 29, 1997	SEP	DISC
@	EQ 300MG BASE	N74662 002	AUG 29, 1997	SEP	DISC

RIBAVIRIN
CAPSULE; ORAL
REBETOL

+ SCHERING PLOUGH RES	200MG	N20903 002	JUL 25, 2001	AUG	NEWA

RIFAMPIN
CAPSULE; ORAL
RIFAMPIN

AB VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA
AB	300MG	N65028 002	MAR 14, 2001	MAR	NEWA

RIMANTADINE HYDROCHLORIDE
TABLET; ORAL
FLUMADINE

AB + FOREST LABS	100MG	N19649 001	SEP 17, 1993	NOV	CFTG

RIMANTADINE HCL

AB COREPHARMA	100MG	N75916 001	NOV 02, 2001	NOV	NEWA

RISPERIDONE
TABLET; ORAL
RISPERDAL
JANSSEN

	0.5MG	N20272 007	JAN 27, 1999	APR	CRLD
+	1MG	N20272 001	DEC 29, 1993	APR	CRLD
	4MG	N20272 004	DEC 29, 1993	APR	CRLD

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM

@ ICN	100MG	N85477 001	DEC 10, 1981	FEB	WDRP

SECRETIN
INJECTABLE; INJECTION
SECRETIN-FERRING

@ FERRING	75CU/VIAL	N18290 001	MAY 29, 1981	JUN	DISC

SILVER SULFADIAZINE							
DRESSING; TOPICAL							
SILDAFLO							
@ FRANKLIN PHARMS		1%	N19608 001	NOV 30, 1989	NOV	CAHN
@ QUESTCOR PHARMS		1%	N19608 001	NOV 30, 1989	MAY	CTNA
SIMVASTATIN							
TABLET; ORAL							
ZOCOR							
MERCK		5MG	N19766 001	DEC 23, 1991	APR	CTEC
SODIUM IODIDE, I-131							
CAPSULE; ORAL							
SODIUM IODIDE I 131							
@ CIS		100uCi	N17316 002	NOV 10, 1976	OCT	DISC
SODIUM POLYSTYRENE SULFONATE							
SUSPENSION; ORAL, RECTAL							
SPS							
AA + CAROLINA MEDCL		15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD
SODIUM TETRADECYL SULFATE							
INJECTABLE; INJECTION							
SOTRADECOL							
@ ELKINS SINN		1%	N05970 004	AUG 13, 1946	JUL	DISC
@		3%	N05970 005	AUG 13, 1946	JUL	DISC
SOMATROPIN RECOMBINANT							
INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS							
SAIZEN							
+ SERONO		8.8MG/VIAL	N19764 003	AUG 29, 2000	AUG	NEWA
SOTALOL HYDROCHLORIDE							
TABLET; ORAL							
SORINE							
AB UPSHER SMITH		80MG	N75500 001	APR 27, 2001	APR	NEWA
AB		120MG	N75500 004	APR 27, 2001	APR	NEWA
AB		160MG	N75500 002	APR 27, 2001	APR	NEWA
AB		240MG	N75500 003	APR 27, 2001	APR	NEWA
SOTALOL HCL							
AB MUTUAL PHARM		80MG	N75515 001	OCT 15, 2001	OCT	NEWA
AB		120MG	N75515 004	OCT 15, 2001	OCT	NEWA
AB		160MG	N75515 002	OCT 15, 2001	OCT	NEWA
AB		240MG	N75515 003	OCT 15, 2001	OCT	NEWA
SPIRONOLACTONE							
TABLET; ORAL							
SPIRONOLACTONE							
AB MYLAN		25MG	N40424 001	AUG 20, 2001	AUG	NEWA
AB		50MG	N40424 002	AUG 20, 2001	AUG	NEWA
AB		100MG	N40424 003	AUG 20, 2001	AUG	NEWA

STREPTOMYCIN SULFATE
INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

	@ PFIZER	EQ 1GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
	@	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC
	+ PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC

SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
BLEPH-10

	@ ALLERGAN	10%	N84015 001	JAN 07, 1975	MAY	DISC
	CETAMIDE						
AT	+ ALCON	10%	N80021 001	SEP 27, 1972	MAY	CTEC
	SODIUM SULAMYD						
	@ SCHERING	10%	N05963 002	NOV 26, 1947	MAY	DISC

SOLUTION/DROPS; OPHTHALMIC
BLEPH-10

AT	+ ALLERGAN	10%	N80028 001	MAY 25, 1971	MAY	CRLD
	BLEPH-30						
AT	+ ALLERGAN	30%	N80028 002	MAY 25, 1971	MAY	CRLD
	SODIUM SULAMYD						
	@ SCHERING	10%	N05963 001	AUG 01, 1946	MAY	DISC
	@	30%	N05963 003	NOV 26, 1947	MAY	DISC
	SULF-10						
	@ NOVARTIS	10%	N80025 001	JUN 03, 1971	FEB	CAHN
AT		10%	N80025 001	JUN 03, 1971	SEP	CMFD
	SULF-15						
AT	NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN
	SULTEN-10						
	@ BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP

SULFAMETHOXAZOLE
TABLET; ORAL
GANTANOL

	+ ROCHE	500MG	N12715 002	NOV 17, 1961	MAY	CTEC
	SULFAMETHOXAZOLE						
	@ GENEVA PHARMS	500MG	N85844 001	MAR 23, 1978	MAY	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM
INJECTABLE; INJECTION
BACTRIM

AP	+ WOMEN FIRST HLTHCARE	80MG/ML;16MG/ML	N18374 001	JUN 23, 1981	OCT	CAHN
	SUSPENSION; ORAL						
	@ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 001	APR 16, 1975	OCT	CAHN
	BACTRIM PEDIATRIC						
AB	+ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 002	DEC 10, 1979	OCT	CAHN
	TRIMETH/SULFA						
	@ NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP

TABLET; ORAL
BACTRIM

AB	WOMEN FIRST HLTHCARE	400MG;80MG	N17377 001	JUL 30, 1973	OCT	CAHN
	BACTRIM DS						

SULFAMETHOXAZOLE; TRIMETHOPRIM
TABLET; ORAL
BACTRIM DS

AB	+	WOMEN FIRST HLTHCARE	800MG;160MG	N17377 002	MAR 01, 1978	OCT	CAHN
		SULFAMETHOXAZOLE AND TRIMETHOPRIM					
		@ ROXANE	400MG;80MG	N72768 001	AUG 30, 1991	OCT	DISC
		@ TEVA	400MG;80MG	N18242 001	MAY 19, 1981	MAY	DISC
		@	800MG;160MG	N18242 002	MAY 19, 1981	MAY	DISC
		SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH					
		@ ROXANE	800MG;160MG	N72769 001	AUG 30, 1991	SEP	DISC
AB		TEVA	800MG;160MG	N70037 001	JUN 02, 1987	OCT	CAHN

SULFANILAMIDE
CREAM; VAGINAL
AVC

AT	+	NOVAVAX	15%	N06530 003	JAN 27, 1987	JAN	CAHN
		SUPPOSITORY; VAGINAL					
	+	NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	JAN	CAHN

SULFISOXAZOLE
TABLET; ORAL
SULFISOXAZOLE

		@ GENEVA PHARMS	500MG	N85628 001	JUN 13, 1977	JUL	DISC

TECHNETIUM TC-99M APCITIDE
INJECTABLE; INJECTION
ACUTECT

		BERLEX LABS	N/A	N20887 001	SEP 14, 1998	MAY	CAHN
		DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998	JUL	CAHN
			N/A	N20887 001	SEP 14, 1998	APR	CAHN

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE; INJECTION
MPI DTPA KIT - CHELATE

		@ NYCOMED AMERSHAM	N/A	N17255 001	APR 15, 1976	SEP	WDAG

TEMAZEPAM
CAPSULE; ORAL
RESTORIL

		TYCO HLTHCARE	7.5MG	N18163 003	OCT 25, 1991	JUN	CAHN
AB			15MG	N18163 001	FEB 27, 1981	JUN	CAHN
AB	+		30MG	N18163 002	FEB 27, 1981	JUN	CAHN

TENOFOVIR DISOPROXIL FUMARATE
TABLET; ORAL
VIREAD

	+	GILEAD	300MG	N21356 001	OCT 26, 2001	OCT	NEWA

TERAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
TERAZOSIN HCL

AB		TORPHARM	EQ 1MG BASE	N75498 001	APR 12, 2001	APR	NEWA
AB			EQ 2MG BASE	N75498 002	APR 12, 2001	APR	NEWA

AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA
AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA
AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA

TERBUTALINE SULFATE

TABLET; ORAL

BRETHINE

AB	NOVARTIS	2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG
AB +		5MG	N17849 002	MAY 17, 1976	JUN	CFTG

TERBUTALINE SULFATE

AB	IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001	JUN	NEWA
AB		5MG	N75877 002	JUN 26, 2001	JUN	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

PANMYCIN

@	PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC

ROBITET

@	WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
@		500MG	N61734 002	JUN 06, 1973	MAY	DISC

TETRACYCLINE HCL

@	DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
@		500MG	N62343 002	OCT 02, 1981	MAY	DISC
@	EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
@	WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC
@		500MG	N60768 002	NOV 07, 1977	MAY	DISC
@	WYETH AYERST	250MG	N61685 001	DEC 11, 1972	JUL	DISC
@		500MG	N61685 002	DEC 11, 1972	JUL	DISC

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP	MOUNT SINAI MEDCTR	1mCi/ML	N75569 001	NOV 21, 2001	NOV	NEWA

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

@	CHELSEA LABS	10MG	N88561 001	MAY 11, 1984	JUL	DISC
@	TEVA	10MG	N88493 001	MAY 17, 1985	JUL	DISC
@	ZENITH GOLDLINE	50MG	N88194 001	APR 14, 1983	JUL	DISC

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

AP +	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG

THIOTEPA

AP	AAIPHARMA	15MG/VIAL	N75698 001	SEP 20, 2001	SEP	NEWA
AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA

		@ IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC
		THYROGLOBULIN					
		TABLET; ORAL					
		THYROGLOBULIN					
		@ IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC
		TICARCILLIN DISODIUM					
		INJECTABLE; INJECTION					
		TICAR					
		@ SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC
		TOBRAMYCIN					
		SOLUTION; INHALATION					
		TOBI					
	+	CHIRON	300MG/5ML	N50753 001	DEC 22, 1997	SEP	CAHN
		SOLUTION/DROPS; OPHTHALMIC					
		TOBRAMYCIN					
		@ ALCON UNIVERSAL	0.3%	N63176 001	MAY 25, 1994	MAY	DISC
	AT	ALTANA	0.3%	N65026 001	SEP 11, 2001	SEP	NEWA
		TOBRAMYCIN SULFATE					
		INJECTABLE; INJECTION					
		NEBCIN					
	AP +	LILLY	EQ 1.2GM BASE/VIAL	N50519 001	JUN 11, 1979	AUG	CFTG
		TOBRAMYCIN					
	AP	PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013 001	AUG 17, 2001	AUG	NEWA
		TOBRAMYCIN SULFATE					
>D>	AP	ABBOTT	EQ 40MG BASE/ML	N63116 001	MAY 18, 1992	DEC	CRLD
>A>	AP +		EQ 40MG BASE/ML	N63116 001	MAY 18, 1992	DEC	CRLD
		@ ASTRAZENECA	EQ 10MG BASE/ML	N63119 001	OCT 31, 1994	AUG	DISC
		@	EQ 40MG BASE/ML	N63121 001	OCT 31, 1994	MAY	DISC
		@ ELKINS SINN	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	MAY	DISC
		@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	MAY	DISC
		@ LEDERLE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	MAY	DISC
		TOLMETIN SODIUM					
		CAPSULE; ORAL					
		TOLMETIN SODIUM					
		@ GENEVA PHARMS	EQ 400MG BASE	N73462 001	APR 30, 1992	JUL	DISC
		TOPIRAMATE					
		CAPSULE; ORAL					
		TOPAMAX SPRINKLE					
>D>		JOHNSON RW	15MG	N20844 001	OCT 26, 1998	DEC	CAHN
>D>	+		25MG	N20844 002	OCT 26, 1998	DEC	CAHN
>D>	@		50MG	N20844 003	OCT 26, 1998	DEC	CAHN
>A>		ORTHO MCNEIL	15MG	N20844 001	OCT 26, 1998	DEC	CAHN
>A>	+		25MG	N20844 002	OCT 26, 1998	DEC	CAHN
>A>	@		50MG	N20844 003	OCT 26, 1998	DEC	CAHN
		TABLET; ORAL					
		TOPAMAX					
>D>	+	JOHNSON RW	25MG	N20505 004	DEC 24, 1996	DEC	CAHN

	+	25MG	N20505 004	DEC 24, 1996	MAR	CRLD
>D>	@	50MG	N20505 005	DEC 24, 1996	DEC	CAHN
>D>		100MG	N20505 001	DEC 24, 1996	DEC	CAHN
>D>		200MG	N20505 002	DEC 24, 1996	DEC	CAHN
		200MG	N20505 002	DEC 24, 1996	MAR	CRLD
>D>	@	300MG	N20505 003	DEC 24, 1996	DEC	CAHN
>D>	@	400MG	N20505 006	DEC 24, 1996	DEC	CAHN
>A>	+ ORTHO MCNEIL	25MG	N20505 004	DEC 24, 1996	DEC	CAHN
>A>	@	50MG	N20505 005	DEC 24, 1996	DEC	CAHN
>A>		100MG	N20505 001	DEC 24, 1996	DEC	CAHN
>A>		200MG	N20505 002	DEC 24, 1996	DEC	CAHN
>A>	@	300MG	N20505 003	DEC 24, 1996	DEC	CAHN
>A>	@	400MG	N20505 006	DEC 24, 1996	DEC	CAHN
	TRAVOPROST					
	SOLUTION/DROPS; OPHTHALMIC					
	TRAVATAN					
	+ ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001	MAR	NEWA
	TRIAMCINOLONE					
	TABLET; ORAL					
	TRIAMCINOLONE					
	@ IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC
	TRIAMCINOLONE ACETONIDE					
	AEROSOL, METERED; INHALATION					
	AZMACORT					
	+ AVENTIS	0.1MG/INH	N18117 001	APR 23, 1982	SEP	CAHN
	AEROSOL, METERED; NASAL					
	NASACORT					
	+ AVENTIS	0.055MG/INH	N19798 001	JUL 11, 1991	SEP	CAHN
	CREAM; TOPICAL					
	TRIAMCINOLONE ACETONIDE					
	@ TARO	0.025%	N40038 001	OCT 26, 1994	MAY	DISC
	@ TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
	@	0.1%	N89275 001	FEB 21, 1989	FEB	WDRP
	@	0.5%	N89276 001	FEB 21, 1989	FEB	WDRP
	OINTMENT; TOPICAL					
	ARISTOCORT					
	@ FUJISAWA HLTHCARE	0.5%	N80745 002	MAY 28, 1974	JUL	DISC
	ARISTOCORT A					
	@ FUJISAWA HLTHCARE	0.5%	N80745 003	SEP 23, 1975	JUL	DISC
	TRIAMCINOLONE ACETONIDE					
	@ G AND W LABS	0.025%	N89795 001	DEC 23, 1988	JUL	DISC
	@	0.1%	N89796 001	DEC 23, 1988	JUL	DISC
AT	THAMES	0.025%	N40374 001	JUN 05, 2001	JUN	NEWA
AT		0.5%	N40386 001	JUN 05, 2001	JUN	NEWA
	SPRAY; TOPICAL					
	KENALOG					
	+ APOTHECON	0.147MG/GM	N12104 001	DEC 24, 1959	JUL	CDFR
	SPRAY, METERED; NASAL					
	NASACORT AQ					
	+ AVENTIS	0.055MG/SPRAY	N20468 001	MAY 20, 1996	SEP	CAHN

TRICHLORMETHIAZIDE
TABLET; ORAL
TRICHLOREX
@ LANNETT 4MG N83436 001 AUG 11, 1980 MAY DISC
@ 4MG N85630 001 MAY 16, 1977 FEB WDRP
TRICHLORMETHIAZIDE
@ IMPAX LABS 4MG N83967 001 JAN 17, 1978 OCT DISC

TRIFLUOPERAZINE HYDROCHLORIDE
CONCENTRATE; ORAL
TRIFLUOPERAZINE HCL
@ GENEVA PHARMS EQ 10MG BASE/ML N85787 001 APR 15, 1982 MAY DISC
TABLET; ORAL
AB GENEVA PHARMS TECH EQ 1MG BASE N40153 001 OCT 25, 1996 JAN CAHN
AB EQ 2MG BASE N40153 002 OCT 25, 1996 JAN CAHN
AB EQ 5MG BASE N40153 003 OCT 25, 1996 JAN CAHN
AB EQ 10MG BASE N40153 004 OCT 25, 1996 JAN CAHN

TRIHEXYPHENIDYL HYDROCHLORIDE
ELIXIR; ORAL
TRIHEXYPHENIDYL HCL
AA PHARM VENTURES 2MG/5ML N89514 001 APR 07, 1989 NOV CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
@ STERIS 100MG/ML N86577 001 OCT 19, 1982 JUL DISC

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION; ORAL
PRIMSOL
@ ASCENT PEDS EQ 25MG BASE/5ML N74374 001 JUN 23, 1995 JUN DISC

TRIMIPRAMINE MALEATE
CAPSULE; ORAL
SURMONTIL
SIDMAK LABS EQ 25MG BASE N16792 001 JUN 12, 1979 AUG CAHN
EQ 50MG BASE N16792 002 JUN 12, 1979 AUG CAHN
+ EQ 100MG BASE N16792 003 SEP 15, 1982 AUG CAHN

TRIPELENNAMINE HYDROCHLORIDE
TABLET; ORAL
TRIPELENNAMINE HCL
@ IMPAX LABS 50MG N80785 001 AUG 07, 1973 OCT DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
CREAM; VAGINAL
TRIPLE SULFA
@ FOUGERA 3.7%;2.86%;3.42% N86424 001 MAY 31, 1979 JUN DISC

TRIPTORELIN PAMOATE
INJECTABLE; INTRAMUSCULAR
TRELSTAR
+ DEBIO RECHERCHE 11.25MG/VIAL N21288 001 JUN 29, 2001 JUN NEWA
+ PHARMACIA AND UPJOHN 11.25MG/VIAL N21288 001 JUN 29, 2001 SEP CAHN
TRELSTAR DEPOT
+ DEBIO RECHERCHE EQ 3.75MG BASE/VIAL N20715 001 JUN 15, 2000 JUN CDFR
+ PHARMACIA AND UPJOHN EQ 3.75MG BASE/VIAL N20715 001 JUN 15, 2000 SEP CAHN

TUBOCURARINE CHLORIDE
INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP + BRISTOL MYERS SQUIBB 3MG/ML N05657 001 FEB 20, 1945 NOV CAHN
@ LILLY 3MG/ML N06325 001 NOV 28, 1947 SEP WDAG

URACIL MUSTARD
CAPSULE; ORAL
URACIL MUSTARD
@ SHIRE PHARM 1MG N12892 001 SEP 13, 1962 JUN DISC

UREA, C-13
FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI
+ MERETEK EQ 75MG /POUCHE N20586 002 MAY 10, 2001 AUG NEWA
MERETEK UBT KIT (W/ PRANACTIN)
@ MERETEK 125MG/VIAL N20586 001 SEP 17, 1996 AUG DISC

VALDECOXIB
TABLET; ORAL
BEXTRA
SEARLE 10MG N21341 002 NOV 16, 2001 NOV NEWA
+ 20MG N21341 003 NOV 16, 2001 NOV NEWA

VALGANCICLOVIR HYDROCHLORIDE
TABLET; ORAL
VALCYTE
+ SYNTEX (USA) INC LLC EQ 450MG BASE N21304 001 MAR 29, 2001 MAR NEWA

VALPROIC ACID
CAPSULE; ORAL
VALPROIC ACID
@ PAR PHARM 250MG N70431 001 FEB 28, 1986 MAY DISC
@ SCHERER RP 250MG N70195 001 JUL 02, 1987 JUL DISC

VALSARTAN
TABLET; ORAL
DIOVAN
NOVARTIS 80MG N21283 001 JUL 18, 2001 JUL NEWA
160MG N21283 002 JUL 18, 2001 JUL NEWA
+ 320MG N21283 003 JUL 18, 2001 JUL NEWA

VANCOMYCIN HYDROCHLORIDE
INJECTABLE; INJECTION
VANCOMYCIN HCL
@ ELKINS SINN — EQ 500MG BASE/VIAL — N62879 001 AUG 02, 1988 MAY DIS
@ — EQ 1GM BASE/VIAL — N62879 002 AUG 02, 1988 MAY DIS

VECURONIUM BROMIDE
INJECTABLE; INJECTION
VECURONIUM BROMIDE
+ ABBOTT — 4MG/VIAL — N75558 001 SEP 11, 2001 SEP NEW

VERAPAMIL HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
VERAPAMIL HCL
>A> @ BARR — 120MG — N75072 001 MAY 25, 1999 DEC DISC
>A> @ — 240MG — N75072 003 MAY 25, 1999 DEC DISC
>D> AB DURAMED — 120MG — N75072 001 MAY 25, 1999 DEC DISC
>D> AB — 240MG — N75072 003 MAY 25, 1999 DEC DISC

VINBLASTINE SULFATE
INJECTABLE; INJECTION
VELBAN
@ LILLY — 10MG/VIAL — N12665 001 MAR 06, 1961 MAY DISC
VINBLASTINE SULFATE
AP + BEDFORD — 10MG/VIAL — N89395 001 APR 09, 1987 MAY CRLD

VITAMIN A PALMITATE
CAPSULE; ORAL
VITAMIN A
@ WEST WARD — EQ 50,000 UNITS BASE — N80967 001 MAY 04, 1973 FEB WDRP
INJECTABLE; INJECTION
AQUASOL A
+ NEOSAN PHARMS — EQ 50,000 UNITS BASE/ML — N06823 001 MAY 18, 1949 AUG CAHN

WARFARIN SODIUM
TABLET; ORAL
COUMADIN
AB DUPONT MERCK — 2.5MG — N09218 018 NOV 29, 1961 JUL CRLD
AB + — 5MG — N09218 007 FEB 17, 1964 JUL CRLD
AB — 5MG — N09218 007 FEB 17, 1964 AUG CRLD

ZIPRASIDONE HYDROCHLORIDE
CAPSULE; ORAL
GEODON
PFIZER — 20MG — N20825 001 FEB 05, 2001 FEB NEWA
— 40MG — N20825 002 FEB 05, 2001 FEB NEWA
— 60MG — N20825 003 FEB 05, 2001 FEB NEWA
+ — 80MG — N20825 004 FEB 05, 2001 FEB NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+	NOVARTIS	EQ 4MG BASE/VIAL	N21223 001	AUG 20, 2001	SEP	CPOT
+		4.264MG/VIAL	N21223 001	AUG 20, 2001	AUG	NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

	ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA

	ACETAMINOPHEN						
	SUPPOSITORY; RECTAL						
	ACETAMINOPHEN						
	@ ABLE	120MG	N73106 001	FEB 27, 1995	SEP	WDAG
	@	325MG	N73107 001	FEB 27, 1995	SEP	WDAG
	@	650MG	N73108 001	FEB 27, 1995	SEP	WDAG
	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
	+	650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN
	ACETAMINOPHEN; ASPIRIN; CAFFEINE					
	TABLET; ORAL					
	ACETAMINOPHEN, ASPIRIN AND CAFFEINE					
	PERRIGO	250MG;250MG;65MG	N75794 001	NOV 26, 2001	NOV	NEWA
	ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE					
	TABLET; ORAL					
	TAVIST ALLERGY/SINUS/HEADACHE					
	+ NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA
	ALCOHOL; CHLORHEXIDINE GLUCONATE					
	SOLUTION; TOPICAL					
	AVAGARD					
	+ 3M	61%;1%	N21074 001	JUN 07, 2001	JUN	NEWA
	ASPIRIN					
	TABLET; ORAL					
	BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN					
	+ BAYER	500MG	N21317 001	OCT 18, 2001	OCT	NEWA
	BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE					
	TABLET, EXTENDED RELEASE; ORAL					
	BROMATAPP					
	@ COPLEY PHARM	12MG;75MG	N71099 001	JUL 02, 1987	JUL	DISC
>A>	BUTENAFINE HYDROCHLORIDE					
>A>	CREAM; TOPICAL					
>A>	LOTRIMIN ULTRA					
>A>	+ SCHERING PLOUGH	1%	N21307 001	DEC 07, 2001	DEC	NEWA
	CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE					
	TABLET, EXTENDED RELEASE; ORAL					
	TAVIST-D					
	@ NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
	@	1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC
	CLOTRIMAZOLE					
	CREAM; VAGINAL					
	TRIVAGIZOLE 3					
	TARO	2%	N21143 001	APR 12, 2000	JUL	CRLD

CROMOLYN SODIUM
SPRAY, METERED; NASAL
CROMOLYN SODIUM

	ALPHARMA	5.2MG/INH	N74800 001	JUL 26, 2001	JUL	NEWA
	BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	JUL 03, 2001	JUL	NEWA
>A>	PERRIGO	5.2MG/SPRAY	N75427 001	DEC 12, 2001	DEC	NEWA

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE

	DANBURY PHARMA	10MG	N75404 001	NOV 28, 2001	NOV	NEWA
	DR REDDYS LABS LTD	10MG	N75758 001	AUG 17, 2001	AUG	NEWA
>A>	GENPHARM	10MG	N75674 001	DEC 21, 2001	DEC	NEWA
	TEVA	10MG	N75312 001	MAY 31, 2001	MAY	NEWA
	ZENITH GOLDLINE	10MG	N75512 001	JUL 26, 2001	JUL	NEWA

IBUPROFEN
TABLET; ORAL
ACHES-N-PAIN

	@ LEDERLE	200MG	N71065 001	MAY 28, 1987	OCT	DISC

IBUPROFEN

>A>	BASF	200MG	N75661 001	DEC 12, 2001	DEC	NEWA
	DR REDDYS LABS INC	100MG	N76117 001	NOV 20, 2001	NOV	NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
IBUPROHM COLD AND SINUS

	OHM LABS	200MG;30MG	N74567 001	APR 17, 2001	APR	NEWA

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN

+	NOVO NORDISK	100 UNITS/ML	N18381 001	MAR 17, 1980	MAY	CTEC

INSULIN RECOMBINANT HUMAN
INJECTABLE; INJECTION
NOVOLIN R

+	NOVO NORDISK	100 UNITS/ML	N19938 001	JUN 25, 1991	MAY	CTEC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INJECTABLE; INJECTION
HUMULIN 50/50

+	LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992	MAY	CTEC

NOVOLIN 70/30

+	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991	MAY	CTEC

INSULIN RECOMBINANT PURIFIED HUMAN
INJECTABLE; INJECTION
VELOSULIN BR HUMAN

	@ NOVO NORDISK	100 UNITS/ML	N19450 001	MAY 30, 1986	SEP	WDAG

LOPERAMIDE HYDROCHLORIDE
TABLET; ORAL
LOPERAMIDE HCL
>D> ABLE 2MG N73528 001 NOV 30, 1993 DEC DISC
>A> @ 2MG N73528 001 NOV 30, 1993 DEC DISC

MICONAZOLE NITRATE
CREAM; TOPICAL
MONISTAT 3 COMBINATION PACK
\+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 FEB NEWA
CREAM; TOPICAL, VAGINAL
\+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 MAY CDFR
CREAM; VAGINAL

MINOXIDIL
SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)
PERRIGO 5% N75598 001 JUN 13, 2001 JUN NEWA
MINOXIDIL EXTRA STRENGTH FOR MEN
NOVEX 5% N75839 001 OCT 01, 2001 OCT NEWA

NICOTINE POLACRILEX
GUM, CHEWING; BUCCAL
NICORETTE (ORANGE)
\+ SMITHKLINE BEECHAM EQ 4MG BASE N20066 004 SEP 25, 2000 OCT NEWA
NICORETTE (ORANGE)
\+ SMITHKLINE BEECHAM EQ 2MG BASE N18612 004 SEP 25, 2000 OCT NEWA

PERMETHRIN
LOTION; TOPICAL
PERMETHRIN
>A> CLAY PARK 1% N76090 001 DEC 20, 2001 DEC NEWA

TIOCONAZOLE
OINTMENT; VAGINAL
TIOCONAZOLE
PERRIGO 6.5% N75915 001 NOV 21, 2001 NOV NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER '01

NO DECEMBER 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
December 2001

Generic Name: **T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of chronic granulomatous disease*
Sponsor: Nexell Therapeutics Inc.
Address: 9 Parker, Irvine CA 92618-1605
Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name: **(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]aceta mide**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of circadian rhythm sleep disorders in blind people with no light perception*
Sponsor: Phase 2 Discovery, Inc.
Address: 3130 Highland Avenue, Third Floor, Cincinnati OH 45219-2374
Date Designated: 10/3/2001
Market Approval Date: Not currently Approved

Generic Name: **2-chloroethyl-3-sarcosinamide-1-nitrosourea**
Trade Name: Sarmustine
Designated Indication: *Treatment for malignant glioma*
Sponsor: Pangene Corporation
Address: 5500 Stewart Avenue, Fremont CA 94538
Date Designated: 11/15/2001
Market Approval Date: Not currently Approved

Generic Name: **2-chloroethyl-3-sarcosinamide-1-nitrosourea**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment for malignant gliomas*
Sponsor: Lawrence Panasci, MD
Address: Professor of Medicine, McGill University, 3755 Cote Ste Catherine, Montreal, Quebec H3T 1E2
Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **2-methoxyestradiol**
Trade Name: Panzem

Designated Indication: *Treatment of multiple myeloma*

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850

Date Designated: 7/10/2001
Market Approval Date: Not currently Approved

Generic Name: **3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione**
Trade Name: Revimid (proposed)

Designated Indication: *Treatment for multiple myeloma*

Sponsor: Celegene Corporation
Address: 7 Powder Horn Drive
Warren NJ 07059

Date Designated: 9/20/2001
Market Approval Date: Not currently Approved

Generic Name: **9-nitro-20-(S)-camptothecin**
Trade Name: Camvirex

Designated Indication: *Treatment of pediatric HIV infection/AIDS*

Sponsor: NovoMed Pharmaceuticals, Inc.
Address: P.O. Box 900
Germantown MD 20875-0900

Date Designated: 5/15/2001
Market Approval Date: Not currently Approved

Generic Name: **acetylcysteine**
Trade Name: Acetadote

Designated Indication: *For the intravenous treatment of moderate to severe acetaminophen overdose*

Sponsor: Cumberland Pharmaceuticals Inc.
Address: 209 10th Street South
Suite 332
Nashville TN 37203

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Generic Name: **Adeno-associated viral vector containing the gene for human coagulation factor IX**
Trade Name: Coagulin-B

Designated Indication: *Intramuscular treatment of patients with moderate to severe hemophilia*

Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway
Alameda CA 94502

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Adeno-associated viral vector containing the gene for human coagulation factor IX**
Trade Name: Coagulin-B
Designated Indication: *Intrahepatic treatment of patients with moderate to severe hemophilia*
Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway, Alameda CA 94502
Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **adenovirus-mediated herpes simplex virus-thymidine kinase gene**
Trade Name: NONE ASSIGNED
Designated Indication: *Use with gancyclovir in the treatment of malignant glioma*
Sponsor: Ark Therapeutics Ltd
Address: 6 Warren Mews, London W1T6AR UK
Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **Alendronate disodium**
Trade Name: Fosamax
Designated Indication: *Treatment of the bone manifestations of Gaucher disease*
Sponsor: Richard J. Wenstrup, M.D.
Address: Division of Human Genetics, Children's Hospital Research Foundation, Cincinnati OH 45229-3039
Date Designated: 2/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Angiotensin 1-7**
Trade Name: MARstem
Designated Indication: *Treatment of myelodysplastic syndrome*
Sponsor: Maret Pharmaceutical Corporation
Address: 4041 MacArthur Boulevard, Suite 375, Newport Beach CA 92660
Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **arsenic**
Trade Name: Trisenox
Designated Indication: *Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7*
Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West, Suite 400, Seattle WA 98119
Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **arsenic trioxide**
Trade Name: Trisenox

Designated Indication: *Treatment of chronic myeloid leukemia*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West
Suite 400
Seattle WA 98119

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **augmerosen**
Trade Name: Genasense

Designated Indication: *Treatment of acute myelocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way
Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **augmerosen**
Trade Name: Genasense

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Genta Incorporated
Address: Two Oak Way
Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **augmerosen**
Trade Name: Genasense

Designated Indication: *Treatment of chronic lymphocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way
Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **azacitidine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatament of myelodysplastic syndromes*

Sponsor: Pharmion Corporation
Address: 4865 Riverbend Road
Boulder CO 80301

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **B Lymphocyte Stimulator**
Trade Name: BLyS
Designated Indication: *Treatment of common variable immunodeficiency (CVID)*
Sponsor: Human Genome Sciences, Inc.
Address: 9410 Key West Avenue, Rockville MD 20850
Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **beclomethasone 17,21-dipropionate**
Trade Name: NONE ASSIGNED
Designated Indication: *Prevention of gastrointestinal graft-versus-host disease*
Sponsor: Enteron Pharmaceuticals, Inc.
Address: 1680 Michigan Ave., Suite 700, Miami FL 33139
Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide**
Trade Name: Total Block VL SPF 75
Designated Indication: *For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy*
Sponsor: Fallien Cosmeceuticals Ltd.
Address: 677 W. Dekalb Pike, King of Prussia PA 19406
Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Generic Name: **bryostatin-1**
Trade Name: NONE ASSIGNED
Designated Indication: *For use in combination with paclitaxel in the treatment of esophageal cancer*
Sponsor: GPC Biotech, Inc.
Address: 610 Lincoln Street, Waltham MA 02451
Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Busulfan**
Trade Name: Spartajet-Busulfan
Designated Indication: *Intrathecal therapy for neoplastic meningitis*
Sponsor: SuperGen, Inc.
Address: 4140 Dublin Boulevard, Dublin CA 94568
Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Coenzyme Q10**
Trade Name: NONE ASSIGNED

Designated Indication: *For the treatrment of Huntington's disease*

Sponsor: Vitaline Corporation
Address: 385 Williamson Way
Ashland OR 97520

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name: **conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant tumors of the central nervous system*

Sponsor: INTELLIgene Expressions Inc.
Address: 1938-94 St.
Edmonton, AB T6N 1J3

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name: **deferiprone**
Trade Name: Ferriprox

Designated Indication: *Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy*

Sponsor: Apotex Research Inc.
Address: 150 Signet Drive
Toronto, Canada M9L 1T9

Date Designated: 12/12/2001
Market Approval Date: Not currently Approved

Generic Name: **DHA-paclitaxel**
Trade Name: Taxoprexin

Designated Indication: *Treatment of pancreatic cancer*

Sponsor: Protarga, Inc.
Address: 2200 Renaissance Blvd.
Suite 450
King of Prussia PA 19406

Date Designated: 9/25/2001
Market Approval Date: Not currently Approved

Generic Name: **digitoxin**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of soft tissue sarcomas*

Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **digitoxin**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of ovarian cancer*
Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933
Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Generic Name: **docosahexanoic acid-paclitaxel**
Trade Name: Taxoprexin
Designated Indication: *Treatment of hormone-refractory prostate cancer.*
Sponsor: Protarga, Inc.
Address: 1100 East Hector Street
Suite 450
Conshohocken PA 19428-2377
Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name: **Glatiramer acetate for injection**
Trade Name: Copaxone
Designated Indication: *Treatment of primary-progressive multiple sclerosis*
Sponsor: TEVA Pharmaceuticals, USA
Address: 1090 Horsham Road
North Wales PA 19454
Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name: **h5G1.1mAb**
Trade Name: NONE ASSIGNED
Designated Indication: *Idiopathic membranous glomerular nephropathy*
Sponsor: Alexion Pharmaceuticals, Inc.
Address: 352 Knotter Drive
Cheshire CT 06410
Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name: **Hsp E7**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of recurrent respiratory papillomatosis (RRP)*
Sponsor: StressGen Biotechnologies, Inc.
Address: 409 2nd Avenue
Suite 201
Collegeville PA 19426-2655
Date Designated: 3/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **Hu1D10, humanized monoclonal antibody** Trade Name: Remitogen

Designated Indication: *For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma*

Sponsor: Protein Design Labs, Inc.
Address: 34801 Campus Drive
Fremont CA 94555

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name **human gammaglobulin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for juvenile rheumatoid arthritis*

Sponsor: Protein Therapeutics, Inc
Address: 9040 S. Rita Rd., Suite 1100
Tucson AZ 84747

Date Designated: 5/25/2001
Market Approval Date: Not currently Approved

Generic Name **humanized monoclonal antibody against Shiga-like toxin II** Trade Name: NONE ASSIGNED

Designated Indication: *To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.*

Sponsor: Teijin America, Inc.
Address: 600 Alexander Park
Suite 304
Princeton NJ 08540

Date Designated: 9/12/2001
Market Approval Date: Not currently Approved

Generic Name **iduronate-2-sulfatase** Trade Name: NONE ASSIGNED

Designated Indication: *Long term enzyme replacement therapy for patients with MPS II (Hunter Syndrome)*

Sponsor: Transkaryotic Therapies Inc.
Address: 195 Albany Street
Cambridge MA 02139

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name **IL13-PE38QQR** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant glioma*

Sponsor: NeoPharm, Inc.
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Imatinib**
Trade Name: Gleevec
Designated Indication: *Treatment of chronic myelogenous leukemia*
Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10, East Hanover NJ 07936-1080
Date Designated: 1/31/2001
Market Approval Date: 5/10/2001

Generic Name: **imatinib mesylate**
Trade Name: Gleevec
Designated Indication: *Treatment of gastrointestinal stromal tumors*
Sponsor: Novartis Pharmaceuticals Corp.
Address: One Health Plaza, East Hanover NJ 07936-1080
Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name: **Imexon**
Trade Name: n/a
Designated Indication: *Treatment of metastatic malignant melanoma*
Sponsor: AmpliMed Corporation
Address: 2321 Camino La Zorrela, Tucson AZ 85718
Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **INH-A00021**
Trade Name: NONE ASSIGNED
Designated Indication: *Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.*
Sponsor: Inhibitex, Inc.
Address: 8995 Westside Parkway, Suite 150, Alpharetta GA 30004
Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Interferon-alfa-1b**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of multiple myeloma*
Sponsor: Ernest C.Borden
Address: Center for Cancer Drud Discovery and, 9500 Euclid Avenue, Clevland OH 44195
Date Designated: 4/17/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Intraoral fluoride releasing system** Trade Name: IFRS

Designated Indication: *Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer*

Sponsor: Digestive Care, Inc.
Address: 1120 Win Drive
Bethlehem PA 18017

Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **L-glutamine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease*

Sponsor: Orphan Drugs International, LLC (d.b.a. Hope
Address: PO Box 0401
Montrose CA 91021-0401

Date Designated: 8/1/2001
Market Approval Date: Not currently Approved

Generic Name: **Latrodectus immune F(ab)2** Trade Name: Aracmyn

Designated Indication: *Treatment of black widow spider envenomations*

Sponsor: Rare Disease Therapeutics, Inc.
Address: 1101 Kermit Drive, Suite 608
Nashville TN 37217

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Medroxyprogesterone acetate** Trade Name: Hematrol

Designated Indication: *Treatment of immune thrombocytopenic purpura.*

Sponsor: InKine Pharmaceutical Company, Inc.
Address: 1787 Sentry Parkway West
Building 18, Suite 440
Blue Bell PA 19422

Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Generic Name: **metreleptin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **metreleptin**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of metabolic disorders secondary to lipodystrophy*
Sponsor: Amgen, Inc.,
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799
Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Generic Name: **MTC-DOX for Injection**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of hepatocellular carcinoma*
Sponsor: FeRx Incorporated
Address: 4330 La Jolla Village Drive
Suite #250
San Diego CA 92122
Date Designated: 1/3/2001
Market Approval Date: Not currently Approved

Generic Name: **muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of children and adolescent osteosarcoma*
Sponsor: Jenner Biotherapies, Inc.
Address: 541 Kenosa Street
Walworth WI 53184
Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name: **nitazoxanide**
Trade Name: Cryptaz
Designated Indication: *Treatment for intestinal amebiasis*
Sponsor: Romark Laboratories, L.C.
Address: 6200 Courtney Campbell Causeway
Suite 880
Tampa FL 33607
Date Designated: 10/23/2001
Market Approval Date: Not currently Approved

Generic Name: **Nitisinone**
Trade Name: Orfadin
Designated Indication: *Treatment of alkaptonuria*
Sponsor: Swedish Orphan AB
Address: Kungsgatan 37, 7th Floor
SE-111 56
Stockholm, Sweden
Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Nitroprusside** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.*

Sponsor: Thomas, MD, Jeffrey Evan
Address: Thomas Jefferson University and Wills
834 Walnut Street, Suite 650
Philadelphia PA 19107-5102

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **nolatrexed** — Trade Name: THYMITAQ

Designated Indication: *Treatment of hepatocellular carcinoma*

Sponsor: Zarix, Inc.
Address: 1055 Westlakes Drive
Suite 200
Berwyn PA 19312

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Novel Acting Thrombolytic (NAT)** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of peripheral arterial occlusion (PAO)*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Generic Name: **NZ-1002** — Trade Name: NONE ASSIGNED

Designated Indication: *Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.*

Sponsor: Novazyme Pharmaceuticals, Inc.
Address: 800 Research Parkway
Suite 200
Oklahoma City OK 73104

Date Designated: 4/11/2001
Market Approval Date: Not currently Approved

Generic Name: **oglufanide disodium** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer*

Sponsor: Cytran, Inc.
Address: 10230 NE Points Dr., NE
Suite 530
Kirkland WA 98033-7869

Date Designated: 9/24/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt**
Trade Name: NONE ASSIGNED

Designated Indication: *For the treatment of cystic fibrosis*

Sponsor: Inspire Pharmaceuticals, Inc.
Address: 4222 Emperor Blvd.
Suite 470
Durham NC 27703

Date Designated: 3/7/2001
Market Approval Date: Not currently Approved

Generic Name: **pemetrexed disodium**
Trade Name: Alimta

Designated Indication: *Treatment of malignant pleural mesothelioma*

Sponsor: Eli Lilly and Company
Address: Lilly Corporate Center
Indianapolis IN 46285

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Perflubron**
Trade Name: LiquiVent

Designated Indication: *Treatment of acute respiratory distress disease (ARDS) in adults*

Sponsor: Alliance Pharmaceutical Corp.
Address: 3040 Science Park Road
San Diego CA 92191

Date Designated: 4/26/2001
Market Approval Date: Not currently Approved

Generic Name: **Polyethylene glycol (PEG)-uricase**
Trade Name: NONE ASSIGNED

Designated Indication: *To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy contraindicated or has been ineffective.*

Sponsor: Bio-Technology General Corporation
Address: 70 Wood Avenue South
Iselin NJ 08830

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **porfimer**
Trade Name: Photofrin

Designated Indication: *For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy*

Sponsor: Axcan Scandipharm Inc.
Address: 22 Inverness Parkway
Suite 310
Birmingham AL 35242

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Pyruvate**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of interstitial lung disease.*
Sponsor: Cellular Sciences, Inc
Address: 84 park Avenue
P.O. Box 968
Flemington NJ 08822
Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **recombinant human alpha 1-antitrypsin (rAAT)**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of cystic fibrosis*
Sponsor: Arriva Pharmaceuticals, Inc.
Address: 2020 Challenger Drive
Alameda CA 94501
Date Designated: 11/20/2001
Market Approval Date: Not currently Approved

Generic Name: **recombinant human alpha-1 antitrypsin (rAAT)**
Trade Name: NONE ASSIGNED
Designated Indication: *To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis*
Sponsor: Baxter Healthcare Corporation
Address: 550 N. Brand Blvd.
Glendale CA 91203
Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Recombinant Human Alpha-Fetoprotein (rhAFP)**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of myasthenia gravis*
Sponsor: Atlantic Biopharmaceuticals, Inc.
Address: 50 Church Street
5th floor
Cambridge MA 02138
Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Generic Name: **recombinant human endostatin protein**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of neuroendocrine tumors.*
Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850
Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Reviparin sodium** Trade Name: Clivarine

Designated Indication: *Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients*

Sponsor Address: Knoll AG, Ludwigshafen, Germany

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Reviparin sodium** Trade Name: Clivarine

Designated Indication: *Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients*

Sponsor Address: Knoll AG, Ludwigshafen, Germany

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **squalamine lactate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer refractory or resistant to standard chemotherapy*

Sponsor Address: Genaera Corporation, 5110 Campus Drive, Plymouth Meeting PA 19462

Date Designated: 5/11/2001
Market Approval Date: Not currently Approved

Generic Name: **Synthetic Human Parathyroid Hormone 1-34** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hypoparathyroidism*

Sponsor Address: Orphan Pharmaceuticals, U.S., Inc., 1101 Kermit Drive, Suite 608, Nashville TN 37217

Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Generic Name: **Thyrotropin alfa** Trade Name: Thyrogen

Designated Indication: *Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroi*

Sponsor Address: Genzyme Corporation, One Kendall Square, Cambridge MA 02139-1562

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment for hepatocellular carcinoma*
Sponsor: Cell Works Inc.
Address: 6200 Seaforth Street, Baltimore MD 21224-6506
Date Designated: 11/23/2001
Market Approval Date: Not currently Approved

Generic Name: **Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of renal cell carcinoma.*
Sponsor: Wilex Biotechnology GmbH
Address: Grillparzerstrasse 10B, 81675 Munich, Germany DE
Date Designated: 3/22/2001
Market Approval Date: Not currently Approved

Generic Name: **Vasoactive intestinal peptide**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of Acute Respiratory Distress Syndrome.*
Sponsor: Sami I. Said, M.D.
Address: State University of New York at Stony Brook, Health Sciences Center T17, 040, Stony Brook NY 11794-8172
Date Designated: 3/9/2001
Market Approval Date: Not currently Approved

Generic Name: **Virulizin**
Trade Name: Virulizin
Designated Indication: *Treatment of pancreatic cancer.*
Sponsor: Lorus Therapeutics Inc.
Address: 7100 Woodbine Avenue, Suite 215, Markham, ON L3R 5J2, Canada
Date Designated: 2/1/2001
Market Approval Date: Not currently Approved

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
020977 001	ABACAVIR SULFATE;ZIAGEN	6180639*PED	JUL 30, 2018	U-248		
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
020978 001	ABACAVIR SULFATE;ZIAGEN	6294978	MAY 14, 2018	U-65		
		6294978*PED	NOV 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6294540	MAY 14, 2018	U-65		
021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
020949 001	ALBUTEROL SULFATE;ACCUNEB				NCE	DEC 18, 2002
020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020950 001	ALBUTEROL SULFATE;DUONEB				NP	APR 30, 2004
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA				NP	MAR 21, 2004
		6251368	DEC 04, 2012		I-235	SEP 23, 2001
021074 001	ALCOHOL;AVAGARD				I-262	JUN 02, 2002
020560 001	ALENDRONATE SODIUM;FOSAMAX	5897031	JUN 21, 2016		NC	JUN 07, 2004
020560 004	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
021001 001	ALMOTRIPTAN MALATE;AXERT	6225294	JUL 17, 2018			
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5565447	MAR 27, 2014		NCE	MAY 07, 2006
		5360800	FEB 02, 2010			
019787 001	AMLODIPINE BESYLATE;NORVASC	6284770	OCT 05, 2018	U-405		
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
019787 002	AMLODIPINE BESYLATE;NORVASC	4572909*PED	JAN 31, 2007			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
019787 003	AMLODIPINE BESYLATE;NORVASC	4572909*PED	JAN 31, 2007			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10				NDF	OCT 11, 2004
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20				NDF	OCT 11, 2004
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30				NDF	OCT 11, 2004
020883 001	ARGATROBAN;ACOVA	5214052	MAR 13, 2012			
021317 001	ASPIRIN;BAYER EXTRA STRENGTH				NP	OCT 18, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 08, 2017			
>ADD>	020702 002	ATORVASTATIN CALCIUM;LIPITOR	6126971*PED	JUL 19, 2013			
>ADD>			4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 18, 2017			
>ADD>	020702 003	ATORVASTATIN CALCIUM;LIPITOR	6126971*PED	JUL 19, 2013			
>ADD>			4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 08, 2017			
>ADD>	020702 004	ATORVASTATIN CALCIUM;LIPITOR	6126971*PED	JUL 19, 2013			
>ADD>			4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 08, 2017			
>ADD>			6126971*PED	JUL 19, 2013			
	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
			5053432	OCT 01, 2008			
			6291488	NOV 25, 2013			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
			6291488	NOV 25, 2013	U-406		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
		5962731	OCT 05, 2016			
		5466861	NOV 14, 2012			
020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
		5712251	SEP 18, 2001	U-391		
021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
021290 001	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NCE	SEP 06, 2001
					PED	MAR 06, 2002
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U-394	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-394	PED	MAR 06, 2002
		6194415*PED	DEC 28, 2015	U-394		
		6248741*PED	DEC 28, 2015	U-394		
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U-395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U-399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U-399	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-395	PED	MAR 06, 2002
		6194415	JUN 28, 2015	U-395		
		6248741*PED	DEC 28, 2015	U-395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
020816 001	BRINZOLAMIDE;AZOPT	5378703	APR 01, 2012	U-224		
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017			
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX				I-333	JUN 06, 2004
018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001		PED	MAY 16, 2005
		6051567	AUG 02, 2019		M-14	NOV 16, 2004
		4308264*PED	JUL 28, 2001			
		6051567*PED	FEB 02, 2020			
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001		PED	MAY 16, 2005
			6051567	AUG 02, 2019		M-14	NOV 16, 2004
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
			6265392	AUG 02, 2019			
			6274169	AUG 02, 2019			
			6274169*PED	FEB 02, 2020			
			6265392*PED	FEB 02, 2020			
	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
						I-341	SEP 07, 2004
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
						I-341	SEP 07, 2004
	020297 001	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 002	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 003	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 004	CARVEDILOL;COREG				I-343	NOV 01, 2004
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
>ADD>	021222 001	CEFDITOREN PIVOXIL;SPECTRACEF				NCE	AUG 29, 2006
	020998 001	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	020998 002	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	021197 001	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
	021197 002	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
	021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
>ADD>	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	5576328	JAN 31, 2014	U-432		
			4847265	NOV 17, 2011			
	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
	021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
			4863931	SEP 15, 2008			
			4804666	FEB 14, 2006	U-428		
			5595997	DEC 30, 2014	U-429		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U-421		
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
			5922736	DEC 04, 2015	U-423		
			6255325	DEC 04, 2015	U-424		
>ADD>	020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	FEB 03, 2017	U-392		
>ADD>	020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	FEB 03, 2017	U-392		
	021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
			5792753	AUG 11, 2015			
			5852002	JUN 17, 2014	U-402		
			5914322	AUG 11, 2015			
			5929048	JUL 27, 2016	U-402		
			5985850	NOV 16, 2016			
	020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			
	020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			
	020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			
	020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
		5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U-180		
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
	021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
			6245911	DEC 01, 2018			
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	5985864	DEC 30, 2016			
			6140321	DEC 30, 2016			
			6245911	DEC 01, 2018			
			5985864	DEC 30, 2016			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6248735	APR 17, 2011			
	021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
	021319 001	DUTASTERIDE;DUTASTERIDE				NCE	NOV 20, 2006
>ADD>	021360 001	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
>ADD>	021360 002	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U-403		
			5441958	DEC 08, 2013	U-404		
	020668 001	ENALAPRIL MALEATE;LEXXEL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
	020668 002	ENALAPRIL MALEATE;LEXXEL	4374829	DEC 30, 2001	U-3		
			4472380	SEP 18, 2001			
			4703038	OCT 07, 2005	U-3		
			4803081	APR 03, 2007			
			4264611	JUN 19, 2001	U-3		
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
						M-7	FEB 13, 2004
	018998 001	ENALAPRIL MALEATE;VASOTEC				PED	AUG 13, 2004
	018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
						PED	AUG 13, 2004
	018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
						PED	AUG 13, 2004
	018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
						PED	AUG 13, 2004
	020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
		5652233	FEB 02, 2013			
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5952323	MAY 15, 2017			
		5017609	MAY 21, 2008			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6310094	JAN 12, 2021			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		5017609	MAY 21, 2008			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4593119	JUN 03, 2003			
		4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
020870 001	ESTRADIOL;COMBIPATCH	4508905	FEB 20, 2001			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	5010070	APR 23, 2008		I-331	JUL 01, 2004
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	5010070	APR 23, 2008		I-331	JUL 01, 2004
021187 001	ETHINYL ESTRADIOL;NUVARING				NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA				NP	NOV 20, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
	020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
	020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
			RE35524	MAY 17, 2010			
	020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
			RE35524	MAY 17, 2010			
	075312 001	FAMOTIDINE;FAMOTIDINE				PC	NOV 28, 2001
	020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
						PED	MAY 09, 2002
	019834 001	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4803081*PED	OCT 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
	019834 002	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
	019834 004	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
>ADD>	021203 001	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
			6277405	JAN 09, 2018			
			6074670	JAN 09, 2018			
>ADD>	021203 003	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
			6277405	JAN 09, 2018			
			6074670	JAN 09, 2018			
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
>ADD>	019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
>ADD>	019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
>ADD>	019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
>ADD>	019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-340	OCT 10, 2004
>ADD>	021112 001	FLUOCINOLONE ACETONIDE;TRI-LUMA				NC	JAN 18, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			
	074803 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075049 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075465 003	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075506 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075755 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
	075755 002	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
	020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
	020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
	020261 001	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
	020261 002	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
	021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413		
			5356896	DEC 12, 2011			
>ADD>	020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM				I-306	FEB 07, 2005
>ADD>	020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM				I-306	FEB 07, 2005
>ADD>	021345 001	FONDAPARINUX SODIUM;ARIXTRA				NCE	DEC 07, 2006
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021279 001	FORMOTEROL FUMARATE;FORADIL				I-342	SEP 25, 2004
						NCE	FEB 16, 2006
>ADD>	021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U-436	NCE	NOV 08, 2006
>ADD>			5616603	APR 01, 2014	U-436		
>ADD>			5637611	JUN 10, 2014	U-436		
>ADD>			5827871	OCT 27, 2015	U-436		
>ADD>			5962501	DEC 16, 2013	U-436		
>ADD>			5917054	DEC 16, 2013	U-437		
>ADD>			5618947	DEC 08, 2014	U-437		
>ADD>			5618948	APR 08, 2014	U-437		
	020235 001	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020235 002	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020235 003	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020882 001	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020882 002	GABAPENTIN;NEURONTIN				PED	APR 12, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021129 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	APR 12, 2004
			5084479	JAN 02, 2010	U-258		
			4894476*PED	NOV 02, 2008			
			5084479*PED	JUL 02, 2010	U-258		
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021061 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021061 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021062 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021062 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	6294548	MAY 04, 2019			
	020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
			6294548	MAY 04, 2019			
	021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002			
	019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 001	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 002	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 003	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
>ADD>	020769 001	HYDROCORTISONE BUTYRATE;LOCOID LIPOCREAM	5635497	JUN 03, 2014			
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
>ADD>	074567 001	IBUPROFEN;IBUPROHM COLD AND SI				PC	APR 06, 2002
	021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
						ODE	MAY 10, 2008
>ADD>						ODE	FEB 01, 2009
	021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
						ODE	MAY 10, 2008
>ADD>						ODE	FEB 01, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020685 006	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
						NR	DEC 21, 2004
	020986 001	INSULIN ASPART;NOVOLOG				NC	NOV 01, 2004
	021172 001	INSULIN ASPART;NOVOLOG MIX 70/30	5656722	SEP 12, 2014			
	021081 001	INSULIN GLARGINE;LANTUS	5656722*PED	MAR 12, 2015			
						I-327	OCT 27, 2003
	020394 001	IPRATROPIUM BROMIDE;ATROVENT	6342247	JUN 07, 2015			
>ADD>	020757 001	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015			
>ADD>	020757 002	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015			
>ADD>	020757 003	IRBESARTAN;AVAPRO	4464394	AUG 07, 2001			
	018662 002	ISOTRETINOIN;ACCUTANE	4464394*PED	FEB 07, 2002			
			4464394	AUG 07, 2001			
	018662 003	ISOTRETINOIN;ACCUTANE	4464394*PED	FEB 07, 2002			
			4464394	AUG 07, 2001			
	018662 004	ISOTRETINOIN;ACCUTANE	4464394*PED	FEB 07, 2002			
						I-332	MAY 09, 2004
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
	020966 001	ITRACONAZOLE;SPORANOX	4454151	MAR 22, 2002	U-75		
	019700 001	KETOROLAC TROMETHAMINE;ACULAR	5110493	MAY 05, 2009			
			4454151*PED	SEP 22, 2002	U-75		
			5110493*PED	NOV 05, 2009	U-75		
					U-75		
	020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002			
			4454151*PED	SEP 22, 2002			
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
			6180639*PED	JUL 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
			6180639*PED	JUL 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
			6180639*PED	JUL 30, 2018	U-248		
	021003 001	LAMIVUDINE;EPIVIR-HBV				I-339	AUG 16, 2004
						PED	FEB 16, 2005
	021004 001	LAMIVUDINE;EPIVIR-HBV				PED	FEB 16, 2005
						I-339	AUG 16, 2004
	021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021343 001	LEUPROLIDE ACETATE;ELIGARD				NP	JAN 23, 2005
	019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
	020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JAN 02, 2013			
			5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5814342	FEB 01, 2011			
			6036976	DEC 13, 2016			
	020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5575987	SEP 02, 2013			
			5476663	NOV 01, 2004			
			6036976	DEC 13, 2013			
	020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5643607	JAN 02, 2013			
			5814342	FEB 01, 2011			
			6036976	DEC 13, 2016			
	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5643607	JAN 02, 2013			
			5814342	FEB 01, 2011			
			6036976	DEC 13, 2016			
	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U-332	I-347	JAN 30, 2005
>ADD>	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U-332	I-347	JAN 30, 2005
>ADD>	020182 001	LEVOCARNITINE;CARNITOR	6335369	JAN 18, 2022	U-433		
	019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019777 001	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 002	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 003	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 004	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 005	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
>ADD>	021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	SEP 28, 2010	U-434		
>ADD>			6103260	JUL 17, 2017			
	021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
			6284767	FEB 14, 2016	U-401		
	021251 001	LOPINAVIR;KALETRA	6284767	FEB 14, 2016	U-401		
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
	021249 001	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
	021249 002	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
	021249 003	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				PC	JAN 12, 2002
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD				NDF	APR 03, 2004
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			
	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	6153635	NOV 28, 2020			
			5514698	MAR 21, 2014			
	019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
>ADD>	020717 001	MODAFINIL;PROVIGIL	RE37516	OCT 06, 2014	U-255		
>ADD>	020717 002	MODAFINIL;PROVIGIL	RE37516	OCT 06, 2014	U-255		
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001		I-285	DEC 02, 2002
			5837699	JAN 27, 2014	U-249	PED	JUN 02, 2003
			6127353	OCT 03, 2017			
			4472393*PED	MAR 18, 2002			
			5837699*PED	JUL 27, 2014	U-249		
			6127353*PED	APR 03, 2018			
	019543 001	MOMETASONE FUROATE;ELOCON	4472393	SEP 18, 2001			
			4472393*PED	MAR 18, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
			4472393	SEP 18, 2001			
			4472393*PED	MAR 18, 2002			
			4808610*PED	APR 02, 2007			
	019796 001	MOMETASONE FUROATE;ELOCON	4775529	MAY 21, 2007			
			4472393	SEP 18, 2001			
			4472393*PED	MAR 18, 2002			
			4775529*PED	NOV 21, 2007			
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
			5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
			5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	I-300	MAR 03, 2003
			5565473*PED	AUG 03, 2012	U-228	NS	MAR 03, 2003
						NCE	FEB 20, 2003
						PED	SEP 03, 2003
						PED	AUG 20, 2003
						PED	SEP 03, 2003
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
	021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHL				NCE	DEC 10, 2004
						NDF	NOV 30, 2004
						I-329	APR 27, 2004
	075179 001	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	075189 001	NABUMETONE;NABUMETONE				PC	FEB 16, 2002
	075189 002	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
>ADD>	019886 001	NAFARELIN ACETATE;SYNAREL	4234571	JUN 11, 2001			
	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
	021204 002	NATEGLINIDE;STARLIX	5488150	JAN 30, 2013			
			RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
			5674710	OCT 07, 2014			
	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
			5633008	JUN 14, 2008	U-389		
	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
>ADD>	021232 001	NITISINONE;ORFADIN				NCE	JAN 18, 2007
>ADD>						ODE	JAN 18, 2009
>ADD>	021232 002	NITISINONE;ORFADIN				NCE	JAN 18, 2007
>ADD>						ODE	JAN 18, 2009
>ADD>	021232 003	NITISINONE;ORFADIN				NCE	JAN 18, 2007
>ADD>						ODE	JAN 18, 2009
	019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U-407		
	020592 001	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 002	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 003	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 004	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
			5605897	FEB 25, 2014	U-176		
			6251895	SEP 23, 2017			
	020592 006	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
			5229382	APR 23, 2011	U-149		
			5605897	FEB 25, 2014	U-176		
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184		
	019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			4508905*PED	OCT 02, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014			
			5629305*PED	AUG 04, 2014	U-166		
			6147103*PED	APR 09, 2019	U-188		
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			4508905*PED	OCT 02, 2002			
	019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
			6147103	OCT 09, 2018		PED	DEC 29, 2001
			6166213	NOV 10, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			4508905*PED	OCT 02, 2002			
>ADD>	020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020403 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE	5578628	FEB 16, 2005	U-44		
>ADD>	020007 003	ONDANSETRON;ZOFRAN ODT	5578628	FEB 16, 2005	U-330		
>ADD>	020781 001		4753789	JUN 24, 2006	U-330		
>ADD>	020781 002	ONDANSETRON;ZOFRAN ODT	5578628	FEB 16, 2005	U-330		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
			5866601	FEB 02, 2016		NDF	DEC 14, 2003
>ADD>	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	5952375	FEB 02, 2016		NCE	OCT 27, 2004
>ADD>			4783337	SEP 16, 2003		NP	DEC 16, 2001
>ADD>			5674895	MAY 22, 2015		PED	JUN 16, 2002
>ADD>			5082668	SEP 16, 2003			
>ADD>			5840754	MAY 22, 2015			
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
>ADD>			5912268	MAY 22, 2015			
>ADD>			6124355	MAY 22, 2015	U-378		
>ADD>			6262115	MAY 22, 2015	U-393		
>ADD>			4783337*PED	MAR 16, 2004			
>ADD>			4519801*PED	JAN 12, 2003			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			5674895*PED	NOV 22, 2015			
>ADD>			5840754*PED	NOV 22, 2015			
>ADD>			5912268*PED	NOV 22, 2015			
>ADD>			6124355*PED	NOV 22, 2015	U-378		
>ADD>	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6262115*PED	NOV 22, 2015	U-393		
>ADD>			5840754	MAY 22, 2015		NP	DEC 16, 2001
>ADD>			5674895	MAY 22, 2015		PED	JUN 16, 2002
>ADD>			5082668	SEP 16, 2003			
>ADD>			4783337	SEP 16, 2003			
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
>ADD>			5912268	MAY 22, 2015			
>ADD>			6124355	MAY 22, 2015	U-378		
>ADD>			6262115	MAY 22, 2015	U-393		
>ADD>			4783337*PED	MAR 16, 2004			
>ADD>			4519801*PED	JAN 12, 2003			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			5674895*PED	NOV 22, 2015			
>ADD>			5840754*PED	NOV 22, 2015			
>ADD>			5912268*PED	NOV 22, 2015			
>ADD>			6124355*PED	NOV 22, 2015	U-378		
>ADD>	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6262115*PED	NOV 22, 2015	U-393		
>ADD>			5912268	MAY 22, 2015		NP	DEC 16, 2001
>ADD>			4612008	SEP 16, 2003		PED	JUN 16, 2002
>ADD>			4519801	JUL 12, 2002			
>ADD>			5840754	MAY 22, 2015			
>ADD>			5674895	MAY 22, 2015			
>ADD>			5082668	SEP 16, 2003			
>ADD>			4783337	SEP 16, 2003			
>ADD>			6124355	MAY 22, 2015	U-378		
>ADD>			6262115	MAY 22, 2015	U-393		
>ADD>			4783337*PED	MAR 16, 2004			
>ADD>			4519801*PED	JAN 12, 2003			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			5674895*PED	NOV 22, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>			5840754*PED	NOV 22, 2015			
>ADD>			5912268*PED	NOV 22, 2015			
>ADD>			6124355*PED	NOV 22, 2015	U-378		
>ADD>			6262115*PED	NOV 22, 2015	U-393		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
			5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
			6150398	MAY 08, 2011	U-380		
	020262 001	PACLITAXEL;TAXOL				D-68	AUG 20, 2004
	020036 001	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 003	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 004	PAMIDRONATE DISODIUM;AREDIA				PC	MAY 05, 2002
	075290 001	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
	075290 003	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				I-330	JUN 12, 2004
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NDF	MAR 22, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV				NCE	FEB 02, 2005
						I-337	OCT 19, 2004
	020819 001	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U-314		
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020031 002	'PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
						I-345	DEC 14, 2004
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017	U-431		
	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017	U-431		
	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017	U-431		
	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017	U-431		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	6121291	MAR 17, 2017	U-431		
			4721723	DEC 29, 2006			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			5789449	JAN 06, 2009	U-286		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
			6172233	JAN 15, 2018			
	021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
			5547656	APR 05, 2011			
	021302 001	PIMECROLIMUS;ELIDEL	5769080	JUL 20, 2010			
			5912238	JUN 15, 2016		NCE	DEC 13, 2006
>ADD>	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	5912238*PED	DEC 15, 2016		PED	JUN 13, 2007
			6303640	AUG 09, 2016	U-425		
			6211205	JUN 19, 2016	U-410		
			6166042	JUN 19, 2016	U-414		
			6172090	JUN 19, 2016	U-416		
			6150383	JUN 19, 2016	U-418		
			6329404	JUN 19, 2016	U-430		
			6150384	JUN 19, 2016	U-419		
			5965584	JUN 19, 2016	U-417		
			6166043	JUN 19, 2016	U-415		
>ADD>	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6271243	JUN 19, 2016	U-411		
			6303640	AUG 09, 2016	U-425		
			6211205	JUN 19, 2016	U-410		
			6166042	JUN 19, 2016	U-414		
			6172090	JUN 19, 2016	U-416		
			6150383	JUN 19, 2016	U-418		
			6329404	JUN 19, 2016	U-430		
			6150384	JUN 19, 2016	U-419		
			5965584	JUN 19, 2016	U-417		
			6166043	JUN 19, 2016	U-415		
>ADD>	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6271243	JUN 19, 2016	U-411		
			6303640	AUG 09, 2016	U-425		
			6211205	JUN 19, 2016	U-410		
			6166042	JUN 19, 2016	U-414		
			6172090	JUN 19, 2016	U-416		
			6150383	JUN 19, 2016	U-418		
			6329404	JUN 19, 2016	U-430		
			6150384	JUN 19, 2016			
			5965584	JUN 19, 2016	U-417		
			6166043	JUN 19, 2016	U-415		
			6271243	JUN 19, 2016	U-411		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	074726 001	POTASSIUM CHLORIDE;KLOR-CON M20				PC	FEB 28, 2002
>ADD>	020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
			4886812	MAR 25, 2011			
>ADD>	020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
	019898 002	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
	019898 003	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
	019898 004	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
	019898 008	PRAVASTATIN SODIUM;PRAVACHOL				NS	DEC 18, 2004
	019627 002	PROPOFOL;DIPRIVAN				D-70	DEC 18, 2004
						I-322	FEB 20, 2004
	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		PED	AUG 20, 2004
	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
>ADD>	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385	I-346	FEB 12, 2005
			5035899	APR 04, 2009	U-385		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
	019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				PED	APR 29, 2003
	020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				PED	APR 29, 2003
	020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
	020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U-235	PED	JUN 09, 2002
			5914128	DEC 22, 2017		PED	DEC 03, 2001
			6051252	DEC 22, 2017			
			6063772	JAN 23, 2016	U-375		
			6172046	SEP 21, 2017	U-377		
			5767097*PED	JUL 23, 2016	U-235		
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
			6063772*PED	JUL 23, 2016	U-375		
			6172046*PED	MAR 21, 2018	U-377		
			6335032	DEC 22, 2017			
			6335032*PED	JUN 22, 2018			
			6337090	DEC 22, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020903 002	RIBAVIRIN;REBETOL	6337090*PED	JUN 22, 2018			
			6335032	DEC 22, 2017			
			6335032*PED	JUN 22, 2018			
			5767097	JAN 23, 2016	U-235		
			5767097*PED	JUL 23, 2016	U-235		
			5914128	DEC 22, 2017			
			5914128*PED	JUN 22, 2018			
			6051252	DEC 22, 2017			
			6051252*PED	JUN 22, 2018			
			6063772	JAN 23, 2016	U-375		
			6063772*PED	JUL 23, 2016			
			6172046	SEP 21, 2017	U-377		
			6172046*PED	MAR 21, 2018	U-377		
			6337090	DEC 22, 2017			
			6337090*PED	JUN 22, 2018			
	018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
	020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	020692 001	SALMETEROL XINAFOATE;SEREVENT	5290815	MAR 01, 2011	U-386		
	020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2010			
>ADD>	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
>ADD>			4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
>ADD>			4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
>ADD>			4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
>ADD>			4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	PED	JUN 07, 2003
>ADD>			4962128	NOV 02, 2009	U-12	PED	FEB 06, 2005
>ADD>			4536518*PED	JUN 30, 2006	U-152	M-11	AUG 06, 2004
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	PED	JUN 07, 2003
>ADD>			4962128	NOV 02, 2009	U-12	PED	FEB 06, 2005
>ADD>			4536518*PED	JUN 30, 2006	U-152	M-11	AUG 06, 2004
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
>ADD>			4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
>ADD>			4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286	M-11	AUG 06, 2004
>ADD>			4536518*PED	JUN 30, 2006	U-286	PED	FEB 06, 2005
	020478 001	SEVOFLURANE;ULTANE	6288127	JAN 27, 2017			
			6288127*PED	JUL 27, 2017			
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
>ADD>	019766 001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
>ADD>	019766 002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019766 003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>	019766 004	SIMVASTATIN;ZOCOR	RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
>ADD>			4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>	019766 005	SIMVASTATIN;ZOCOR	RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
>ADD>			4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
	021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	MAY 18, 2013	U-359		
>ADD>	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019865 001	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 002	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008			
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
021184 002	TAZAROTENE;TAZORAC				I-344	OCT 11, 2004
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U-248	NCE	OCT 26, 2006
		6043230	JUL 25, 2017	U-248		
		5935946	JUL 25, 2017	U-248		
		4808716	APR 25, 2006	U-248		
		6057305	MAY 02, 2017	U-248		
		5922695	JUL 25, 2017	U-248		
019964 001	TERCONAZOLE;TERAZOL 3	4358449	NOV 09, 2001			
020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010			
		5602006	FEB 11, 2014			
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020397 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX				NCE	NOV 27, 2001
020771 001	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		
>ADD>	021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	MAY 05, 2015	U-318		
>ADD>	021228 002	TOLTERODINE TARTRATE;DETROL LA	5559269	MAY 05, 2015	U-318		
	020505 001	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 002	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 003	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 004	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 005	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 006	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
>ADD>	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435		
>ADD>			6339105*PED	APR 12, 2020	U-435		
>ADD>	020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435		
>ADD>			6339105*PED	APR 12, 2020	U-435		
	020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 003	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020591 001	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 002	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 003	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 004	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
			5631287	DEC 22, 2014	U-382		
			5849792	DEC 22, 2014	U-383		
			5889052	AUG 03, 2013	U-383		
			6235781	JUN 15, 2019	U-382		
	019963 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
	021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
			4603146	JUL 29, 2003	U-131		
	020475 001	TRETINOIN;RETIN-A MICRO	5955109	SEP 21, 2016	U-134		
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
			5192741	MAR 09, 2010		NCE	JUN 15, 2005
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5776885	JUL 07, 2015			
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020586 002	UREA, C-13;BREATHTEK UBT FOR H-	4830010	OCT 27, 2009	U-147		
			5140993	AUG 24, 2009			
					U-148		
	019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
			4845077	JUL 04, 2006	U-408		
			4725579	FEB 21, 2005	U-408		
	019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
			4845077	JUL 04, 2006	U-408		
			4725579	FEB 21, 2005	U-408		
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
>ADD>	021341 002	VALDECOXIB;BEXTRA				NCE	NOV 16, 2006
>ADD>	021341 003	VALDECOXIB;BEXTRA				NCE	NOV 16, 2006
	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
	021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
			5916923	JUN 28, 2013	U-398		
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
			5916923	JUN 28, 2013	U-398		
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017			
			5916923	JUN 28, 2013	U-398		
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
			5916923	JUN 28, 2013	U-398		
	021119 001	VERTEPORFIN;VISUDYNE	4833790	JAN 20, 2007	U-357	I-336	AUG 22, 2004
			5283255	JAN 20, 2007	U-357		
	020547 001	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
	020547 003	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
	020859 001	ZALEPLON;SONATA				M-8	FEB 22, 2004
	020859 002	ZALEPLON;SONATA				M-8	FEB 22, 2004
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
021223 001	ZOLEDRONIC ACID;ZOMETA	4939130	NOV 13, 2007	U-53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE

MISCELLANEOUS EXCLUSIVITY CODES

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION

PATENT USE CODES

U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODES

U-379 METHOD OF TREATING ONYCHROMYCOSIS

U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS

U-381 TREATMENT OF HYPERPHOSPHATEMIA

U-382 METHOD OF STABLIZING PROSTAGLANDIN

U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

U-394 METHOD OF USE OF ALPHAGAN

U-395 METHOD OF USE OF ALPHAGAN P

U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION

U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA

U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER

U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS

U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS

U-402 TREATMENT OF ACTINIC KERATOSES

U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS

U-405 METHOD OF USE OF LOTRONEX

U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL

U-407 METHOD OF TREATING OTOPATHY

U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION

U-412 TREATMENT OF TYPE 2 DIABETES

U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS

U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODES

U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN ECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION, OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION

*U.S. Government Printing Office: 2002 — 491-214/40007

New 22nd Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

_____
(Authorizing Signature)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

Thank you for your order!

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.